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Despite the unprecedented investment and tremendous progress in the field of 
drug discovery and development, discovering a new drug molecule is still a 
challenging task. Target and lead discoveries are two critical steps in drug 
discovery, and the quality of their relevant works may dramatically affect the 
final outcome. Computational methods can be applied in these two steps for 
facilitating and economizing drug discovery process. This thesis describes my 
studies on the computational analysis and prediction of therapeutically 
relevant molecules in these two steps with three directions: (1) analysis of 
natural products (NPs) for drug lead discovery, (2) prediction of protein 
functional families and their interactions related to target discovery, (3) 
disease, drug and target data collection and the development of molecular 
profile prediction software as to update Therapeutic Targets Database (TTD)  
and construct Molecular Feature Server (Molfeat). 
NPs have been and continue to be rich sources for drug discovery. Compared 
with the typical synthetic library, NPs have quite distinct physicochemical 
properties in chemical space. Collective analysis of 132 approved drugs and 
their NP leads in 2008-2012 with respect to the 1,940 pre-2008 approved 
drugs reveals discovery trends, lead characters, and development strategies 
useful for guiding future discovery efforts. Renewed interest in NP drug 
discovery also raises an old question of what and where to explore them.  New 
clues are obtained by re-examining the 442 natural product leads of drugs 
(NPLDs) in the chemical space represented by the scaffold and substructure-
fingerprint trees of 137,836 non-redundant NPs. We derive the most 
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comprehensive distribution patterns of NPLDs in the chemical space, and 
show that NPLDs tend to cluster together in the chemical space because of 
their preferential binding to the privileged target-sites, and study the 
usefulness of these insights for NPLD discovery by a test of the recognition of 
the new NPLDs of 2013-2014 approved drugs. 
Proteins are the most important sources for therapeutic targets and 
understanding their functions is a critical step in drug target discovery. In this 
study, we build an integrative method for functional classification of a protein 
using three machine learning algorithms: Support Vector Machine, 
Probabilistic Neural Network and K-Nearest Neighbors. Up to now, 157 
protein families have been covered. Furthermore, protein-protein interaction 
(PPI) is also an interesting class of therapeutic targets, and the analysis of PPI 
networks can help for understanding of pathogenic mechanisms. A support 
vector machine model has been developed for predicting PPIs. The model is 
trained and tested by using 30,672 core PPIs from Hprd, DIP, BIND, MIPS 
and IntAct databases, and 123,034 non-PPIs representing non-PPI-containing 
Pfam protein family pairs, and further estimated by a yeast genome study. The 
estimated sensitivity and specificity are 61.6% and 91.4%. The result suggests 
that the method is potentially useful for drug target discovery and PPI network 
study. 
TTD is one of the most widely used target and drug discovery sources. For 
better serving the bench-to-clinic communities, we update TTD by adding 
search tools for using the International Classification of Disease codes to 
retrieve the target, drug and newly added biomarker information. Moreover, 
based on the data collected from this thesis, we also significantly update TTD 
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contents by expanding information of new drugs and targets. Scaffolds for 
drugs and drug leads are also included. Molfeat is another useful tool that 
developed to facilitate the drug discovery since most cheminformatics tools 
are either commercial or not easy to use. In this work, a collective web-server 
combining four kinds of analytical directions are proposed, including three 
types of methods that used in the thesis, which are molecular representation 
methods, clustering methods and classification methods, and additional 21 
















                                                                                               LIST OF TABLES 
X 
 
List of Tables 
Chapter 1 
Table 1-1 Drug design approaches for the identification of hits ...................... 8 
Table 1-2 Classification of natural product derivative drugs according to the 
classification of Newman and Cragg .............................................................. 13 
Chapter 2 
Table 2-1 Classes of feature vectors for representing proteins and peptides. 27 
Table 2-2 Classes of descriptors for representing small molecules ............... 28 
Table 2-3 Sections of fingerprints for representing small molecules ............ 30 
Table 2-4 Possible overfitting sources ........................................................... 57 
Chapter 3 
Table 3-1 Statistics of the drug targets, drugs and their structure and potency 
data in 2014 version of TTD database ............................................................ 66 
Chapter 4 
Table 4-1 Types of molecular descriptors and fingerprints in Molfeat .......... 75 
Table 4-2 Quantitative Structure-Activity Relationship (QSAR) models ...... 82 
Chapter 5 
Table 5-1 Statistics of nature-derived FDA approved drugs in 2008-2012 ... 89 
Table 5-2 Statistics of the 33 main branches of the molecular-fingerprint 
Tanimoto-coefficient similarity clustering tree of the natural product chemical 
space represented by 137,836 natural products and 442 natural product    
leads .............................................................................................................. 100 
Table 5-3 Top-ranked drug lead productive clusters with higher number of 
approved leads in the natural product chemical space represented by 137,836 
natural products and 442 natural product leads ............................................ 102 
Table 5-4 List of 20 target site superclasses and their corresponding target site 
classes with examples ................................................................................... 108 
                                                                                               LIST OF TABLES 
XI 
 
Table 5-5 Chronological data of the natural product leads with the first 
approved drugs and the drug lead productive clusters during every five-year 
period from 1963 to 2012 ............................................................................. 116 
Table 5-6 List of drugs targeting 27 “new” targets first successfully explored 
since year 1990 ............................................................................................. 116 
Table 5-7 The list of natural product derived drugs approved by FDA from 
2013 to 2014 June ......................................................................................... 121 
Chapter 6 
Table 6-1 The testing set performances of three types of models for sample 
protein families ............................................................................................. 127 
Table 6-2 The independent set performances of three types of models for 
sample protein families ................................................................................. 127 
Table 6-3 PPI databases and their brief descriptions .................................... 136 
Table 6-4 Performances of SVM models based on different parameters ..... 140 
Appendices 
Table S1 Detailed information of nature-derived small molecule drugs 
approved in year 2008-2012 ......................................................................... 167 
Table S2 Statistics of the 62 drug lead productive scaffolds in the scaffold 
hunter derived molecular scaffold trees of 134,097 natural products and 411 
natural product leads ..................................................................................... 183 
Table S3 Statistics of the 60 drug lead productive clusters in the molecular-
fingerprint Tanimoto-coefficient similarity clustering tree of the natural 
product chemical space represented by 137,836 natural products and 442 
natural product leads ..................................................................................... 201 
Table S4 List of protein families, statistics of datasets and prediction     
results ............................................................................................................ 211 
 
                                                                                              LIST OF FIGURES 
XII 
 
List of Figures 
Chapter 1 
Figure 1-1 A brief workflow of the modern rational drug discovery and 
development process......................................................................................... 4 
Figure 1-2 Overview of system-based and molecular approaches for the drug 
target discovery................................................................................................. 6 
Figure 1-3 An example of  lead discovery process ........................................ 10 
Figure 1-4 Classification of 2,173 approved drugs by FDA or similar entities 
in other countries from year 1560 to 2012 ..................................................... 12 
Chapter 2 
Figure 2-1 An example of dendrogram structure of hierarchical clustering .. 33 
Figure 2-2 K-means clustering with two classes ............................................ 36 
Figure 2-3 Extraction of meaningful ring scaffolds ....................................... 38 
Figure 2-4 Creation of branches in a hierarchical scaffold tree ..................... 38 
Figure 2-5 A procedure of the generation of  a hierarchical scaffold tree ...... 39 
Figure 2-6 An example of a hierarchical scaffold tree ................................... 40 
Figure 2-7 Maximum margin hyperplanes for a SVM trained with data points 
from two classes ............................................................................................. 42 
Figure 2-8 Different hyperplanes used to separate data points ...................... 43 
Figure 2-9 Mapping a low-dimensional input space into a higher-dimensional 
feature space ................................................................................................... 47 
Figure 2-10 An example of KNN classification ............................................. 51 
Figure 2-11 Four layers network architecture of PNN ................................... 55 
Chapter 3 
Figure 3-1 The homepage of TTD .................................................................. 68 
Figure 3-2 An example for drug information presented in the updated TTD – 
Part I ............................................................................................................... 69 
                                                                                              LIST OF FIGURES 
XIII 
 
Figure 3-3 An example for target information presented  in the updated    
TTD ................................................................................................................ 70 
Figure 3-4 An example for drug information presented in the updated TTD – 
Part II .............................................................................................................. 70 
Figure 3-5 The interface for drug scaffolds search......................................... 71 
Figure 3-6 An example for drug scaffold information presented in the updated 
TTD ................................................................................................................ 71 
Chapter 4 
Figure 4-1 The interface for molecular descriptors and fingerprints  
calculation ....................................................................................................... 75 
Figure 4-2 The interface for hierarchical clustering ....................................... 76 
Figure 4-3 The interface for K-means clustering ........................................... 77 
Figure 4-4 The interface for machine learning methods ................................ 78 
Figure 4-5 An example result page for model development .......................... 79 
Figure 4-6 The interface for making prediction ............................................. 80 
Figure 4-7 The interface for Activity prediction base on published QSAR 
models ............................................................................................................. 83 
Figure 4-8 The interface for Molfeat homepage ............................................ 84 
Chapter 5 
Figure 5-1 Distribution of the natural product leads of approved and clinical 
trial drugs in branch 5 of the Scaffold-Hunter derived molecular scaffold trees 
of the 134,097 natural products and 411 natural product leads ...................... 97 
Figure 5-2 The main branches of the MFTCS clustering tree of the 137,836 
natural products and 442 natural product leads .............................................. 99 
Figure 5-3 Distribution of the natural product leads of approved and clinical 
trial drugs in branch 3 of the substructure-fingerprint clustering tree of the 
137,836 natural products and 442 natural product leads .............................. 101 
                                                                                              LIST OF FIGURES 
XIV 
 
Figure 5-4 Distribution of the approved NP-related drugs, grouped into 45 
target-site classes (TCs) of 20 target-site super-classes (TSs), in the drug-
productive clusters DC1 to DC60 ................................................................. 113 
Figure 5-5 Distribution of the approved NP-related drugs, grouped into 
specific disease classes, in the drug-productive clusters DC1 to  DC60 ...... 119 
Chapter 6 
Figure 6-1 The homepage of SVM-Prot ....................................................... 130 
Figure 6-2 An example of SVM-Prot output page for the multiple-sequence 
submission .................................................................................................... 130 
Figure 6-3 An example of SVM-Prot output page for the single-sequence 
submission .................................................................................................... 131 
Figure 6-4 An example of top 20 similar proteins identified by BLAST..... 132 
Figure 6-5 The species distribution of positive training dataset ................... 137 
 Appendices 
Figure S1 Distribution of the natural product leads of approved and clinical 
trial drugs in branches 1-4 of the molecular scaffold trees of the 134,097 
natural products and 411 natural product leads ............................................ 225 
Figure S2 Distribution of the natural product leads of approved and clinical 
trial drugs in branches 5-8 of the molecular scaffold trees of the 134,097 
natural products and 411 natural product leads ............................................ 226 
Figure S3 Distribution of the natural product leads of approved and clinical 
trial drugs in branches 9-12 of the molecular scaffold trees of the 134,097 
natural products and 411 natural product leads ............................................ 227 
Figure S4 Distribution of the natural product leads of approved and clinical 
trial drugs in branches 13-16 of the molecular scaffold trees of the 134,097 
natural products and 411 natural product leads ............................................ 228 
Figure S5 Distribution of the natural product leads of approved and clinical 
trial drugs in branches 17-20 of the molecular scaffold trees of the 134,097 
natural products and 411 natural product leads ............................................ 229 
                                                                                              LIST OF FIGURES 
XV 
 
Figure S6 Distribution of the natural product leads of approved and clinical 
trial drugs in branches 1-9 of the molecular-fingerprint Tanimoto-coefficient 
similarity clustering tree of the 137,836 natural products and 442 natural 
product leads ................................................................................................. 230 
Figure S7 Distribution of the natural product leads of approved and clinical 
trial drugs in branches 10-18 of the molecular-fingerprint Tanimoto-
coefficient similarity clustering tree of the 137,836 natural products and 442 
natural product leads ..................................................................................... 231 
Figure S8 Distribution of the natural product leads of approved and clinical 
trial drugs in branches 19-27 of the molecular-fingerprint Tanimoto-
coefficient similarity clustering tree of the 137,836 natural products and 442 
natural product leads ..................................................................................... 232 
Figure S9 Distribution of the natural product leads of approved and clinical 
trial drugs in branches 28-33 of the molecular-fingerprint Tanimoto-
coefficient similarity clustering tree of the 137,836 natural products and 442 
natural product leads ..................................................................................... 233 
Figure S10 Distribution of the bioactive natural products (green colored lines) 
with respect to the leads of approved and clinical trial drugs (the red, purple 
and blue lines on top of the clustering tree) in branches 1-9 of the molecular-
fingerprint Tanimoto- coefficient similarity clustering tree of the 137,836 
natural products and 442 natural product leads ............................................ 234 
Figure S11 Distribution of the bioactive natural products with respect to the 
leads of approved and clinical trial drugs in branches 10-18 of the molecular-
fingerprint Tanimoto-coefficient similarity clustering tree of the 137,836 
natural products and 442 natural products and 442 natural product leads ... 235 
Figure S12 Distribution of the bioactive natural products with respect to the 
leads of approved and clinical trial drugs in branches 19-27 of the molecular-
fingerprint Tanimoto-coefficient similarity clustering tree of the 137,836 
natural products and 442 natural product leads ............................................ 236 
                                                                                              LIST OF FIGURES 
XVI 
 
Figure S13 Distribution of the bioactive natural products with respect to the 
leads of approved and clinical trial drugs in branches 28-33 of the molecular-
fingerprint Tanimoto-coefficient similarity clustering tree of the 137,836 
natural products and 442 natural products and 442 natural product leads ... 237 
Figure S14 The exploration times of the bioactive natural products (green 
colored lines on top of the clustering tree) and the leads of approved and 
clinical trial drugs (the red, purple and blue lines on top of the clustering tree) 
in branches 1-9 of the molecular-fingerprint Tanimoto-coefficient similarity 
clustering tree ............................................................................................... 238 
Figure S15 The exploration times of the bioactive natural products and the 
leads of approved and clinical trial drugs in branches 10-18 of the molecular-
fingerprint Tanimoto-coefficient similarity clustering tree .......................... 239 
Figure S16 The exploration times of the bioactive natural products and the 
leads of approved and clinical trial drugs in branches 19-27 of the molecular-
fingerprint Tanimoto-coefficient similarity clustering tree .......................... 240 
Figure S17 The exploration times of the bioactive natural products and the 
leads of approved and clinical trial drugs in branches 28-33 of the molecular-









                                                                              LIST OF ABBREVIATIONS 
XVII 
 
List of Abbreviations 
FDA Food and Drug Administration 
HTS High-Throughput Screening 
NME New Molecular Entity 
ADME Absorption, Distribution, Metabolism and Excretion 
PK Pharmacokinetic 
SAR Structure-Activity Relationship 
SPR Structure-Property Relationship 
NP Natural Products 
TTD Therapeutic Target Database 
GPCR G-Protein-Coupled Receptor 
EC Enzyme Classification 
GO Gene Ontology 
PPI Protein-Protein Interaction 
SVM Support Vector Machine 
KNN K-Nearest Neighbors 
PNN Probabilistic Neural Networks 
QSAR Quantitative Structure-Activity Relationship 
ESSSR Extended Smallest Set of Smallest Rings 
SMARTS SMiles ARbitrary Target Specification 
WCSS Within-Cluster Sum of Squares 
MMH Maximum-Margin Hyperplane 
                                                                              LIST OF ABBREVIATIONS 
XVIII 
 
QP Quadratic Programming 
RBF Radial Basis Function 




MCC Matthews Correlation Coefficient 
ATC Anatomical Therapeutic Chemical 
WHO World Health Organization 
ICD International Classification of Disease 
Molfeat Molecular Feature Server 
LTS Low-Throughput Screening 
NPLD Natural Product Leads of Drugs 
DC  Drug-Productive Cluster 
DS Drug-Productive Scaffold 
TC Target-Site Class 
TS Target-Site Super-Class 





                                                                                  LIST OF PUBLICATIONS 
XIX 
 
List of Publications 
1. Tao L, Zhu F, Qin C, Zhang C, Chen SY, Zhang P, Zhang CL, Tan CY, 
Gao CM, Chen Z, Jiang YY, Chen YZ. Clustered Distribution of Natural 
Product Drug Leads in the Chemspace Influenced by the Privileged 
Target-Sites. Submitted 
2. Tao L, Zhu F, Qin C, Zhang C, Xu F, Tan CY, Jiang YY, Chen YZ. 
Nature’s contribution to today’s pharmacopeia. Nat Biotechnol. 
32(10):979-80 (2014). 
3. Zhang C, Qin C, Tao L, Zhu F, Chen SY, Zhang P, Yang SY, Wei YQ, 
Chen YZ. A resource for facilitating the development of tools in the 
education and implementation of genomics-informed personalized 
medicine. Clin Pharmacol Ther. 2014 Jun;95(6):590-1. doi: 
10.1038/clpt.2014.39. Epub 2014 Feb 20. 
4. Qin C, Zhang C, Zhu F, Xu F, Chen SY, Zhang P, Li YH, Yang SY, Wei 
YQ, Tao L, Chen YZ. Therapeutic target database update 2014: a resource 
for targeted therapeutics. Nucleic Acids Res. 2014 Jan;42(Database 
issue):D1118-23. doi: 10.1093/nar/gkt1129. Epub 2013 Nov 21.  
5. Zhao J, Yang PY, Li F, Tao L, Ding H, Rui YC, Cao ZW, Zhang WD. 
Therapeutic effects of Astragaloside IV on myocardial injuries: multi-
target identification and network analysis. PLoS One. 2012;7(9):e44938. 
doi: 10.1371/journal.pone.0044938. Epub 2012 Sep 17. 
6. Zhu F, Ma XH, Qin C, Tao L, Liu X, Shi Z, Zhang CL, Tan CY, Chen YZ, 
Jiang YY. Drug discovery prospect from untapped species: indications 
from approved natural product drugs. PLoS One. 2012;7(7):e39782. Epub 
2012 Jul 11. 
7. Zhu F, Shi Z, Qin C, Tao L, Liu X, Xu F, Zhang L, Song Y, Liu X, Zhang 
J, Han B, Zhang P, Chen Y. Therapeutic target database update 2012: a 
resource for facilitating target-oriented drug discovery. Nucleic Acids Res. 
2012 Jan;40(Database issue):D1128-36. Epub 2011 Sep 24. 
8. Zhu F, Qin C, Tao L, Liu X, Shi Z, Ma X, Jia J, Tan Y, Cui C, Lin JS, Tan 
CY, Jiang YY,Chen YZ. Clustered patterns of species origins of nature-
                                                                                  LIST OF PUBLICATIONS 
XX 
 
derived drugs and clues for future bioprospecting. PNAS. 2011 Aug 
2;108(31):12943-8. Epub 2011 Jul 18. 
9. Liu X, Zhu F, Ma X, Tao L, Zhang J, Yang S, Wei Y, Chen YZ. The 
Therapeutic Target Database: an Internet resource for the primary targets 
of approved, clinical trial and experimental drugs. Expert Opin Ther 
Targets. 2011 Aug;15(8):903-12. Epub 2011 May 28. 
10. Ye H, Ye L, Kang H, Zhang D, Tao L, Tang K, Liu X, Zhu R, Liu Q, 
Chen YZ, Li Y, Cao Z. HIT: linking herbal active ingredients to targets. 

















                                                                          CHAPTER 1 INTRODUCTION 
1 
 
Chapter 1 Introduction 
The discovery and development of drug molecules for effective prevention or 
treatment of human diseases play critical roles in the field of medicine. 
Despite the unprecedented investment and tremendous progress in this field, 
the number of drug molecules which newly approved  by the US Food and 
Drug Administration (FDA) is still low (1). Discovering a new drug molecule 
remains a difficult task. This difficulty stems from various factors such as high 
failure rates, complexity of problems, stricter and changing regulatory rules. 
Taking advantage of modern scientific knowledge and computational 
capabilities, computational methods have now become one of the core 
approaches towards pharmaceutical research. They have been broadly applied 
to most steps in the process of drug discovery and development, including 
target discovery, lead discovery, and even preclinical trials (2-5), for 
increasing the efficiency and reducing attrition rates. According to a previous 
study, the application of computational methods could reduce the cost of drug 
discovery and development by up to 50% (6). As various kinds of new 
innovative computational approaches continue to be developed, their impact 
on drug discovery and development may undoubtedly keep on increasing. 
This thesis uses different computational methods to study therapeutically 
useful molecules. This chapter serves to introduce relevant background 
information and is divided into five sections. In Section 1.1, an overview of 
the process of drug discovery and development in pharmaceutical research is 
given. Natural products and proteins are the most important sources of drug 
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lead discovery and drug target discovery, respectively. As such, I introduce the 
role of natural products in drug lead discovery in Section 1.2, and proteins as 
drug targets in Section 1.3. Protein-protein interactions are another important 
topic for target discovery, so I describe it in Section 1.4. In the last section 
(Section 1.5), the objectives and outline of this thesis are presented. 
1.1  Overview of Drug Discovery and Development 
Drug discovery and development is typically a long and complex process that 
involves various steps. Target discovery and lead discovery are the two most 
critical steps in this process. Target discovery corresponds to target 
identification and validation while lead discovery corresponds to lead 
identification and optimization.  
1.1.1 Process of Drug Discovery and Development 
Drug discovery may be historically categorized into three important periods (7, 
8). The first period refers to the nineteenth century where drugs were mainly 
derived from medicinal plants and extracts of animal species. In this period, 
drug discovery relied mainly upon the coincidence and serendipity. The 
second period started around the early twentieth century with the discovery of 
penicillin by Alexander Fleming (9). The introduction of structure of penicillin 
began the new era of antibiotics, and greatly improved control, treatment and 
prevention of bacterial infections (10). The development of new powerful 
techniques such as combinatorial chemistry, molecular modeling, automated 
high-throughput screening (HTS), recombinant DNA technology, and the 
launch of the “Omics” revolution in the 21st century have given rise to the 
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approach of modern rational drug discovery and development, which has been 
named the third period. 
The modern rational drug discovery and development process can be broadly 
classified into three phases (Figure 1-1): research phase, clinical phase and 
applied phase. The research phase consists of target identification and 
validation, and lead identification and optimization. The clinical phase 
consists of evaluating the safety and efficacy of the new molecular entity 
(NME) that originated from the research phase, first in animal models, and 
then in human populations. Once the NME has shown therapeutic effects, it 
may be approved by medical authorities such as the FDA. The NME then be 
preceded to manufacturing and marketing. The final applied phase is consists 
of post marketing surveillance. It uses a number of approaches to monitor and 
assess the safety of approved drugs, such as prescription event monitoring, 
spontaneous reporting databases, and electronic health records (11). 




Figure 1-1 A brief workflow of the modern rational drug discovery and 
development process (8). It is a time-consuming, expensive and complex 
process with a high failure rate.  
 
The drug discovery and development process is generally recognized to be 
complex, time-consuming, costly, and most importantly, risky. According to 
the Pharmaceutical Research and Manufacturers of America, a leading 
research based pharmaceutical group, only about 250 in 5,000-10,000 
compounds may enter the preclinical testing. Out of these 250 compounds, 
only five enter human clinical trials, and finally only one succeeds. The whole 
process typically takes approximately 13 years, with an average development 
cost of more than 800 million USD (12). Therefore, increasing the efficiency 
and reducing the cost and time in this process are major goals in the modern 
drug discovery. Target discovery and lead discovery in the research phase are 
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pivotal steps in the process since they are foundations of the next two phases. 
Many studies have focused on these two steps to reach these goals. 
1.1.2 Target Discovery 
The target discovery, which involves the selection of disease model, the 
identification of disease modifying targets, and the validation of identified 
targets, is the essential first step in the drug discovery and development 
process. A drug target is a broad term which commonly used to describe a 
range of biological entities, including, for example, genes, proteins and RNAs, 
whose activities are modified by drugs, and resulting in desirable therapeutic 
effects. In addition, protein-protein interactions, biological pathways, and 
essential nodes in a regulatory system are also potential sources for targets. A 
successful target needs to be safe, efficacious, and meet the clinical and 
commercial needs. It plays a pivotal role in final outcomes of drug lead 
identification activities (13). Once the target is identified, the next step is to 
validate its critical role in disease initiation or perpetuation. The initial steps of 
target validation are usually started in vitro or in animal models. However, for 
the final validation, it should be achieved only by clinical experiments 
conducted in human. 
During the last two decades or so, many techniques have been developed and 
applied in the target identification and validation step. They can be generally 
classified into two strategies as shown in Figure 1-2: the system-based 
approach and  the molecular approach (14). 




Figure 1-2 Overview of system-based and molecular approaches for the drug 
target discovery (14). Target discovery consists of three steps: the selection of 
disease model, the identification of target and the validation of target. The 
system-based approach uses studies in clinical and in vivo to identify potential 
drug targets, whereas the molecular approach uses techniques such as 
proteomics, genomics and genetic association. During the validation, before 
passing into the step of drug discovery, the role of the target should be 
confirmed by using modulations of protein function or gene expression in both 
cell and animal models. 
 
Traditionally, the system-based approach has been the major strategy for 
target discovery. In this approach, people carry out target discovery through 
the study of diseases in a whole organism manner, and the knowledge of 
targets is mainly derived from the clinical or in vivo studies of animals. 
Currently, it still plays an important role in the treatments of certain diseases 
whose phenotypes can only be identified at the whole-organism level, such as 
heart failure, obesity, stroke, atherosclerosis, behavioural disorders, 
hypertension, neurodegenerative diseases, etc. 
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Different from the system-based approach which using the whole-genome 
study manner to understand and identify drug targets, the molecular approach 
attempts to identify drug targets by understanding the cellular mechanism. In 
this approach, studies are focusing on clinical samples or cell models which 
implicated in the interested disease, and techniques such as expression 
profiling genomics, molecular genetics and proteomics are applied. This 
approach plays the major role in modern target discovery process, and is more 
likely to be used to identify intracellular targets, such as structural, metabolic 
and regulatory proteins.  
1.1.3 Lead Discovery 
Once a potential therapeutic target has been identified, the next step for the 
drug discovery process is to develop a suitable target assay to monitor it and 
identify its modulators with adequate activity (lead identification). Leads with 
high quality lay the foundation for the development of successful clinical 
phase candidates. Therefore, the identification of leads is also the most 
important part of the drug discovery process.  
The typical process for identification of leads consists of a number of activities. 
It generally starts with the identification of new hits through the screening of a 
compound library which varies widely in size and complexity. The concept of 
a hit molecule is generally defined as a compound which exhibits the desired 
and promising activity in an intended compound screening, and its activity is  
further confirmed by retesting (15). The identification of such initial hits can 
be conducted by a number of approaches as shown in Table 1-1, depending on 
the level of available information. Therefore, in order to facilitate the 
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identification of therapeutically relevant molecules, employing alternative 
approaches for being able to tackle a variety of therapeutic targets effectively 
is very important for the hit identification (13). 















































































The screening of hits forms the basis for a lead discovery. Once a number of 
initial hits are identified using one or more screening strategies, they need to 
be characterized and evaluated thoroughly, in order to remove those which do 
not interact with the target and to define which hits are the best for 
optimization. The initial process of refinement generates dose response curves 
for each hit in the primary assay, and is then followed by a target selectivity 
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assay. Hits which are selected by previous assays are then tested by a second 
messenger assay or tissue/cell based bioassay, in order to confirm that these 
hits are able to modulate more intact systems rather than simply interacting 
with the isolated target.  Finally, remaining hits may be processed to various 
kinds of in vitro assays to measure the other important information such as 
absorption, distribution, metabolism and excretion (ADME), biological and 
physicochemical properties.  
In the above hit refinement stage, hits may be grouped into clusters or series 
simply by the visual inspection of molecule structures or using various 
clustering methods based on molecular fingerprints/descriptors, or analysis of 
ring system scaffolds. This allows the focusing of efforts on areas which hold 
the most promise. With the knowledge of potency, target selectivity, 
functional and ADME properties, those highly ranked series are then subjected 
to the hit-to-lead optimization.  The purpose of the hit-to-lead stage is to 
optimize each hit series in order to get more selective and potent compound 
analogs which possess adequate pharmacokinetic (PK) properties for 
examining their efficacies in available in vivo models (15). In this stage, the 
work consists of intensively studying the structure-activity relationship (SAR) 
or structure-property relationship (SPR) of each key analog structure, with the 
magnitude establishment of its activity and selectivity. In addition, studies of 
in vitro ADME and physicochemical properties with more detailed profiling 
are also carried out, coupled with solubility and permeability assessments. If 
any of these properties are less than expected, it is necessary to conduct 
another screening which focusing on those properties to get more compounds 
specifically. Finally, we are left with key compounds, also called leads, which 
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meet the ideal target potency and selectivity, as well as most of the ADME 
and physicochemical criteria. An example of the lead discovery process is 
shown in Figure 1-3. 
 
Figure 1-3 An example of  lead discovery process (16). Screening hits forms 
the basis of a lead discovery. A series of bioassays are conducted to evaluate 
and refine different kinds of biological, physicochemical, ADME and 
mechanistic profiles on hits. Once fully characterized hits are identified, 
iterative optimization through synthetic modification with SAR/SPR 
evaluation is carried out to generate and optimize leads. 
 
Over the past several years, there have been tremendous advances in many of 
the scientific and technological aspects of the drug discovery and development 
process. However, these remarkable advances have failed to translate into the 
introduction of more drugs to market (1). In fact, the efficiency of drug 
discovery and development has declined based on the number of drugs 
introduced to market per billion dollars spent over the course of drug 
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development (1, 17). Thus, the discovery of new drug molecules remains a 
difficult and problematic process.  
1.2  Natural Products in Drug Lead Discovery 
Nature has proven to be one of the richest sources for therapeutically useful 
compounds and plays an invaluable role in drug discovery. A natural product 
(NP) is traditionally defined as a chemical compound which produced by 
living organisms and processes biological or pharmacological activity. 
However, we note that an NP may also be synthesized and thus is chemically 
similar to its natural counterpart.  
1.2.1 Natural Products as Drug Leads 
As mentioned in Subsection 1.1.1, in the first period of drug discovery, drugs 
were mainly derived from medicinal plants and extracts of animal species. 
Before the advent of combinatorial chemistry and HTS, more than 80% of 
drug molecules were purely natural products or were inspired by the 
molecules derived from natural sources (18). During the last two decades, the 
focus of drug discovery has shifted from looking to NPs as sources to 
screening various synthetic compounds libraries using HTS. Despite this shift 
in focus, NPs and their derivatives still contribute to today’s new drugs with 
NP-related small molecule drugs representing 29.5% of the 132 FDA 
approved drugs in year 2008-2012. Collective analysis of 2,173 drugs that 
have been approved by FDA or similar entities in other countries from year 
1560 to 2012 indicates that more than half of them are NPs or NP derivatives 
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(Figure 1-4), where the classification of natural product derivative drugs is 
based on the classification of Newman and Cragg (Table 1-2)  (19). 
Anti-cancer and anti-infectives are two areas that most depend on NPs and 
their structures. Cragg and Newman estimated that over 78.6% of anti-cancer 
drugs and about 77.4% of all anti-infectives are natural product derivatives or 
inspired based on the marketed drugs from years 1940-2010 and 1981-2010, 
respectively (19). In addition, many other therapeutic areas are also 
represented by natural product derivatives, including neuropharmacological, 
cardiovascular/gastrointestinal, inflammation, and metabolic, etc. (20).   
 
Figure 1-4 Classification of 2,173 approved drugs by FDA or similar entities 
in other countries from year 1560 to 2012. More than half of approved drugs 
are natural products or natural product derivatives. 
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Table 1-2 Classification of natural product derivative drugs according to the 
classification of Newman and Cragg (19). 
Category Brief Description 
B 
biological entities, including peptides, nucleic acids, proteins 
and antibodies 
V Vaccines 
N unmodified natural products 
NB a natural botanical-defined 
ND 
derived from a natural product and is usually a semisynthetic 
modification 
S 
synthetic compounds without any relationship to a natural 
product 
S* 
made by total synthesis based on the pharmacophore from a 
natural product 
S/NM made by total synthesis inspired by a natural product 
S*/NM 
made by total synthesis inspired by the pharmacophore from a 
natural product 
 
1.2.2 Characteristics of Natural Products 
The high level of productivity in NP-based drug discovery may be related to 
the fact that chemical structures of NPs have been biologically pre-validated 
by the evolutionary selection, which selects structural prerequisites of NPs for 
interacting with proteins to aid the survival of organisms (21). NPs represent 
privileged starting points for drug discovery, and compared to synthetic 
molecules, they have quite distinct structural characteristics. Better exploration 
of distinguished physicochemical properties and biologically pre-validated 
structural scaffolds of NPs could potentially increase the success rate of 
finding more active leads. 
Compared with synthetic compounds, NPs are considered high in ‘sterical 
complexity’ and occupy a substantially distinct and larger chemical space (22). 
They usually have the tendency of containing a different molecular 
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composition, a higher number of ring systems, more chiral centers, and sp3 
hybridized bridgehead atoms, etc. (23). Studies on scaffolds in NPs and drugs 
show that NPs not only contain more scaffolds, but also have an important 
proportion of ring systems which are not exist in drugs (24). Those 
unexploited scaffolds may be new promising starting points for drug discovery. 
Nowadays there is an increasing trend to the synthesis of complex NP and NP-
like libraries using the diversity-oriented synthesis approach (25). These facts 
together with the recent public tendency of ‘coming back to nature’ are 
opening a huge window for research and attracting a number of scientists to 
explore the hidden parts of nature for searching new drug leads (26). 
1.3  Proteins in Drug Target Discovery 
Proteins are responsible for a number of the most important functions in living 
organisms, and the understanding of their functions plays a key role in the 
comprehension of the complex cellular machinery. Due to their enzymatic 
nature, proteins are generally among the preferred targets in drug discovery 
and development process. This makes the understanding of knowledge of their 
functions a critical step in any drug target discovery effort. However, the 
traditional experimental procedures for protein function prediction cannot 
keep up with the growing rate of new protein sequences which have benefitted 
from the rapid advances in genome sequencing technologies (27). This 
challenge motivates the use of computational methods to close the gap 
between the amount of sequence information and functional characterization.    
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1.3.1 Proteins as Therapeutic Targets 
Drug discovery process typically starts with the identification of suitable drug 
targets. There are only four types of macromolecule in biological systems with 
which we can interfere using therapeutic agents, they are proteins, nucleic 
acids, lipids and polysaccharides (28). Among them, proteins are the most 
important source of therapeutic targets for drug discovery and development. 
By 2011, they comprised 32% of new drugs approved by the FDA (29).  
The Human Genome Project suggests that there are about 23,500 genes (30), 
and the number of proteins is likely to be much higher due to alternative 
splicing of genes and post-translational modification of proteins. Many of 
these proteins are potential therapeutic targets for the drug intervention to 
control diseases or injuries; popular estimates are in the range of 5,000 to 
10,000 (10). Currently, drugs on the market mediate their therapeutic effects 
through only a relatively limited number of protein targets. The estimated 
number of current human drug targets ranges from 200 to 500 based on 
previous studies (28, 31, 32). The Therapeutic Target Database (TTD) which 
developed by our group collected 388 successful, 461 clinical trial and 1,331 
research targets, with 3,147 clinical trial and 14,853 experimental drugs (33) 
in its 2014 update.  
In 2002, Hopkins and Groom proposed a concept of ‘druggable genome’. In 
their work, they estimated that 130 protein families represent the known drug 
targets, which cover only about 10% of all the genes in the human genome 
(28). Since then, many studies have been conducted on this topic, and have led 
to the finding that the majority of protein targets simply fall into a small 
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number of protein families like enzymes, G-protein-coupled receptors 
(GPCRs), protein kinases, ion channels, proteases, nuclear hormone receptors, 
and phosphodiesterases (28, 34). However, this finding is assessed based on 
the currently available molecular targets. So it is important to keep in mind 
that protein families not currently known to be druggable, can still yield novel 
targets. 
1.3.2 Gap between Protein Sequence and Function  
Since the successful completion of the Human Genome Project in 2003, there 
has been an explosion in the number and diversity of genome sequences due to 
advances in genetic sequencing technology, from the old Sanger sequencing to 
the new Next-Generation Sequencing. Besides a few thousand ongoing 
genome projects, there are nine hundred or so that are complete, and 
collectively yield over 13 million protein sequences (35), we now have 
unprecedented access to a large number of potential therapeutic targets.   
However, there is a large gap between the amount of protein sequence 
information and those that are characterized functionally. For example, more 
than half of the proteins in Homo Sapiens, likewise about one-third of the 
proteins in the Saccharomyces Cerevisiae, are uncharacterized (36).  In the 
UNIPROT database (37), only 1% of the proteins have experimental 
annotations, 64% carry inferred annotations, and the remaining 35% are 
unannotated, and are labeled as “hypothetical”, “putative”, “uncharacterized”, 
or “unknown function” (35). Moreover, for those proteins which carry inferred 
annotations, their annotations are not always accurate. Therefore, it is critical 
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to improve the coverage and accuracy of protein function prediction using 
both experimental and computational methods. 
1.3.3 Protein Function Prediction  
The experimental approaches including targeted mutations, gene knockout, 
and gene expression inhibition (38), were the major methods used for 
predicting protein function in the early time, and usually focused only on a 
specific target protein, or a small set of protein complexes. However, 
regardless of the details, these approaches are always facing low throughput 
problem because of huge human efforts required in just analyzing a single 
protein or complex. As the number of sequenced genomes increases rapidly, 
the understanding of these genomes becomes more and more important. 
Nowadays, a number of high-throughput experimental approaches have been 
developed to study the mechanisms, and these approaches lead to the 
understanding of proteins’ functions with different types of insights, such as 
gene expression data sets (39-41) and protein-protein interactions (42).  
However, all these experimental approaches are time-consuming and 
expensive, so increasing efforts are directed at the development of 
computational tools for protein function prediction (43-46). Based on the huge 
amount of experimental data that has accumulated over the years, various 
computational methods have been developed. The simplest way to predict the 
function of an unannotated sequence is to find its obvious homologues which 
are well characterized (47-49). However, sequence homology prediction has 
limitations. Firstly, databases do not always contain such close relatives. 
Secondly, annotations which extrapolated from the sequence similarity are 
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prone to produce errors (50, 51). Hence, to complement those traditional 
sequence similarity-based methods, separated or integrative approaches based 
on a structure-based approach (52), evolutionary analysis (53, 54), 
protein/gene fusion (55, 56), phylogenetic profile (57-59), protein interaction 
(60-62), family classification by sequence clustering (63, 64) and machine 
learning methods (65) can be applied to the prediction. All these approaches 
can provide valuable hints for protein function prediction. 
Protein function annotations have been steadily accumulating over the years. 
Up to now, a large number of databases have been created to provide scientific 
communities with comprehensive and freely accessible resources of protein 
sequences with functional information. Among them, Swiss-Prot (66) is a very 
standardized and professionally maintained protein function database. Besides 
these databases, many sequence pattern databases have also been developed, 
such as Pfam (67), Prosite (68), and Prints (69). For standardizing the protein 
function annotation and to facilitate computation, several classification 
systems have been proposed. The earliest classification system is the Enzyme 
Classification (EC) which proposed by the International Union of 
Biochemistry and Molecular Biology (70). The Munich Information Center for 
Protein Sequence functional catalog (71) is also a well-accepted classification 
system. However, the most commonly used functional classification is the 
Gene Ontology (GO) (72). At the highest level, GO provides three hierarchical 
classifications: molecular function ontology, biological process and cellular 
component, each of which addresses a different aspect of a protein’s function. 
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1.4  Protein-Protein Interactions to Drug Target 
Discovery 
Protein-Protein interactions (PPIs) appear in most biological processes of 
living organisms, such as embryogenesis, signal transduction pathways, 
metabolism, homeostasis and proliferation. Therefore, such interactions are 
most likely to be closely related to disease states across a wide range of 
therapeutic areas, and attract a growing number of pharmacological studies. 
They constitute one of the next most interesting classes of therapeutic targets. 
In addition, the study of PPI networks can greatly contribute to the 
understanding of living systems in general, particularly in pathology, and can 
further provide useful clues for the target discovery.  
1.4.1 Protein-Protein Interactions as Therapeutic Targets 
It has been revealed that over 80% of proteins do not carry out their function 
alone but in complexes (73). PPIs are the most important type of interactions 
which involved in virtually all cellular processes and affect their outcomes. 
According to their contrasting functional and structural characteristics, PPIs 
may be classified into different types. Depending on the basis of their contact 
surfaces, they can be characterized as homo-oligomers or hetero-oligomers; 
regarding their stabilities, they can be classified into obligate or nonobligate; 
concerning their strengths, they can be permanent or transient. The type of a 
PPI can be a combination of these three specific type pairs. The permanent 
interactions form stable protein complexes as subunits, while transient 
interactions can form signaling pathways. There is much interest in targeting 
                                                                          CHAPTER 1 INTRODUCTION 
20 
 
interfaces among interacting proteins for therapeutic purposes with small 
molecules. Many efforts have been devoted to finding ways to exploit PPIs as 
drug targets and the results have been shown promising. Maraviroc, an CCR5-
gp120 interaction inhibitor, Titrobifan, an glycoprotein IIb/IIIa inhibitor, are 
successfully developed and approved as anti HIV and cardiovascular drugs, 
respectively (74). The development of inhibitors for MDM2-p53 interaction is 
also a good example. To date, at least three compounds have been advanced 
into early clinical development (74, 75).  
However, there are a number of challenges for targeting PPIs due to their 
intrinsic characteristics, some of which include: (I) contact surfaces of PPIs 
are large compared with those of protein-small-molecular interactions, (II)  
contact surfaces of PPIs are often flat which lack the grooves and pockets for 
binding small molecules, (III) contact surfaces of PPIs are not contiguous in 
the protein sequence, and (IV) unlike enzymes and GPCRs which have natural 
partners, PPIs  are lack of natural substrates or ligands (76). To tackle these 
challenges, many new approaches and concepts have been proposed. Clackson 
and Wells raised the concept of ‘Hot spots’ and described that there is a 
central hydrophobic region within a protein-protein interface which is 
responsible for much of free energy, and these ‘Hot spots’ enable the binding 
of a range of structurally diverse partners to the same proteins (77). Therefore, 
fragment-based methods are developed to target these ‘Hot spots’  for 
inducing adaptive changes (78). Besides ‘Hot spots’, there is a finding that 
many interactions involve a continuous epitope with a well-defined groove or 
small pockets (79). Such observation has stimulated the development of 
stapled peptides approaches to modulate interfaces (80). Moreover,  other 
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approaches such as alternatives of competitive inhibition assay and the use of 
antibodies also have been developed to enable small molecule discovery for 
targeting PPIs (81). All these new advances in the technological field expand 
the range for finding new therapeutics that modulate PPIs.  
1.4.2 Network Analysis of Protein-Protein Interactions 
Biological systems are made up of large numbers of different components 
which interacting at various scales. The mechanisms of many prevalent 
diseases such as cancer, diabetes and metabolic disorders are very complex, 
and their pathogeneses are related to multiple genetic and environmental 
factors. A network perspective of the system is therefore extremely important. 
PPI networks are increasingly being studied and serving as tools for 
understanding of pathogenic mechanisms that trigger the onset and 
progression of diseases (82). A PPI network can be represented as a network 
of proteins which are connected by interactions, where proteins are 
represented as nodes, and interactions are represented as edges. To exploit the 
useful information from PPI networks, the graph theory usually employed. It 
provides a means of analysis that ranks the importance or centrality of nodes 
within a network, using centrality measures such as degree centrality, 
closeness centrality, between-ness centrality, and eigenvector centrality (83). 
There are many applications for PPI networks to disease related studies, 
including studying network properties, identifying disease related sub-
networks, and identifying important disease-related proteins. 
However, the construction of PPI networks should be supported by 
experimental and computational techniques. Construction of accurate 
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networks at a large scale is still the bottleneck in this approach, since complete 
PPI data may not always be available for all components, and hence gaps can 
exist. Both experimental and computational PPI prediction methods play key 
roles for reconstructing PPI networks. 
1.4.3 Protein-Protein Interaction Prediction 
A number of experimental approaches have been used for investigating PPIs 
(84-87). These include yeast two-hybrid systems (86, 88), protein complex 
purification by using mass spectrometry (89, 90), protein chip (91), correlated 
messenger RNA expression profiles (92) and genetic interaction data (93). 
These experimental methods are labor-intensive, time-consuming, expensive 
and suffering from high rates of both false positive and false negative 
prediction (94, 95), which makes it unfeasible to construct whole protein 
interaction maps by only experimental studies. In the meantime, efforts have 
also been directed at exploring computational methods for predicting PPIs to 
help validate and extend experimentally derived protein interaction maps. On 
the other hand, experimental PPI databases, such as DIP (96), MINT (97), 
BIND (98), Hprd (99) and IntAct (100), catalog the data gained by previous 
experimental techniques to serve researchers dealing with protein interactions 
and also facilitate the PPI prediction using computational approaches. 
Over the past few years, a large number of computational methods have been 
developed for PPI prediction, which utilize information that from various 
sources at different levels. These computational methods can be roughly 
separated into three broad groups. The first infers functional association by 
using phylogenetic profiles (101-104), gene ontology and annotations (105), 
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gene order conservation (106), and gene fusion events (55, 56). The second 
determines PPIs by analyzing such genomic and structural properties as 
multiple genomic features (107), surface profiles (108, 109), sequence patterns 
and structural relationships (110-112), and protein-protein docking (113, 114). 
The third predicts PPIs from protein sequence-derived properties (61, 115-117) 
and signatures (118-121). Moreover, integrative approaches have also been 
introduced to predict PPIs from multiple profiles (87). However, so far, all 
three types of computational methods suffer from high false positive 
identification rates, and none of them are able to construct a complete PPI map 
by scanning genome sequences data. 
1.5  Objectives and Outline of This Thesis 
1.5.1 Objectives 
The purpose of this thesis is to use computational methods to study the 
therapeutically relevant molecules, and finally aid the drug discovery process. 
This objective may be divided into three sub-objectives, each related to a 
certain aspect of drug discovery, as follows: 
1. Collection of disease, drug and target-related data and integration of 
various computational analysis methods. The data is further used to 
update the Therapeutic Target Database while the analysis methods are 
used to develop an integrative software (Molecular Feature Server) for 
small molecules analysis. 
2. Analysis of natural products and drugs in different development and 
clinical stages, in an attempt to reveal the discovery trends, lead 
                                                                          CHAPTER 1 INTRODUCTION 
24 
 
characters, development strategies and distribution patterns in chemical 
space of natural product derivative drugs. This should guide future drug 
lead discovery. 
3. Using machine-learning methods with new strategies in the construction 
of putative negative samples to enhance the prediction of protein 
functional families and their interactions for facilitating target discovery. 
1.5.2 Outline 
Chapter 1, an overview of drug discovery and development process in current 
pharmaceutical research is given at first, and then followed by introductions of 
roles of two therapeutically relevant molecules as NPs and proteins with three 
sections: (1) NPs for drug leads discovery, (2) proteins for drug targets 
discovery, and (3) PPIs for drug targets discovery.   
Chapter 2, four types of computational methodologies that are commonly 
used in this thesis are introduced: (1) molecule representation methods which 
include features for proteins and peptides, descriptors and fingerprints for 
small molecules, (2) clustering methods including hierarchical clustering, K-
means clustering and hierarchical scaffold clustering, and (3) classification 
methods including support vector machine, k-nearest neighbors and 
probabilistic neural networks. The strategy for model validation is also 
introduced. 
Chapter 3, this chapter is related to the data collection of therapeutically 
relevant molecules for this thesis. In addition, the work of implementing the 
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TTD 2014 update for better serving the bench-to-clinic communities is 
described. 
Chapter 4, this chapter describes the work of integrating various kinds of 
computational methods for small molecules analysis which are used in this 
thesis, and how to develop them as a web server (Molecular Feature Server) 
with a user-friendly manner. 
Chapter 5, two studies related to NPs are introduced. The first study discusses 
nature’s contribution in today’s new drugs discovery and attempts to reveal 
the discovery trends, lead characters, and development strategies. The second 
study attempts to find the distribution patterns of NP leads of drugs in the NP 
chemical space using clustering methods, and provide useful clues for future 
NP drug leads discovery. 
Chapter 6, there are two studies described in this chapter, related to the target 
proteins. The development of an integrative approach combining support 
vector machine, probabilistic neural networks and K-nearest neighbors for 
predicting functional protein classes is demonstrated at first, followed by the 
introduction of PPI prediction using support vector machine with a new 
strategy for constructing non-PPIs. Both studies are using amino acid 
sequence as input. 
Chapter 7, major findings and contributions of the work are summarized. 
Suggestions for future work are also made in this chapter. 
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Chapter 2 Background Computational Methods 
In this chapter, I introduce three types of computational methodologies which 
applied in this thesis. Section 2.1 introduces molecular representation methods 
where three methods are described. They are features representation for 
proteins and peptides, descriptors representation for small molecules, and 
fingerprints representation for small molecules. Section 2.2 focuses on 
methods used for clustering which include hierarchical clustering, K-means 
clustering, and hierarchical scaffold clustering. In the last section (Section 2.3), 
three classification methods are discussed. These three methods are: support 
vector machine (SVM), K-nearest neighbors (KNN), and probabilistic neural 
networks (PNN). Moreover, strategies for performances evaluation and 
problems such as overfitting that related to the classification are discussed in 
the end of this section. 
2.1 Molecular Representation Methods 
Many contemporary analysis approaches or applications in the computer-aided 
drug discovery and cheminformatics fields depend on the representation of 
molecules. Such approaches or applications include diversity analysis, 
clustering analysis and virtual screening. Molecular representation methods 
capture the inherent characteristics and properties or molecules, and which 
could be categorical, binary or continuous. In this thesis, we use features 
derived from amino acid sequence to represent proteins and peptides, 
molecular descriptors and fingerprints to represent small molecules. 
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2.1.1 Features for Proteins and Peptides 
The representation of proteins and peptides by amino acid sequence derived 
physicochemical and structural features is a highly useful method. It has been 
widely used in the development of statistical learning models for predicting 
such as protein-protein interactions (61, 122), protein structural and functional 
classes (123, 124), and sub-cellular locations (125).  
In this thesis, a 188-dimensional feature vector of each protein is computed by 
our in-house software. This feature vector is formed using encoded 
representations of tabulated amino acid residue properties as nine classes for 
each residue in the protein sequence (Table 2-1).  
Table 2-1 Classes of feature vectors for representing proteins and peptides. 
Symbol Feature Class 
No. of Features in 
Class 
1 Amino acid composition 20 
2 Hydrophobicity 21 
3 Van der Waals volume 21 
4 Polarity 21 
5 Polarizability 21 
6 Charge 21 
7 Surface Tension 21 
8 Secondary structure 21 
9 Solvent accessibility 21 
Total: 188 
 
2.1.2 Molecular Descriptors 
The molecular descriptor can be defined as a final result of a logic and 
mathematical procedure, where the chemical information is represented in a 
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useful value or number for a property in consideration. It quantitatively 
represents physicochemical and structural characteristics or features of a 
molecule, and has been widely used to develop statistical models, such as 
SVM and Quantitative Structure-Activity Relationship (QSAR). 
Each molecular representation represents a different way to look at the 
molecular structure and its chemical meaning. Currently, there are more than 
3,700 types of molecular descriptors, which are broadly classified into three 
classes according to their dimensionality: 1D-, 2D- and 3D-descriptors which 
encode the chemical composition, topology, 3D shape and functionality, 
respectively (126, 127). Here, we select 98 1D and 2D descriptors from 594 
descriptors computed by our software (Table 2-2), and these descriptors have 
been successfully used in our previous studies for developing virtual screening 
models of a variety of target classes including GPCR ligands to screen large 
chemical libraries such as Pubchem compounds (128-130). 











no. of C, N, O, P, S, no. of total atoms, no. of 
rings, no. of bonds, no. of non-H bonds, MW, 
no. of rotatable bonds, no. of H-bond donors, 
no. of H-bond acceptors, no. of 5-member 
aromatic rings, no. of 6-member aromatic 
rings, no. of N heterocyclic rings, no. of O 




Sanderson electronegativity, molecular 
polarizability, aLogp 







Schultz molecular topological index, Gutman 
molecular topological index, Wiener index, 
Harary index, gravitational topological index, 
molecular path count of length 1-6, total path 
count, Balaban index J, 0-2nd valence 
connectivity index, 0-2nd order delta chi 
index, Pogliani index, 0-2nd solvation 
connectivity index, 1-3rd order Kier shape 
index, 1-3rd order kappa alpha shape index, 
Kier molecular flexibility index, topological 
radius, graph-theoretical shape coefficient, 





sum of estate of atom type sCH3, dCH2, 
ssCH2, dsCH, aaCH, sssCH, dssC, aasC, 
aaaC, sssC, sNH3, sNH2, ssNH2, dNH, 
ssNH, aaNH, dsN, aaN, sssN, ddsN, aOH, 
sOH, ssO, sSH; sum of estate of all heavy 
atoms, all C atoms, all hetero atoms; sum of 
estate of H-bond acceptors; sum of H estate 
of atom type HsOH, HdNH, HsSH, HsNH2, 
HssNH, HaaNH, HtCH, HdCH2, HdsCH, 
HaaCH, HCsats, HCsatu, Havin; sum of H 
estate of H-bond donors 
Total: 98 
 
2.1.3 Molecular Fingerprints 
The molecular fingerprint is an ordered list of binary (1/0) bits that represent a 
Boolean determination of the presence or absence of particular substructures 
in a chemical structure. Because of its properties such as computational 
efficiency, easy to use, and often surprising effectiveness in active molecule 
identifications (131), it is widely used in computational research fields such as 
medicinal chemistry, and also acts as a popular tool for the similarity 
searching in chemical database mining (132) and virtual screening (133). 
Various type of fingerprints now are available with different designs, 
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including substructure (134), extended connectivity (135), pharmacophore 
(136), and molecular property fingerprints (131, 136).  In this thesis, a 881-bits 
Pubchem fingerprint is computed by Padel software (137) and shown in Table 
2-3. 
Table 2-3 Sections of fingerprints for representing small molecules. 
Bit substructure section 
No. of bits in 
section 
Hierarchic Element Counts 115 
Rings in a canonic ESSSR ring set 148 
Simple atom pairs 64 
Simple atom nearest neighbors 89 
Detailed atom neighborhoods 44 
Simple SMARTS patterns 253 
Complex SMARTS patterns 168 
Total:881 
 
The description for each section is shown as blow: 
 section hierarchic element counts tests for the presence or count of 
individual chemical atoms represented by their atomic symbol. 
 section rings in a canonic Extended Smallest Set of Smallest Rings 
(ESSSR) ring set tests for the presence or count of the described 
chemical ring system. 
 section simple atom pairs tests for the presence of patterns of bonded 
atom pairs. 
 section simple atom nearest neighbors tests for the presence of atom 
nearest neighbor patterns.  
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 section detailed atom neighborhoods tests for the presence of detailed 
atom neighborhood patterns. 
 section simple SMiles ARbitrary Target Specification (SMARTS) 
patterns tests for the presence of simple SMARTS patterns.  
 section complex SMARTS patterns tests for the presence of complex 
SMARTS patterns.  
2.2 Clustering Methods 
In past few decades, more and more data are produced and deposited from 
various sources. Scientists are always facing the difficulties of interpreting 
these data. Therefore, the need for extracting the information from these big 
raw data is highly in demand. One approach to resolve these difficulties is 
using cluster analysis. The cluster analysis tries to cluster a large set of data 
points into a number of groups where data points in the same group are more 
similar to each other than to those in other groups, so as to simplify the data 
for analysis. This strategy has been used in many fields, such as machine 
learning, pattern recognition, information retrieval, and bioinformatics. 
There are a number of clustering algorithms have been developed to perform 
the cluster analysis. The selection of appropriate clustering method and the 
setting of various parameters depend on the individual dataset and the use of 
results intended.  Typical cluster methods include: connectivity based, 
partition based, distribution based, density based, subspace based, group based 
and graph-based clustering. However, the cluster analysis is not an automatic 
task, but an iterative process of knowledge discovery. It may often be 
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necessary to check and modify the data preprocessing and model parameters 
until the final result achieves the desired properties. In this thesis, two basic 
types of connectivity based (hierarchical) and partition based (K-means) 
clustering methods and one hierarchical scaffold clustering method which is 
based on explicit topological chemical graphs are applied. 
2.2.1 Hierarchical Clustering 
The concept of hierarchical clustering is based on the idea that data points are 
more related to nearby ones than to those farther away. The clustering 
algorithm connects data points to form clusters using distances among each 
other.  Here, a final cluster is represented largely upon the maximum distance 
of data points, where different clusters form at different distances. So the 
algorithm of hierarchical clustering does not provide users a simple 
partitioning of the dataset, but instead provides an extensive hierarchy of 
clusters that merge with each other at certain distances. The final cluster 
obtained is represented like a ‘tree’ with many branches and leafs. By cutting 
the tree at a desired level, a clustering of data points with disjoint groups (sub-
clusters) can be obtained. As shown in Figure 2-1, the X-axis shows data 
points which are placed along it, while the Y-axis are the distance at which the 
clusters merge. 




Figure 2-1 An example of dendrogram structure of hierarchical clustering. 
The X-axis shows data points which are placed along it, while the Y-axis are 
the distance at which the clusters merge. The molecular similarity cutoff is 
typically set at 0.85 in Tanimoto coefficient, at which small molecules show 
significantly similar structures. 
 
Hierarchical clustering can be implemented by either merging smaller clusters 
into larger ones (bottom up), or by splitting larger clusters into smaller ones 
(top down).  These two clustering methods differ in the strategies on deciding 
which two small clusters should be merged together or which large cluster 
should be split. In order to decide which clusters should be combined or split, 
a dissimilarity measure between sets of observations is required. In most cases, 
it is achieved by the use of an appropriate distance metric, and a linkage 
criterion which specifies the dissimilarity of set as a function of the pairwise 
distances between observations in the dataset. 
 The selection of an appropriate distance metric may influence the structure of 
the clusters, as some data points may be close to one another according to one 
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distance metric but farther away according to another. Euclidean distance, 
Tanimoto distance, Manhattan distance, Maximum distance and Cosine 
similarity are some commonly used metrics for the hierarchical clustering. In 
this thesis, we use Tanimoto distance as the metric distance for hierarchical 
clustering.  If 1 2( , ,..., )na a a a  and 1 2( , ,..., )nb b b b  are two data points in 
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The distances between sets of groups are given by the linkage criteria. The 
commonly used linkage criteria between two sets of groups are shown as 
follows: 
 Single linkage: min{ ( , ) : , }d a b a A b B   
 Complete linkage:  max{ ( , ) : , }d a b a A b B   
 Average linkage:  
1
( , )
a A b B
d a b
A B  
  
The single linkage criterion defines the distance according to the distance 
between their nearest members. The complete linkage defines the distance 
between their most remote pair of members. The average linkage takes the 
average distance between all pairs of members in the two groups. Single 
linkage can lead to a lot of singleton clusters, and clusters that look string-like 
in high dimensions. Complete linkage tends to lead to more compact spherical 
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structures. Average linkage is between single and complete linkage, in terms 
of the type of clusters it outputs. 
2.2.2 K-means Clustering 
The classical K-means clustering is one of the simplest unsupervised and 
centroid-based machine learning method, which classes the input data space 
into a Voronoi diagram structure. Different from the hierarchical clustering, 
users should determine how many clusters to be generated at first, and then the 
algorithm of K-means can determine the size of clusters based on the data 
structure. Given a set of data points 1 2( , ,..., )nx x x , where each point is a d -
dimensional real vector, K-means clustering aims to cluster the n points into 













, where i  is the mean of points in 
iS . Due to its low computational cost and easily parallelized property, the K-
means clustering method has often been applied to solve large-scale data 
clustering problems. 
Given an initial set of k  means (1) (1)
1 ,..., km m , the algorithm proceeds by 
alternating between following two steps: 
 Assignment step: assign each data point to the cluster whose mean yields 
the least WCSS. 
2 2
( ) ( ) ( ){ : ,1 }t t ti p p i p jS x x m x m j j k          (2.2) 
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   (2.3) 
The algorithm converges when the centroid assignments no longer change. 
Euclidean distance metric is the mostly used in K-meanings clustering. If 
1 2( , ,..., )np p p p  and 1 2( , ,..., )nq q q q  are two data points, the Euclidean 







d p q q p

   (2.4) 
 Figure 2-2 briefly shows this process in action for five data points and two 
classes.  
 
Figure 2-2 K-means clustering with two classes. Suppose molecules are 
positioned on the two dimensional space. Step 1: the first two cluster centroids 
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(dark circles) are chosen randomly. Step 2: each molecule is assigned to the 
cluster associated with the closest centroid. Step 3: minimizes the within-
cluster distances from the cluster mean by moving the centroid. Step 4: repeat 
step 2 and 3 with new cluster centroids. Step 5: self-consistency check. Run 
step 2, 3 and 4 until no further changes occur. The figure is adapted from 
http://answers.oreilly.com/topic/1076-introducing-k-means-clustering/. 
 
2.2.3 Hierarchical Scaffold Clustering 
The classification and further recognition of shared chemical features which 
present in a large set of compounds are important and difficult tasks (138). It 
is known that medicinal chemists prefer clustering methods whose results are 
easy to interpret. However, traditional clustering methods which based on 
molecular representation methods such as descriptors or fingerprints are often 
abstract and theoretical, and that are difficult for medicinal chemists to 
understand and visualize (139), so developing clustering methods which can 
efficiently navigate the chemical space and its associated biological space in a 
large dataset are in great demand. 
Hierarchical scaffold clustering (138, 140) based on explicit topological 
chemical graphs is a fast and straight forward algorithm for clustering 
compounds. The concept of using a scaffold as a core structure for 
characterizing a group of individual molecules has a long tradition in 
chemistry (141). Experimental results show that molecules share same 
scaffold also share common biological properties. As ring based linkages are 
the most important structural features for drug molecules, using ring system 
scaffolds to visualize chemical classes is widely accepted by the medicinal 
chemists (138).  
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The algorithm of hierarchical scaffold clustering rapidly extracts all possible 
chemically meaningful ring scaffolds within a compound dataset by removing 
all terminal side chains at first (Figure 2-3).  
 
Figure 2-3 Extraction of meaningful ring scaffolds. 
 
Then large ‘child’ scaffolds are sliced by iteratively removing one ring at a 
time to generate smaller ‘parent’ scaffolds (Figure 2-4). The order of 
removing is according to a set of rules which based on chemistry or medicinal 
chemistry, those less characteristic, peripheral rings are removed first.  
 
Figure 2-4 Creation of branches in a hierarchical scaffold tree. 
 
So for a compound dataset, once all of scaffolds are identified, they are 
grouped by shared common scaffolds, and hierarchical relationships of parents 
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and children yield branches that are combined to form a tree (Figure 2.5). For 
those scaffolds which do not exist in the compound dataset but occupying 
intermediate positions on the tree are called ‘virtual scaffolds’ and be 
constructed in silico and added.  
 
Figure 2-5 A procedure of the generation of  a hierarchical scaffold tree. 
 
Finally, a hierarchical scaffold tree is generated. The tree is shown as Figure 
2-6. 




Figure 2-6 An example of a hierarchical scaffold tree. 
 
2.3 Classification Methods 
In the terminology of machine learning, classification is considered as an 
instance of supervised learning. It is the machine learning task which try to 
infer a function from the labeled training data which can then be applied 
speculatively to generate an output for previously unseen inputs (142). 
Currently, a wide range of supervised learning algorithms is available, and has 
been used to great effect in numerous bioinformatics and biomedical research 
fields.  
In the following sections, three supervised learning algorithms used in this 
thesis are introduced, including support vector machine, K-nearest neighbors, 
and probabilistic neural networks. 
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2.3.1 Support Vector Machine 
SVM is based on the structure risk minimization principle which was 
originally invented by Vladimir N. Vapnik in 1995 (143). In linearly separable 
cases, SVM draws a hyperplane which separates two classes of data points 
with a maximum margin. The unlabeled data points are then classified by 
placing them onto this input space to recognize the classification label based 
on their relative positions to the hyperplane. As real world problems appear 
most likely in the non-linear forms, SVM can be extended by applying kernel 
tricks to maximum-margin hyperplanes (MMH). This allows the algorithm to 
map the data points from non-separable low-dimensional input space to a 
higher-dimension feature space where the training data points can be linearly 
separated. The special character of SVM is that it contracts a hyperplane to 
separate two categories of dataset, and minimizes the empirical classification 
error with maximizes the geometric margin, simultaneously.  
SVM has strong theoretical foundations and a good generalization capability, 
over the past years, SVM has attracted much attention and been successfully 
applied to a wide range of real-world problems, including hand-written digit 
recognition (144), tone recognition (145), image classification (146), as well 
as broad fields in biology, such as protein function prediction (65, 147), 
protein-protein interaction prediction (61, 148), protein-ligand binding sites 
(149), etc. In our study, SVM is the primary method we used, so we discuss its 
algorithm with more details. 




Suppose we have some given data points each belongs to one of the two 
classes, SVM aims to separate the data points with the maximum hyperplane, 
and according to which side those new instances locate, we can easily 
determine which class they belong to (Figure 2-7).  
 
Figure 2-7 Maximum margin hyperplanes for a SVM trained with data points 
from two classes. Data points on the margin are called support vectors. 
 
Mathematically, the data points are composed of n examples; each labeled as 
belonging to one of two classes under the same probability distribution
( , )P x y , denoted as 1 2{( , ), , ( , )}n nx y x y  , where 
N
ix R is the n-
dimensional real vector and { 1, 1}iy     indicates its corresponding class 
label. For separating data points of one class (positive points) from those of 
the other ones (negative points), a hyperplane can be drawn as a set of points 
satisfying 0w x b   , where w  is the slope and b is the bias. Moreover, two 
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hyperplances can also be selected in a way that they separate the data points 
and there are no points between them. The region bounded them is called the 
margin. These two hyperplanes can be described as 1w x b    and 
1w x b    .  
Geometrically, all the data points are divided into two regions by a hyperplane. 
As shown in Figure 2-8. However, there are numerous hyperplanes that can 
be drawn. The objective of SVM is to choose the “optimal” hyperplane. As all 
new data points are supposed to be located under the similar distribution as 
training data points, the hyperplane should be chosen such that small shifts of 
data do not result in fluctuations to predicted results. Therefore, the best 
hyperplane is the one that separates data points of two classes with the largest 
margin, which is expected to possess the best generalization performance. 
Such hyperplane is called the MMH.  
 
Figure 2-8 Different hyperplanes used to separate data points. Both two 
sample hyperplances (gray lines and brown dashed lines) can separate the data 
points, but only hyperplances represented by gray lines separate them with the 
maximum margin.  




The data points locating on the margins are called support vectors; whose 
presentation determines the location of hyperplane. MMH could thus be 
represented by a linear combination of support vectors. The margin ( , )i w b of 
a training dataset ix is defined as the distance between the hyperplane and ix : 
( , ) ( )i iw b y w x b        (2.5) 
As we have to prevent data points from falling into the margin, for a set of 
vectors 1{ , , }nS x x , the objective function of SVM changes to minimize 
the distance between the hyperplane to all the vectors in S : 
{ | 1} { | 1}
( , ) ( , )min min max
i
S i
x S x y x y
w x w x





    (2.6) 
So the MMH is the solution to the optimization problem of maximizing
( , )w b , subject to ( , ) 0w b   and 
2
1w  , which is an equivalent 
statement of the problem of minimizing 
21
2
w , subject to: 
( ) 1i iy w x b    (2.7) 
This optimization problem can be efficiently solved by the Lagrange method. 
With the introduction of Lagrangian multipliers 0i  , one for each of the 
inequality constraints, this gives the Lagrangian: 






[ ( ) 1]
2
n
P i i i
i
L w y w x b

      (2.8) 
This is a Quadratic Programming (QP) problem. According to the gradient of 















  (2.9) 
By substituting these two equations into Equation (2.8), the QP problem 






D i i j i j i j
i i j
L y y x x 
 









  and 0i  . 
The corresponding bias 0b  can be calculated as: 
 0 0 0{ | 1} { | 1}
1
( ) ( )
2
min max
x y x y
b w x w x
 
      (2.11) 
This QP problem could be efficiently solved through several standard 
algorithms like sequential minimization optimization or decomposition 
algorithms.  
Once 0w and 0b  are determined, the hyperplane is readily drawn. The points for 
which 0i   are called support vectors, which lie on the margins. 




If data points cannot be linearly separated, for example, there do not have a 
hyperplane to separate them, the soft margin method may be applied to this 
situation. A non-negative slack variable i  is introduced in this method, which 
measure the degree of misclassification of the data ix . 
( ) 1i i iy w x b     , 1 i n   (2.12) 











 to penalize misclassification and margin errors. 










   (2.13) 
subject to  ( ) 1i i iy w x b     , 0i  , where C is a penalty parameter 
which can be chosen by users, a larger value of C corresponding to assigning 
a stricter penalty to errors. Using Lagrange multipliers
i , the function of 




[ ( ) 1 ]
2
n n n
P i i i i i i i
i i i
L w C y w x b    
  
           (2.14) 
According to the gradient of pL , with respect to w and b vanish, result in the 
conditions: 

















 , i iC   , and , , 0i i i    . 






D i i j i j i j
i i j
L y y x x 
 
     (2.15) 








  and 0 i C  . 
Nonlinear SVM 
In addition to be applied to the linear classification, SVM can also be used to 
efficiently perform a non-linear classification by applying kernel tricks to 
MMH. The kernel machine allows the algorithm to map data points from a 
low-dimensional input space into a higher-dimensional feature space, where 
the problem can then be solved in linear forms (Figure 2-9). 
 
Figure 2-9 Mapping a low-dimensional input space into a higher-dimensional 
feature space. Kernel functions may transform data points into a higher 
dimensional space to make it possible to perform the separation. 




Let   denotes an implicit mapping function from the low-dimensional input 
space to the high-dimensional feature space F . Then all previous equations are 
transformed by substituting the input vector ix  and the inner product ( , )ix x  
with ( )ix  and kernel ( , )iK x x  respectively, where ( , ) ( ) ( )i iK x x x x  .  
Noting that the mapping function   is never explicitly computed, which 
would significantly reduce the computation load. Another advantage is that the 
feature space may be infinitely dimensional, such as in the case of Gaussian 
kernel, where the mapping function cannot be explicitly represented. A 
function could be used as a kernel function if and only if it satisfies Merce’s 
condition. Followings are well-known kernel functions: 
 Polynomial ( , ) ( , 1)
pk x z x z     
 Sigmoid ( , ) tanh( , )k x z x z      
 Radial basis function (RBF) 
2
( , ) exp( )k x z x z   , 0  . 
In this thesis, the RBF kernel is used due to its better performance than other 
kernel functions demonstrated in previous studies (130, 150, 151). For the 
SVM classification models based on the RBF kernel, two parameters C and , 
should be carefully optimized. The parameter C affects the trade-off between 
complexity and proportion of nonseparable samples. On one hand, if the factor 
C is too large, a large penalty is assigned to non-separable points, which may 
lead to store too many support vectors and thus overfitting can occur in case 
the presence of noise. On the other hand, if C is too small, which may increase 
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the number of training errors and an underfitting may occur. The  is the 
kernel parameter, it is necessary to scan a number of   values to find the best 
model, which is evaluated by their performances on classification tasks.  
2.3.2 K-Nearest Neighbor 
KNN algorithm is a non-parametric lazy learning method commonly used in 
the fields of classification and regression. It is one of the simplest machine 
learning algorithms. An important feature of KNN is lazy learning. The 
decision procedure of KNN is very simple and intuition by assuming that data 
points which are close together may share the same domain. The learned data 
points are pre-labeled while the new data points may be evaluated based on 
the similarity measure. The conclusions may be claimed on the basis of 
majority vote by the K nearest neighbors closest to the new data point, 
whereas the remaining pre-labeled data points may not be considered for 
making decision. 
As its concept simplicity, easy implementation and good performance in 
particular problems, various forms of KNN methods have been developed and 
applied in dealing with pattern recognition problems of biological information 
widely, such as the classification of protein families (152, 153), microarray 
gene expression analysis (154, 155), phosphorylation site prediction (156), the 
study of QSAR (157, 158), and the detection of myocardial infarction (159).  




The KNN algorithm assumes that the data is in a feature space ( , )i iS x y , i =1, 
2, … n, wherecis the multi-dimensional feature vector, and { 1, 1}iy     is 
associated with the observed class labels. In the training step, the algorithm 
only stores feature vectors and their corresponding class labels. Then in the 
next classification step, the algorithm of KNN constructs a local sub-region 
( )R x  of the input space, which is situated at the unlabeled data point x . Here, 
the ( )R x  contains the closest training data points to x , which is written as 
follows: 
( )( ) { | ( , ) }kR x x D x x d   (2.16) 
where 
( )kd is the k th order statistic of 1{ ( , )}
ND x x , and ( , )D x x is the distance 
metric. Many distance measures can be used in this classification, like 
Euclidean distance, Manhattan Distance, and Mahalanobis distance etc. The 
Euclidean distance shown as Equation (2.4) is the commonly used distance 
measure for continuous variables and is used in our study.  
KNN algorithm is statistically designed for the estimation of posterior 
probability ( | )P y x of the data point x : 
( | ) ( ) [ ]
( | )
( )
p x y p y k y
p y x
p x k
   (2.17) 
where [ ]k y  denotes the number of data points in region ( )R x , which is 
labeled as y . Then for a given data point x , the decision ( )g x is formulated by 
                    CHAPTER 2 BACKGROUND COMPUTATIONAL METHODS  
51 
 
evaluating the values of [ ]k y  and selecting the class that has the highest [ ]k y  
value: 
1, [ 1] [ 1]
( )
1, [ 1] [ 1]
k y k y
g x
k y k y
   
 
    
 (2.18) 
An example of KNN classification is shown as Figure 2-10. The test data 
point represented as a green circle which should be classified either to the first 
class represented as red triangles or to the second class represented as blue 
squares. Then cycles can be drawn according to the distances between the 
unlabeled green point and other labeled data points. When k is three, it is 
assigned to the first class because inside the inner solid line cycle, there are 
two triangles but only one square. When k is five, it is assigned to the second 
class since there are three squares, but only two triangles inside the outer 
dashed line cycle.     
 
Figure 2-10 An example of KNN classification. The unlabeled sample 
represented as a green circle should be classified into the class of red triangles 
if K=3. But if K=5, it belongs to the class of blue squares. 




For the parameter determination, the best k is relying on the data under 
classification. Generally, a larger value of k may reduce the effect of noises on 
the classification, but make boundaries between classes less distinctive. The 
grid searching or exhaustive searching is always an ideal approach to achieve 
a good k value. 
2.3.3 Probabilistic Neural Network 
PNN is a feed-forward and one-pass training algorithm which was first 
introduced by Donald F. Specht in early 1990s (160). It is based on well 
established statistical principles derived from Bayesian network and non-
parametric kernel based estimators of probability density functions (PDF). 
PNN trains immediately but its prediction time is very slow, and it needs a 
large amount of memory space. PNN has been widely used in the fields such 
as: pattern recognition (161, 162), protein family classification (163-166), 
protein subcellular localization prediction(167), and toxicity modeling of 
chemicals (168, 169). 
Classification Theory 
If the PDF of each of classes is known, then an unlabeled data point x  belongs 
to class “ i ” when: 
( ) ( )i jf x f x , all j i  (2.19) 
Here, parameters prior probability and misclassification cost refer to 
probability of an unlabeled data point being drawn from a particular class, and 
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cost of incorrectly classifying an unlabeled data point may be included. This 
leads to the Bayes’ optimal decision rule: 
( ) ( )i i i j j jh c f x h c f x , all j i  (2.20) 












   (2.21) 
Where n is the size of samples,   is a scaling parameter which defines the 
width of the bell curve that surrounds each sample point. ( )W d  is a weight 
function which has its largest value at 0d  . ix x  is the distance between the 
unlabeled data point and a data point in the training dataset. 
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Because of the characteristics such as well behaved, easy to calculate and 
satisfying conditions which required by the Parzen’s estimator, the Gaussian 
function is commonly used as the weight function. So the PDF for multivariate 
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Four Layers Architecture 
The Figure 2-11 displays the four layers network architecture for a PNN 
which recognizes two classes. However, this approach can also be applied to 
any number of classes. The first layer is the input layer which contains n  
nodes. It has as many nodes as the number of input features of a feature vector, 
and can provide input values to all nodes in the next pattern layer, so that each 
node of the pattern nodes can receive the complete input feature vector x . The 
second layer is the pattern layer which consists of Gaussian functions formed 
by using the given set of data points as the centers. The number of pattern 
nodes is determined by the total number of input data points in the training 
dataset, and nodes are collected into groups according to the classes of training 
set. Then all of Gaussians within a class group feed their functional values to 
the same third summation layer node for that class, and this third summation 
layer performs an average operation for each class. The fourth output layer 
performs a vote, selecting the largest value. Then the final class label is 
determined. 




Figure 2-11 Four layers network architecture of PNN.  
 
2.3.4 Model Validation 
Model validation is an essential step for the model development process. It is 
the task of demonstrating that the model is a reasonable representation of the 
actual system, and can be applied to novel data which have not been used to 
develop the prediction model (170). Using a model that does not fit the data 
well cannot be able to provide good answers to the underlying scientific 
questions under investigation.   
Performance Assessment 
Three widely used standard statistical measurements are explored, including 
sensitivity (SE), specificity (SP), and overall prediction accuracy (ACC). The 
SE represents the fraction of positives that are successfully classified. The SP 
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is the fraction of negatives that are properly classified. For the overall 
prediction accuracy (ACC), it measures the proportion of the entire number of 
predictions which are correct. The formulas to calculate these measurements 























where TP, FN, TN, and FP are the number of correctly classified positives, the 
number of positives which are incorrectly classified as negatives, the number 
of correctly classified negatives, and the number of negatives which are 
incorrectly classified as positives, respectively.  
An imbalanced data of the positive and the negative may result in a highly 
accurate value even if either its sensitivity or specificity is low. So evaluating 
a model solely based on the accuracy value is not advisable. Another 
measurement, named as Matthews correlation coefficient (MCC), is used for 
evaluating the randomness of a prediction. It accounts for true and false 
positives and negatives, and is generally regarded as a balanced measure 
which can be used even if the classes are of very different sizes. 
))()()((/)( FNTNFPTNFPTPFNTPFNFPTNTPMCC   (2.27) 
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MCC is a discrete version of Pearson’s correlation coefficient that returns a 
value between -1 and 1. Here, negative values of MCC indicate the 
disagreement between the prediction and observation, while positive values 
are regarded as the agreement. A value of zero means a random correlation. 
Overfitting Problem 
The efficacy of a model is determined by its performance on the unseen data 
but not on the training data. However, when a model tries to memorize the 
training data rather than learning to generalize from the underlying 
relationship, the problem of overfitting occurs. In this situation, the model has 
good performance in fitting known data, but it is less accurate for newly 
predicted data. There are various overfitting problems, and a non-exhaustive 
list is given in Table 2-4 (171).  
Table 2-4 Possible overfitting sources (171). 
Name How Why Remedy 
Traditional 
overfitting 
train a complex 
predictor on too 
few examples 




















features so as to 
optimize test set 
performance can 
achieve this kind 
of overfitting 
 









use a measure of 
performance 
which is especially 














use a human as 
part of a learning 
algorithm and do 
not take into 
account overfitting 
by the entire 
human/computer 
interaction 
this is subtle and 
comes in many 
forms; one 
example is a 
human using a 
clustering 
algorithm (on 





make sure test 
examples are not 




chose to report 
results on some 
subset of datasets 




data set selection 
subverts this and 










alter the problem 















Old datasets create an algorithm 




after a dataset has 
been released, 
algorithms can be 
made to perform 
well on the 












A frequently used strategy for detecting whether a model is overfitting is to 
compare two performance accuracies which determined by using the cross-
validation method and independent validation dataset (172).  A model that not 
overfitted should not have a large difference in the estimation of its predictive 
capability from the cross-validation method to the independent validation 
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dataset. In this thesis, to detect and control the overfitting problem, an 
independent dataset evaluation is an indispensable step in all our machine 
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Chapter 3 Data Collection for Therapeutically 
Relevant Molecules 
3.1 Data Collection 
Data collection is always the initial and essential step for every research work.  
Due to advancement in the field of pharmaceutical research, nowadays, there 
has been an explosion of data which related to therapeutically relevant 
molecules. However, all these data are encoded in a huge amount of research 
literatures and various websites or databases with different kinds of 
expressions and structures, so where and how to obtain sufficient and good 
quality data, further deposit and represent them are challenging tasks. 
In this work, automatic text minging methods with manual curations are 
implemented. According to the topic studied and data wanted, a number of 
PERL scripts are written to roughly parse, extract and format the useful 
information from different resources which are related to our studies, then 
manual curations are conducted to control the qulity of the data which are 
picked up.   After the data collection, how to store, organize and represent 
these data using database knowledges is also another important topic.  
3.1.1 Data of Drugs, Targets and Diseases 
The approved drugs with the information of their targets, related diseases, and 
approval years are from the literatures (173-178), FDA website, and reviews 
(e.g. Nature Biotech, Nature Rev Drug Discov, J ClinP harmacol and Drug 
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Dev Res). Clinical trial drugs are from NIH ClinicalTrial.gov website, 
CenterWatch Drugs in Clinical Trials Database, company reports (e.g. 
Astrazeneca, Amgen, Bayer, Boehringer Ingelheim, Eisai, Genentech, 
Genezyme, GSK, Idenix, Incyte, ISIS, Merck, Milennium, Novartis, Pfizer, 
Roche, Sanofi Aventis, Schering-Plough, Spectrum, Takeda, Teva), the 
Reports of Medicines in Development (biotechnology, HIV/AIDS, cancer, 
children, diabetes, infectious, neurological disorders, rare diseases, and 
women) and other literatures (e.g. Expert Opin Investig Drugs, TiPS, Drug 
Discov Today, Curr Opin Pharmacol, Curr Drug Targets, Curr Topics 
Mechem, Mini Rev Mechem). NP-related drugs are selected based on the 
literature reports (173, 174, 178) and additional literature searches with further 
verification that either their NP leads have been reported or they have been 
explicitly mentioned as NP-derived in the literatures that report their discovery.  
By further combining the data from TTD (179), we finally get 2,173 approved 
drugs (including 1,093 natural product derived drugs) with 388 approved 
targets, 3,147 clinical drugs (including 369 natural product derived drugs ) 
with 461 related targets, and more than 900 disease conditions are covered. 
The Anatomical Therapeutic Chemical (ATC) classification system 
categorizes drug substances at different level according to application area, 
therapeutic properties, chemical and pharmacological properties. It is a 
commonly used classification system for drugs, and recommended by the 
World Health Organization (WHO) for all global drug utilization studies. By 
searching the drug name in the public sources such as KEGG 
(http://www.genome.jp/kegg-bin/get_htext?br08303.keg), Drugbank (180) and 
Wiki web pages, we also collect ATC codes for 1521 approved drugs. 
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3.1.2 International Classification of Diseases 
The International Classification of Diseases (ICD) codes have been developed 
by the WHO, sponsored by the United Nations, adopted by over 110 countries 
and used by physicians, researchers, nurses, health workers, health 
information managers, policy makers, insurers and health program managers 
for defining and studying diseases, monitoring and managing health care and 
allocating resources (181, 182). ICD codes have been regularly revised to the 
current version ICD-10 (183). But the previous version ICD-9 is still used by 
some organizations while proceeding with the transition to ICD-10 (the 
expected completion date for the transition to ICD-10 in the United States is 
October 1, 2014) (184). ICD-10 is composed of 68,000 alphanumeric codes as 
compared with the 13,000 numeric codes in ICD-9, thus offering more 
comprehensive coverage and better representation of medical conditions (183). 
A number of nations have developed their own adaptations of the ICD codes. 
For instance, the United States have developed ICD-9 and ICD-10 clinical 
modification ICD-9-CM (17,000 codes) and ICD-10-CM (155,000 codes) for 
covering additional morbidity details (185), which are used in this work 
because of their more comprehensive coverage. 
Here, the ICD-9-CM and ICD-10-CM codes are matched to the collected 
target and drug entries by the following procedure: first, automated word 
match is conducted for matching the disease name or names of each target or 
drug entry with the disease descriptions of each ICD codes; second, each of 
the fully or partially matched entry is manually checked to either validate the 
match or to find the right ICD codes; third, manual search is conducted for 
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every non-matched entry. So far, we find the ICD codes for 785 targets and 
3,080 drugs related to 732 disease conditions.  
3.1.3 Data of Drug Scaffolds 
The approved and clinical trial drugs are composed of a limited number of 
molecular scaffolds (186-188) in contrast to the high number of bioactive 
molecular scaffolds (189, 190). For instance, many drugs have been derived 
from individual scaffold groups such as macrocycles (191), and 12 FDA-
approved anticancer kinase inhibitor drugs (175, 176) are grouped into three 
scaffold groups (174). Investigation and exploration of these highly privileged 
drug scaffolds are important for discovering new drug-like scaffolds, 
molecular analogs and drugs. To support the relevant efforts, we search the 
literatures for the molecular scaffolds of the approved and clinical trial drugs 
or their drug leads. By using the combination of keywords drug name or 
alternative name, ‘scaffold’, ‘discovery’, ‘synthesis’ to search the Pubchem 
database (192), we extract 210 scaffolds for 714 drugs and drug leads. 
3.2 Therapeutic Targets Database, 2014 Update 
The Therapeutic Target Database (TTD) is developed by our group for 
providing information about specific therapeutic targets, targeted disease 
conditions, and corresponding drugs (179). Since its last 2 updates, TTD has 
become a more useful target and drug discovery resource by adding more 
information such as drug combination, multi-target drugs, natural product-
derived drugs, and integrating various useful computational tools such as 
target validation and QSAR models. 
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However, modern drug development has been transferring from primarily 
focused on targeted therapeutics (31, 193, 194) to the stratified and 
personalized medicines (195-197) with an increasing movement. Extensive 
efforts from research, industry, clinical, regulatory and management 
communities and the chemistry, biology, pharmaceutics and medicine 
disciplines have been collectively directed at discovery, investigation, 
application, monitoring and management of targeted therapeutics and 
biomarkers (195, 198-201).  The knowledge of the efficacy targets and 
biomarkers is useful not only for the discovery and development of targeted 
therapeutics (202, 203) but also for facilitating the development and practice 
of stratified and personalized medicines (195, 204, 205). 
In particular, the information of targeted therapeutics and biomarkers may be 
potentially incorporated into the widely used disease classification systems for 
more refined classification of disease subclasses and patient subpopulations 
responsive to a particular treatment, so as to better facilitate the diagnosis, 
prescription, monitoring and management of patient care in stratified and 
personalized medicines. Although the information about targeted therapeutics 
and biomarkers can be obtained from the establish drug (206), efficacy target 
(207) and biomarker databases (181, 208, 209), the data retrieval tools of these 
databases are not specifically designed for optimally supporting such tasks. 
There is a need to enable data retrieval by using the widely used ICD codes 
(182, 183) for facilitating broader, more convenient and automatic data access, 
processing and exchange by the bench-to-clinic communities, particularly 
non-domain experts. 
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To better serve the multiple bench-to-clinic communities and to facilitate the 
development and practice of stratified and personalized medicines, we have 
made several major improvements to the TTD. First, we add information and 
search tools based on the ICD codes (210, 211) for searching the targets, 
biomarkers, drugs and other TTD data related to various disease conditions. 
For more extensive coverage of potential biomarkers and for enabling their 
convenient access by the ICD codes, we add a significantly higher number 
(1755) of literature-reported biomarkers for more variety of disease conditions 
(365) than those in the existing biomarker databases that primarily focus on 
molecular biomarkers of specific disease chasses (181, 208) or clinically 
prioritized sets (209). We also add information and enabled the search of TTD 
data via drug scaffold names (227 scaffolds for 736 drugs and leads) for 
facilitating the search of the drugs, targets and diseases related to specific 
molecular scaffolds. Moreover, we add the ATC Classification System codes 
for 1521 approved drugs for supporting the convenient and automated access 
of clinical drug data (212). 
We also significantly expand TTD contents to include 388 successful, 461 
clinical trial and 1,467 research targets; 2,003 approved (1,008 nature product 
derived), 3,147 clinical trial, 498 discontinued clinical trial and 14,856 
experimental drugs, 20,818 multi-target agents against 385 target-pairs and the 
activity data of 1,436 drugs against 274 cell lines. These are compared with 
the 364 successful, 286 clinical trial and 1331 research targets; 1,540 approved 
(939 natural product derived), 1,423 clinical trial, 345 discontinued clinical 
trial and 14,853 experimental drugs, and 3,681 multi-target agents active 
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against 108 target pairs in our last update (207). The statistics of our updated 
data is summarized in Table 3-1. 
Table 3-1 Statistics of the drug targets, drugs and their structure and potency 








Number of all targets 2,360 2,025 
Number of successful targets 388 364 
Number of clinical trial targets 461 286 
Number of research targets 1,467 1,331 
Statistics of 
drugs 
Number of all drugs 20,667 17,816 
Number of approved drugs (no of 





Number of clinical trial drugs (no of 





Number of discontinued drugs 498 345 
Number of pre-clinical drugs 163 165 
Number of experimental drugs 14,856 14,853 
Number of multi-target agents 20,818 3,681 






Number of small molecular drugs with 
available structure 
17,012 14,170 
Number of antisense drugs with 








Number of agents with potency data 
against target 
11,810 11,810 
Number of agents with potency data 
against a disease model such as a cell-
line, ex vivo, in vivo model 
1,753 497 
Number of quantitative structure-







This update is a team work in our group, my works are mainly focusing on 
reconstruction of the database tables, web pages redesign, drugs and targets 
information updates, drug scaffolds searching, and participating in ICD codes 
mapping for disease conditions. For the works of construction of ICD search 
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interface and collection the information of biomarkers, they are conducted by 
my lab mates, so I do not include them in this thesis. 
3.2.1 Database Access 
The TTD can be accessed at http://bidd.nus.edu.sg/group/ttd/ttd.asp. As shown 
in Figure 3-1, TTD provides 5 types of search option to access the whole 
database. Different whole database search option may list search results in 
different manners, which is designed to facilitate users with different initial 
searching information. From the TTD ‘Search drugs and targets by disease or 
ICD Identifier’ field, users can search TTD target and drug entries related to a 
specific disease or an ID-9-CM or ICD-10-CM. The search method for TTD 
biomarkers is also using this manner. Users can input a specific disease name 
in the ‘Search for biomarkers’ field or just select an ICD-9-CM or ICD-10-CM 
code for searching. For the fields ‘Search for drugs’ and ‘Search for targets’, a 
specific drug name or target name can be input respectively, or a disease name 
is acceptable for both types of search. The search process leads to the detailed 
drug or target information page with different display style. The information 
of ICD-9-CM and ICD-10-CM are linked with the disease if available. In the 
‘Search for drug scaffolds’ field, users may choose a drug scaffold name, and 
drugs with searched scaffold are listed. A list of target, drug, biomarker entries 
with the corresponding ICD-9-CM and ICD-10-CM can also be downloaded 
from the TTD download page. 




Figure 3-1 The homepage of TTD. 
 
3.2.2 Newly Updated Features 
As shown in Figure 3-2 and Figure 3-3, both ICD-09-CM and ICD-10-CM 
are integrated in the drug and target detailed information pages, which are 
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displayed right after disease conditions. Moreover, for the drug detailed 
information page, ATC codes as described in Subsection 3.1.1 and InChI, 
InChIKey, and SMILES which are collected from the PubChem database (213) 
are also provided (Figure 3-4). The updated information is indicated by red 
rectangles in figures. 
 
Figure 3-2 An example for drug information presented in the updated TTD – 
Part I. 




Figure 3-3 An example for target information presented  in the updated TTD. 
 
 
Figure 3-4 An example for drug information presented in the updated TTD – 
Part II. 
 
An interface for searching drug scaffolds is shown as Figure 3-5. By simply 
selecting a drug scaffold name, users are taken to the scaffold information 
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page. Scaffold name, drug name, lead name and drug source are displayed in 
this page (Figure 3-6). For drug name and lead name, cross-links to their 
detailed information pages on TTD and Pubchem database, respectively, are 
also provided. 
 
Figure 3-5 The interface for drug scaffolds search. 
 
 








Rencently, collective efforts from multiple bench-to-clinic communities are 
increasingly involved in the discovery and application of targeted therapeutics, 
and these efforts are starting to directed at the development of stratified and 
personalized medicines. The drug, target, biomarker and other relevant 
chemical, biological, pharmaceutical and clinical data need to be more 
integrated and be made easily accessible for the study by different bench-to-
clinic communities. These efforts may be partly facilitated by introducing into 
the relevant databases the ICD code-based data retrieval tools coupled with the 
other domain knowledge codes such as the codes of drugs (ATC codes), 
targets and biomarkers. To better serve the multiple bench-to-clinic 
communities in their collective efforts for the discovery, investigation, 
application, monitoring and management of targeted therapeutics, continuous 
efforts may be made to expand the linkage of the ICD to ATC codes to more 
complete sets of drugs, efficacy targets and biomarkers, in addition to provide 
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Chapter 4 Computational Methods Integration 
for Analysis of Therapeutically Relevant Small 
Molecules 
Bioactive small molecules play important roles in living systems. They have 
been traditionally used for studying biological systems, increasingly applied in 
chemical biology, and extensively explored as therapeutic agents. The 
accessibility of large small molecule databases has changed from exclusive in-
house databases of large pharmaceutical companies to publicly available 
sources (214). Currently, there are over 30 million  (215) of distinct small 
molecule structures are available in freely accessible databases, including 
PubChem (213), ZINC (216), CHEMBL(217), KEGG (218) and many others.  
While there are many efforts have been conducted to develop public databases 
of small molecules in recent years, to our knowledge, the number of user-
friendly and freely accessible web services which used for searching, 
analyzing and studying bioactive small molecules is limited. Thus far, most 
available development has been only focused on providing a certain direction 
of  small molecules analysis, such as Model (219), PaDEL (137) for 
computing the molecule descriptor and/or molecule fingerprints,  ChemMine 
(215), ChemBioserver (220) for chemical clustering, Weka package (221) for 
data mining tasks. Moreover, many standalone applications such as Chemistry 
Development Kit (222), Chemcal Descriptors Library (223) and JOELib (224), 
are toward computational rather than experimental scientists. Therefore, for 
efficiently analyzing small molecule resources, the development of novel 
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integrative data mining and chemoinformatic software which are freely 
accessible and with a user-friendly interface is important.  
Molecular Feature Server (Molfeat) is designed and developed to be an 
integrative web server for small molecules analysis with a user-friendly and 
freely-accessible manner. In this work, three types of computational 
methodologies (molecular representation methods, molecules clustering 
methods and molecules classification methods) which introduced in Chapter 
2, and 21 QSAR models are combined together. Excepting the software for 
SVM, other applications for those three types of methodologies are developed 
by our group and have been used in a number of published studies. For the 
software for SVM, libsvm 3.0 (http://www.csie.ntu.edu.tw/~cjlin/libsvm/) is 
employed. The QSAR models were tested by using 20-40 molecules against 
the published data.  
4.1 Integration of Computational Methods 
4.1.1 Molecular Representation Methods 
As shown in Figure 4-1, three types of molecular representation methods have 
been combined into one interface, which are molecular fingerprints, molecular 
descriptors reported in the literatures (126), and Xue molecular descriptor set. 
In this interface, users may upload their file in MOL format for individual 
molecule or SDF format for multiple molecules. Results are displayed right on 
the following result page, or users can also choose to download the result file 
with different format. Table 4-1 lists the brief introduction for these three 
types of features. 




Figure 4-1 The interface for molecular descriptors and fingerprints calculation. 
 








Hierarchic Elecment Count, Ring Sets in a 
canonic ESSSR, Simple Atom Pairs, 
Simple Atom Nearest Neighbors, Detailed 
Atom Neighborhoods, Simple SMARTS 








Constitutational Descriptors, Charge 
Descriptors, Physical chemistry properties, 
Topological Indices, Geometrical 





Simple Molecular Descriptors, Topological 
Molecular Descriptors, Quantum Chemical 
Descriptors, Geometric Molecular 
Descriptors 
 
4.1.2 Molecules Clustering Methods 
Hierarchical clustering and K-means clustering are integrated in this interface. 
Different parameters can be set according to the choice of the type of 
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clustering. As shown in Figure 4-2 and Figure 4-3, users may select a linkage 
for hierarchical clustering, set a K-value and select a distance measurement for 
K-means clustering.  In addition, for the hierarchical clustering, a Tanimoto 
coefficient cutoff can also be set to separate the cluster tree. For the K-means 
clustering, an optimal K value may be calculated automatically if users cannot 
decide the K-value by themself. Clustering results may be downloaded in the 
next result page. 
 
Figure 4-2 The interface for hierarchical clustering. 
 




Figure 4-3 The interface for K-means clustering. 
 
4.1.3 Machine Learning Methods 
In this work, we develop an interface for users to conveniently upload their 
datasets to train their own models for classifying bioactive and inactive 
molecules. We integrate three supervised machine learning methods: SVM, 
KNN and PNN, which are used in this thesis. Before developing the model, 
users should prepare at least two necessary datasets (bioactive training dataset 
and bioactive testing dataset) and one optional independent unlabeled dataset 
for prediction. For the optional unlabeled dataset, users can also provide it in 
the next prediction step. Inactive dataset can either be provided by users or 
generated by Molfeat. Preparing inactive dataset is the most important and 
challenging step in the machine learning classification. I introduce our 
strategies in the next negative dataset construction section with more details. 
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As shown in Figure 4-4, users can select a machine learning method (using 
SVM as an example), set a preferred model name or just use the model name 
(Model-323019) automatically generated by Molfeat in the first step. The 
bioactive, inactive and prediction datasets may be uploaded or set. After 
finishing these, the development process can be launched. The time for the 
model development is estimated to be several hours, and it depends on the 
sizes of the datasets uploaded. 
 
Figure 4-4 The interface for machine learning methods. 
 
Figure 4-5 shows one model development result for the SVM method. 
Molfeat is designed to be able to train a set of parameters and choose an 
optimal model according to the MCC. In addition, sensitivity, specificity and 
accuracy for the selected model are also provided for every selected model. 
Moreover, this final model is saved automatically by Molfeat and listed in the 
prediction page for next reuse. If users provide an independent dataset in the 
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model development step, then a prediction result file can be downloaded. The 
predicted type of every molecule in the independent prediction dataset and its 
probability are included in this file.  Users may also click the button “go back 
to make another prediction“ to go to the prediction page (Figure 4-6) and 
make another prediction. The developments and display styles for KNN and 
PNN are the same as SVM. 
 
Figure 4-5 An example result page for model development. 
 
The prediction page, as shown in Figure 4-6, can be directed from the result 
page of model development, or right through the model development interface 
(Figure 4-4). Here, users may upload their unlabeled dataset and choose the 
corresponding model that just now or previously generated to make the 
prediction. 




Figure 4-6 The interface for making prediction. 
 
Putative Negative Dataset Construction 
Small molecules can be grouped into families by clustering them in the 
chemical space defined by their molecular descriptors or fingerprints. As 
machine learning methods identify bioactive molecules based on their 
molecular descriptors, it makes sense to cluster as well as to represent 
molecules in terms of molecular descriptors. By using the K-means method, 
we generated 7,990 cluster families from the molecules in Pubchem database 
(192). Analogue groups such as steroids and catecholamines are distributed in 
a few families. Because of extensive efforts in searching the known compound 
libraries for identifying active compounds in these target classes, the number 
of undiscovered “active” families in Pubchem database is expected to be 
relatively small, most likely no more than several hundred families. The ratio 
of the undiscovered “active” families (hundreds on less) and the families that 
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contain no known active compound (6,000-7,000 based on current version of 
Pubchem database) for these and possibly many other target classes is 
expected to be < 15%. Therefore, putative inactive molecules can be generated 
by extracting a few representative molecules of those families that contain no 
known active molecule, with a maximum possible “wrong” family 
representation rate of < 15% even when all of the undiscovered bioactive 
molecules are misplaced into the inactive class.  
An advantage of this approach is its independence on the knowledge of known 
inactive molecules and bioactive molecules of other biochemical classes, 
which enables more expanded coverage of the “inactive” chemical space in 
cases of limited knowledge of inactive molecules and molecules of other 
biological classes. A drawback of this approach is the possible inclusion of 
some undiscovered bioactive molecules in the “inactive” class, which may 
affect the capability of machine learning methods for identifying novel 
bioactive molecules. However, as we demonstrated in the previous paragraph, 
such a negative effect is expected to be relatively small for many biochemical 
classes. 
4.1.4 Quantitative Structure-Activity Relationship Models 
21 QSAR models published by our group are integrated in this interface. 
These QSAR models cover 16 chemical types and 12 targets (Table 4-2).  
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Table 4-2 Quantitative Structure-Activity Relationship (QSAR) models. 
Target Chemical Type 
ATP-sensitive potassium 






channel opener Cromakalim analogs 
Carbonic anhydrase Benzenesulphonamide 
Carbonic anhydrase Sulfamide derivatives 
Carbonic anhydrase Water-soluble sulfonamides 
Central benzodiazepine 
receptor Pyrazolo[4,3-c]quinolin-3-ones 
Choline kinase Antiproliferative agents 
COX-1 2-acetoxyphenyl alkyl sulfides 
COX-1 Meclofenamic acid analogues 
COX-2 2,3,5-substituted tetrahydrofurans 
COX-2 2,3-diaryl pyran-4-ones 
COX-2 Diaryl furanones 
COX-2 Meclofenamic acid analogues 
COX-2 Resveratrol analogues 
HIV-1 integrase Substituted 1,3,4-oxadiazole naphthyridines 





















In this interface, as shown in Figure 4-7, only one molecule in MOL format is 
accepted for every prediction, and the input molecule must be of the same 
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chemical type as the selected QSAR model, otherwise the prediction results 
may be inaccurate. 
 
Figure 4-7 The interface for Activity prediction base on published QSAR 
models. 
 
4.2 Web Server Access 
Molfeat is accessible at http://bidd.cz3.nus.edu.sg/cgi-bin/molfeat/molfeat-
new.cgi. As shown in Figure 4-8, four types of functionalities as described in 
the Section 4.1 are integrated in the same webpage, they are:  (I) Molecular 
descriptors and fingerprints, (II) Clustering molecules, (III) Machine learning 
classification of molecules, and (IV) Activity prediction based on published 
QSAR models.  By simply clicking different banner, users can go to the 
corresponding interface and perform a specific analysis. 




Figure 4-8 The interface for Molfeat homepage. 
 




Cheminformatics tools that used for searching, analyzing and studying 
bioactive small molecules from the chemical space play an important role in 
the fields of chemical biology and drug discovery. Molfeat is an online user-
friendly and freely accessible service for small molecules analysis. This 
service is unique in that it integrates a series of cheminformatic programs with 
molecular representation, clustering, classification and activity prediction 
functionalities. One additional outstanding feature of Molfeat is that it has the 
ability to automatically generate putative inactive molecules used for machine 
learning methods. All these features coupled with the user-friendly web page 
design make it accessible to not only scientists with limited computational 
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Chapter 5 Analysis and Modeling of Therapeutic 
Agents 
5.1 Analysis of Contribution of Nature-Derived Drugs 
to Drug Discovery 
As introduced in Section 1.2, natural products (NPs) have been the richest 
sources for drug discovery. About two decades after drug discovery focus has 
shifted away from NPs
 
(173), nature still contribute to today’s new drugs (19, 
174)
 
with nature-derived small molecules constituting 29.5% of the 132 FDA 
approved drugs in year 2008-2012. Collective analysis of these drugs and their 
NP leads with respect to the 1,940 pre-2008 approved drugs can reveal 
discovery trends, lead characters, and development strategies useful for 
guiding future discovery efforts. 
5.1.1 Material and Methods 
Nature-derived approved drugs are identified as follows: The set of approved 
drugs and the year of approval are collected from the literatures (e.g. Quarterly 
and annual reports of FDA drug approval reports in Nature Biotechnology and 
Nature Reviews Drug Discovery,  reference (19) and (174)), FDA website, 
and Drugbank (206)
 
and the TTD (207).  For the 2008-2012 drugs, only new 
molecular entities are included. The initial set of approved nature-derived 
drugs are from the two recent papers (19, 174), which are evaluated against 
the approved drug set to confirm their approval status, then their nature-
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derived status is evaluated via comprehensive literature search to confirm that 
either their natural product leads have been reported or they have been 
explicitly mentioned as nature-derived in the literature that report their 
discovery. For the approved drugs not covered by the initial set of nature-
derived drugs (e.g. FDA approved drugs in year 2011-2012, some approved 
vaccines), we conduct literature search to determine whether or not they are 
nature-derived and, for the nature-derived ones, to find their natural product 
leads.  
Literature search is conducted by searching the original publications and 
review articles by using combinations of such keywords as “drug name and 
alternative names”, “discovery”, “species”, “natural product” and “nature”. 
While possible, the original articles describing the discovery and optimization 
of each drug and lead are selected. The species origin of a lead is determined 
via additional literature search based on the explicit report that the lead 
“originates from”, “derived from”, “isolated from”, or “comes from” a species 
or species-group (e.g. genus or family). The corresponding species-families of 
the host species of these drugs as well as all the known species-families in 
nature are from the NCBI taxonomy database (225). The species families that 
are in preexisting drug-productive families or drug-productive clusters were 
described in our recent publication
 
(174). 
5.1.2 Results and Discussion 
We analyz the nature-derived drugs approved by FDA in 2008-2012 (new 
molecular entities only) with respect to the pre-2008 approved drugs (all drugs 
included) (19, 174). The nature-derived drugs include small molecule NPs and 
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NP derivatives (NP semi-synthetic derivatives, mimetics, and pharmacophore-
guided synthetic molecules) and biologics of non-human sources (peptides, 
nucleic acids, proteins, and antibodies)
 
(19) with their NP leads or connection 
revealed in the literatures reporting their discovery
 
(174). Overall, 6 (4.5%), 33 
(25.0%) and 4 (3.0%) of the 132 drugs approved in 2008-2012, 12 (6.2%), 67 
(34.5%) and 12 (6.2%) of the 194 drugs in 2003-2007, 7 (2.9%), 90 (36.9%) 
and 9 (3.7%) of the 244 drugs in 1998-2002, and 216 (14.4%), 362 (24.1%) 
and 20 (1.3%) of the 1,502 drugs before 1998 are NPs, NP derivatives, and 
biologics respectively. 
 Although the number of NPs and NP derivatives has been steadily reduced 
since 1998 (97, 79 and 39 in 1998-2002, 2003-2007 and 2008-2012), their 
share of new drugs only started to decline in 2008-2012 (38.5%, 39.8%, 40.7% 
and 29.5% in pre-1998, 1998-2002, 2003-2007 and 2008-2012). The share of 
non-NP based drugs slightly declined in 1998-2007 and then rebounded in 
2008-2012 (60.2%%, 56.6%, 53.1% and 67.4% in pre-1998, 1998-2002, 2003-
2007 and 2008-2012). The share of biologics steadily increased in 1998-2007 
and then slightly reduced in 2008-2012 (1.3%, 3.7%, 6.2% and 3.0% in pre-
1998, 1998-2002, 2003-2007 and 2008-2012). 
The focus of drug discovery has moved away from NPs since the 1990s and 
non-flawed combinatorial libraries have been used since 1997
 
(173), which is 
10-15 years before the decline of the share of NPs and NP derivatives. Given 
the 10-15 year drug development time lag
 
(173), the decline is likely a 
consequence of the change of focus. Nonetheless, NPs and NP derivatives still 
represent significant share of new drugs and this share showed no accelerated 
decline in 2008-2012 (Table 5-1). A question is whether these drugs are 
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primarily NP era leftovers with their development started before 1997. We 
surveyed the development history of 32 NPs and NP derivatives approved in 
2008-2012 (SI Appendix, Table S1) and found 21 (65.6%) drugs are post-NP 
era products with their development started in the late 1990s (37.5%) and 
early 2000s (28.1%). 
Table 5-1 Statistics of nature-derived FDA approved drugs in 2008-2012. ND, 
NM, and S* are natural product semi-synthetic derivatives, mimetics, and 
pharmacophore-guided synthetic molecules. Biologics include peptides, 

























2012 37 3 (8.1%) 6 (16.2%) 0 (0.0%) 9 (24.3%) 
2011 28 2 (7.1%) 6 (16.2%) 0 (0.0%) 5 (13.5%) 
2010 22 0 (0.0%) 9 (24.3%) 2 (5.4%) 7 (18.9%) 
2009 25 1 (4.0%) 8 (21.6%) 2 (5.4%) 4 (10.8%) 
2008 20 0 (0.0%) 4 (10.8%) 0 (0.0%) 3 (8.1%) 
 
The development history of these 21 post-NP era drugs further reveals what 
have contributed to their selection and development in competition with other 
leads. The leads of 10 (47.6%), 2 (9.5%), 6 (28.6%) and 3 (14.3%) drugs are 
bioactive NPs, natural ligands, NP derivatives/mimetics and natural ligand 
analogs possessing one or more of the following favorite pharmacological and 
structural features that have led to their selection for further developments. 
These features include high therapeutic potency (14 leads), novelty in 
therapeutic mechanism or drug structure (8 leads), high target selectivity (4 
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leads), advantage in covering drug-resistant illness (1 lead), and broader 
coverage of disease relevant multiple targets (1 lead).  At the start of their 
development, the targets of 5 (23.8%) leads are un-drugged by a preexisting 
approved drug (carfilzomib, everolimus, linagliptin, telaprevir and crofelemer 
leads targeting 20S proteasome, mTOR, dipeptidyl peptidase 4, HCV NS3/4A 
protease, and CFTR and CaCC channel respectively). The 23.8% rate for the 
un-drugged-target leads is higher than the 17.9% average rate for the first-
against-target drugs
 
(31). Hence, NPs and NP-derivatives may still be explored 
for new targets. 
Existing NP drug scaffolds appear to be productive templates for deriving new 
drugs with 16 (76.2%) leads derived from 8 preexisting NP drug scaffold 
groups including GPCR-binding peptide homones (4 leads), macrolides (3 
leads), nucleotides/nucleosides (3 leads), cephalosporins (2 leads), 
progestogens (1 lead), statins (1 lead), taxanes (1 lead) and xanthines (1 lead).  
The high percentage of new drugs derived from preexisting drug scaffolds is 
consistent with the report that drug-like bioactive compounds of specific target 
classes cluster in specific regions of chemical space
 
(173). The leads of 4 out 
of the 5 drugs outside preexisting drug scaffold groups (carfilzomib, telaprevir, 
dabigatran, and romidepsin) are peptides (epoxyketone oligopeptide, NS5A-
5B substrate peptide, thrombin-interacting fragment of fibrinogen, and 
depsipeptide cyclic structure) targeting 20S proteasome, HCV NS3/4A 
protease, thrombin and HDAC, respectively. These further show the 
usefulness of peptides in deriving target-selective drugs against such difficult 




(227). In consistency with the 
report that most nature-derived drugs are from preexisting drug-productive 
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species families and clusters
 
(174), 18 (85.7%) leads are from preexisting 
drug-productive species families and 2 (9.5%) leads are from previously-
unexplored families in preexisting drug-productive clusters,  
Although their development started in the post-NP era, 16 (76.2%) leads have 
been initially discovered in the NP era by low-throughput screening (LTS) (8 
leads), exploration of known target-binders (ETB) such as hormones/factors 
and ligands/substrates (5 leads), focused library screening (FLT) of selected 
structural, target or host species classes (2 leads), and focused bioprospecting 
of unexplored species of drug-productive species families (1 lead). There are 5 
leads discovered in the post-NP era by ETB, FLT, HTS, and incorporation of 
NP component into leads, which suggest that ETB and FLT as well as LTS are 
highly useful for discovering new NP leads. 
The leads of 17 (81%) drugs have one or more of the following deficiencies: 
unfavorable pharmacokinetic properties (11 leads), insufficient potency (4 
leads), lower target selectivity (2 leads), and drug resistance (1 lead). 
Pharmacokinetic deficiencies typically include low half-life or metabolic 
stability (8 leads), poor solubility (4 leads), insufficient oral absorption (1 
lead), and excessive plasma protein binding (1 lead). The strategies for 
overcoming some of these deficiencies have been described in the literatures 
reporting the discovery of these drugs. As these deficiencies are quite common 
in bioactive NPs
 
(228, 229), these strategies may be further expanded and 
more extensively applied in future drug development efforts. 
The low half-life is frequently caused by rapid enzymatic degradation, which 
can be overcome by modifying their metabolism-prone structures (e.g. 
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attachment of methyl group to the indazole of the pazopanib lead
 
(230), O-N 
substitution in the lactone of the ixabepilone lead
 
(231), and replacement of 





leads to hinder their metabolism by P450 isoenzymes, esterase and peptidases), 
and by introducing intra-molecular hydrogen bonds (e.g. p-Ureido-
phenylalanine incorporation into the degarelix lead
 
(234)). Poor solubility can 
be alleviated by adding highly soluble component (e.g. addition of morpholine 
ring to the carfilzomib lead
 
(235) and phosphonoamino group to the 
ceftaroline lead
 
(236)), and by introducing surface-exposed hydrogen bond 
sites (e.g. 4-aminophenylalanine(Hor) incorporation into the degarelix lead
 
(234)). Insufficient oral absorption caused by high polarity can be reverted by 
chemical modifications that increase lipophilicity (e.g. O-alkylation in the 
pasireotide lead
 
(237), and hexylcarbamate attachment to the dabigatran lead 
(232)) and decrease the number of hydrogen bond sites (e.g. removal of non-
essential hydrogen donors in the pazopanib lead
 
(230)). Excessive plasma 
protein binding can be reduced by increased hydrophilicity (e.g. introduction 
of a carboxylate group in the dabigatran lead
 
(232)).  
Lead potency can be enhanced by such fundamental strategies as the addition 
of drug-target hydrogen bonds (e.g. addition of hydrogen donor in the 
heterocycle of the pazopanib lead
 
(230)) and the promotion of drug-target 
hydrophobic or Pi-Pi interactions (e.g. addition of a phenyl group to the 
carfilzomib lead
 
(235)). Target selectivity may be achieved by addition or 
substitution of side chains capable of sterically hindering drug binding to the 
unintended targets without affecting its binding to the intended targets (e.g. 
addition of an acetoxy group into the ulipristal lead
 
(238)). 




5.2 Clustering and Analysis of Natural Product Drug 
Leads in Chemical Space  
There is a renewed interest in discovering drugs (239) from NP privileged 
structures (240) and derivative libraries (241). Knowledge of the distribution 
of the NP leads of drugs (NPLDs) in the natural product chemical space can 
provide useful clues for prioritizing the relevant efforts. 
Although NPs are in well-defined subspaces of the chemical space (242), 
because of their enormous number (189), structural diversity (189, 243) and 
molecular complexity (244), only subsets of NPs can be practically explored. 
Discovery efforts need preferably be prioritized towards the NPs with higher 
discovery potentials. A key issue is which NPs to explore and where to find 
them. Evidences suggest that some NPLDs may congregate in specific drug-
productive regions of the chemical space. Certain chemical classes (e.g. 
steroids and nucleosides) are drug prolific (245). Half of the drugs are made of 
dozens of molecular frameworks (186). The GPCR, kinase and protease 
targeting agents each cluster together in the chemical space (173). The 
important but unanswered questions are to what extent, in what patterns, for 
what reasons, and how distinguished the NPLDs congregate in the chemical 
space. The answers to these questions provide useful clues for lead discovery. 
To study these questions, we determine the distribution patterns of the 348 and 
94 NPLDs of 749 pre-2013 approved and 263 clinical trial small molecule 
drugs in the chemical space represented by the 137,836 non-redundant NPs 
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(174, 216, 246) (comparable to the number of NPs in the earlier chemical 
space studies (140, 189, 247)). The NP-related drugs include NPs and NP 
semi-synthetic derivatives, mimetics, and pharmacophore-guided synthetic 
molecules (174). From different structural perspectives, the NPLD distribution 
patterns in the chemical space are profiled by the molecular scaffold (140) and 
substructure-fingerprint (248, 249) trees. The derived distribution patterns are 
studied from the perspectives of preferential binding to the selected target-sites 
for determining whether it influences the formation of these patterns. We also 
evaluate whether these patterns are distinguished from those of the bioactive 
NPs and how they evolve with time. We further test whether the derived 
insights can be explored for NPLD discovery by using them to retrospectively 
judge the development potential of the new NPLDs of 2013-2014 approved 
drugs unused in finding the patterns. New technologies are expected to 
significantly expand the accessible NP chemical space (250, 251) and their 
potential impact is reflected in this study. 
5.2.1 Material and Methods 
The strategy for collecting drugs in different development and clinical stages 
is as described in Subsection 3.1.1. The information collection of NP-related 
drugs is as introduced in Subsection 5.1.1. A total of 106,391, 57,423 and 
5,223 NPs are respectively collected from the ZINC (216), TCM-ID (252), 
TCM@Taiwan (246) databases and additional literature search (174). For 
database entries with multiple non-linked components, only the largest 
component is selected. Hydrogens are added and salt ions are removed by 
using Corina, Duplicates are identified and removed by structural comparison 
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based on a set of 98 molecular descriptors as described in Subsection 2.1.2, 
which can distinguish different molecules non-distinguishable by the 881-bit 
Pubchem molecular fingerprints (Subsection 2.1.3). We further remove small 
NPs with molecular weight <50 Daltons because drug leads are >100 Daltons 
(253). These processes reduce the number of NPs to 137,836, including 442 
NPLDs of 749 pre-2013 approved and 263 clinical trial small molecule drugs. 
Scaffold hunter software (140) is used to select the NPLDs and  NPs with ring 
structures, cluster them into molecular scaffold trees, and draw the tree graphs 
with additional labels and marks added to indicate the drug-productive 
scaffolds or scaffold parent-child sub-branches (DSs). The 881-bit Pubchem 
molecular fingerprints of the NPs and NPLDs are computed by using the 
Pubchem fingerprint module of the PaDEL software (137). The substructure-
fingerprint tree of these NPs and NPLDs are generated by using the Tanimoto-
coefficient similarity clustering method because of its demonstrated good 
performances despite possessing some inherent biases to the molecular sizes 
(249). For this method, Tanimoto coefficient is used for calculating similarity 
scores of NPs. After calculating pairwise Tanimoto coefficient for all NPs, a 
distance matrix is created. The distance values are calculated by subtracting 
the Tanimoto coefficient from 1. Next, we use this matrix to cluster NPs by 
using a hierarchical clustering function in Matlab statistics toolbox. We use 
‘complete’ as the parameter in the linkage function because the complete 
linkage would be stricter than others. A file of hierarchical tree of NPs then is 
exported in Newick format using the phytreewrite function in Matlab 
bioinformatics toolbox. Finally, the clustering tree graphs are generated by 
using EMBL automatic tree generator in iTOL version-1.8.1 (254) by 
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importing the generated hierarchical tree file in Newick format with additional 
labels and marks added to indicate the drug-productive clusters (DCs). 
5.2.2 Results and Discussion 
We collect 442 NPLDs (173-178) and their NP origin (173, 178) from the 
literatures, and 169,037 NPs from ZINC(216),  TCM-ID (252), TCM@Taiwan 
(246) and the literatures (174). The number of NPs are reduced to 137,836 
after removing the duplicates, small NPs with molecular weight <50 Daltons 
(drug leads are >100 Daltons (253)) and the NPs with incomputable 
substructure-fingerprints. The molecular scaffold and substructure-fingerprint 
trees of the 442 NPLDs and 137,836 NPs are generated by Scaffold hunter 
(140), whose clustering strategy is described in Subsection 2.2.3, and 
Tanimoto-coefficient similarity clustering methods as described in Subsection 
2.2.1.  
There are 411 NPLDs and 134,097 NPs with ring structures. These are 
grouped by Scaffold hunter (140) into molecular scaffold trees of  39,051 
scaffolds (114 are drug-productive). The majority (62.7% approved, 37.4% 
clinical trial) of the NPLDs congregates in 62 drug-productive scaffolds or 
scaffold parent-child sub-branches (DSs) labeled as DS1 to DS62 (Figure 5-1, 
SI Appendix, Table S2 and Figures S1-S5). A DS is defined as a scaffold 
with ≥2 NPLDs that have yielded ≥1 approved drug or a scaffold parent-
child sub-branch with ≥2 NPLD-producing scaffolds that have yielded ≥1 
approved drug. These DSs have collectively yielded 69.6% approved and 44.4% 
clinical trial drugs. The congregation of NPLDs in the DSs coupled with the 
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earlier finding that the GPCR, kinase and protease targeting agents each are 
clustered together in the chemical space (173) indicates that NPLDs of the 
same and different scaffolds against the same classes of targets may on a 
broader scale be clustered together in the chemical space. 
 
Figure 5-1 Distribution of the natural product leads of approved and clinical 
trial drugs in branch 5 of the Scaffold-Hunter derived molecular scaffold trees 
of the 134,097 natural products and 411 natural product leads. The drug-
productive scaffolds or scaffold parent-child sub-branches (DSs) are indicated 
by red dots or red dots connected by red lines, which marked by the respective 
label DS15-DS19. The green triangles indicate the natural product leads 
outside the DSs. 
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To probe the larger-scale distribution patterns of NPLDs in the chemical space, 
we generate a molecular substructure-fingerprint tree of the 442 NPLDs and 
the 137,836 NPs by using the Tanimoto-coefficient similarity clustering 
method. The derived tree is composed of 33 main branches (Figure 5-2 and 
Table 5-2). Most (87.9%) branches are drug-productive, reflecting the fact 
that NPs primarily co-evolve and interact with proteins (240) and a variety of 
chemical classes (19, 174) and target families (193, 194) have been 
therapeutically explored. Nonetheless, NPLDs within each branch are mostly 
clustered together, with 341 (77.2%) NPLDs (82.5% approved, 63.0% clinical 
trial) clustered in 60 drug-lead productive clusters (DCs) labeled as DC1 to 
DC60 (Figure 5-3, SI Appendix,Table S3, and Figures S6-S9). A DC is 
defined as a relatively small region with moderate to high concentration of 
NPLDs yielding ≥1 approved drug. These DCs have collectively yielded 87.9% 
approved and 68.8% clinical trial drugs. In particular, 56.0% approved and 
67.4% clinical trial NPLDs are clustered in 22 NPLD-prolific DCs (Table 5-3) 
that have collectively yielded 68.4% approved and 39.2% clinical trial drugs, 
which is consistent with the report that half of the drugs are made of dozens of 
molecular frameworks (186). 
 




Figure 5-2 The main branches of the MFTCS clustering tree of the 137,836 
natural products and 442 natural product leads. The green digit near each 
branch-end is the number of natural products in that branch. The two red digits 
near the fruit beside each branch label box are the numbers of approved 
(proceed the + sign) and clinical trial leads in that branch. The fruit size 
roughly correlates with the number of leads. The representative molecular 
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Table 5-2 Statistics of the 33 main branches of the molecular-fingerprint 
Tanimoto-coefficient similarity clustering tree of the natural product chemical 
space represented by 137,836 natural products and 442 natural product leads.  






No of Drug Leads 
(Approved/Clinical 
Trial) 




Branch1 801 13 (12/2) 17 (15/2) 
Branch2 329 1 (1/0) 1 (1/0) 
Branch3 3937 72 (59/18) 214 (186/28) 
Branch4 848 29 (25/6) 84 (53/31) 
Branch5 809 0 (0/0) 0 (0/0) 
Branch6 1813 2 (1/1) 3 (2/1) 
Branch7 9553 9 (9/1) 36 (20/16) 
Branch8 1617 3 (2/1) 5 (4/1) 
Branch9 4594 65 (55/17) 161 (124/37) 
Branch10 3224 22 (18/5) 43 (38/5) 
Branch11 1408 5 (5/0) 5 (5/0) 
Branch12 7837 29 (24/7) 51 (39/12) 
Branch13 2286 5 (5/1) 14 (12/2) 
Branch14 5966 27 (17/11) 42 (28/14) 
Branch15 9746 16 (6/11) 19 (7/12) 
Branch16 3763 14 (12/4) 48 (42/6) 
Branch17 7323 25 (17/10) 50 (30/20) 
Branch18 3868 3 (2/1) 3 (2/1) 
Branch19 1136 0 (0/0) 0 (0/0) 
Branch20 9754 23 (19/7) 72 (50/22) 
Branch21 2858 7 (7/1) 11 (9/2) 
Branch22 8360 7 (2/5) 11 (2/9) 
Branch23 164 0 (0/0) 0 (0/0) 
Branch24 6264 16 (14/6) 33 (26/7) 
Branch25 8973 1 (0/1) 1 (0/1) 
Branch26 1262 8 (7/3) 21 (14/7) 
Branch27 2027 3 (2/1) 3 (2/1) 
Branch28 6496 12 (8/4) 21 (13/8) 
Branch29 643 0 (0/0) 0 (0/0) 
Branch30 3457 4 (2/3) 8 (3/5) 
Branch31 3879 1 (1/0) 1 (1/0) 
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Branch32 8696 16 (13/6) 37 (24/13) 




Figure 5-3 Distribution of the natural product leads of approved and clinical 
trial drugs in branch 3 of the substructure-fingerprint clustering tree of the 
137,836 natural products and 442 natural product leads. The drug-lead 
productive clusters are red-orange colored and marked by the respective 
cluster label DC4-DC10. The red, purple and blue lines on top of the 
clustering tree indicate the locations of the approved, approved + clinical trial, 
and clinical trial drug-leads with the height correlating with the number of 
approved + clinical trial drugs. 
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Table 5-3 Top-ranked drug lead productive clusters with higher number of approved leads in the natural product chemical space represented by 














Target Site SuperClass Target Site Class 
DC19 
(14) 
Steroids & derivatives 546 
32/5, 
85/8 







nucleoside phosphate sites, 
aminoacyl-tRNA sites 
DNA metab enzymes nucleoside phosphate, 
ribosome 30s aminoacyl-tRNA sites 
DC13 (4) 
Purine nucleosides, Imidazole 





Nucleoside sites, nucleoside 
phosphate sites 
nucleoside receptor ligand & metabolism 
enzyme substrate sites, Nucleoside 
phosphate receptor ligand, DNA metab 
enzymes nucleoside phosphate sites 
DC7 (3) 
Amino acids with acyclic 





amino acid sites 









amino acid phosphate sites, 
oligopeptide sites,  
lipopolysaccharide sites 
phosphatase substrate, ribosome 23S 
peptidyl transferase, outer membrane 
lipopolysaccharide sites 





Fatty acids & derivatives, 
Prostanoids 
423 8/1, 26/1 
fatty acid, cannabinoid, 
eicosanoid, retinoid, 
coenzyme A  sites 




Cardiac glycosides 176 8/1, 12/1 nucleoside phosphate sites 





Intermediate-sized linear and 
cyclic peptides 
 
33 7/1, 32/2 
Oligopeptide sites, 
lipopolysaccharide sites 
exopeptidase substrate, Neuropeptide 
receptor ligand, outer membrane 
lipopolysaccharide sites 






1696 6/1, 7/2 nucleoside phosphate sites 
steroid metab enzyme nucleoside phosphate, 












457 6/1, 18/1 amine sites, opiate sites 





237 5/0, 17/0 oligopeptide sites serine endopeptidase substrate sites 





Purine base analogs, modified 
purine base analogs 
180 5/0, 9/0 
nucleoside sites, nucleoside 
phosphate sites 
nucleoside receptor ligand, DNA metab 
enzymes nucleoside phosphate sites 
DC14 (7) Larger indole alkaloids 4104 
5/1, 
15/16 
amine sites,  oligopeptide 
sites 
amine receptor ligand & transporter 






phenolic molecules with a 
long tail 
2531 5/4, 9/8 
fatty acid, cannabinoid, 
eicosanoid, retinoid sites 
fatty acid metab enzyme substrate, retinoid 




Oligo-, Poly-,  Cyclic- 
saccharides 
259 5/0, 5/0 
cyclic oligosaccharide drug 
delivery systems 
cyclodextrin drug delivery systems 
DC36 
(20) 
Large cyclic peptides 265 5/6, 6/7 
nucleoside phosphate sites, 
sites within peptidoglycans, 
saccharide sites, 
lipopolysaccharide sites 
calcium channel DHP, cell wall 
peptidoglycan, polysaccharide metab enzyme 





Ergoline-, Ellipticine-,  
Epibatidine- alkaloids 
519 5/3, 8/4 amine sites, nucleobase sites 









512 5/2, 6/4 amine sites amine receptor ligand sites 





Tropane alkaloids 29 5/0, 10/0 amine sites 





alkaloids with an amine group 
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The NPLD-prolific DCs are ranked based on the ratio of the approved NPLDs 
to the NPs in each DC. Because of limited exploration and incomplete 
information, these ratios may not fully reflect the reality but nonetheless 
provide useful indications. We find that 60% of the top-10 NPLD-prolific DCs 
with >100 searchable NPs in Table 5-3 are among top-ranked DCs with 
higher approved NPLD to NP ratios. Thus, drug productivity of these top-
ranked DCs seems to arise from higher NPLD yields instead of the higher 
number of NPs explored. The top-ranked DC38 and DC8 in Table 5-3 are 
excluded because they have <100 searchable NPs. If counted, they are among 
the DCs with highest approved NPLD to NP ratios.  
To determine what causes the clustering of NPLDs within individual DCs with 
particular focus on the possible influence of the targets of their derived drugs, 
we evaluate the 203 targets of the 822 approved and clinical trial drugs of the 
331 NPLDs in the 55 DCs with their target information available in the TTD 
(33). We find that the targets of each individual DC are primarily from one to 
a few target classes (e.g. amine receptors) with their substrates/ligands from 
one to a few chemical classes (e.g. amines). This finding is based on the 
limited target information for 74.9% NPLDs and without considering the 
additional targets of the non-NPLDs in each DC. While the limited target 
information may not enable the full profiling of the influence of drug target-
sites, it nonetheless provides useful hints about the key factors that promote 
the clustering of NPLDs. The 203 targets can be classified based on their 
target-sites into 45 target-site classes (TCs) labeled as TC1 to TC45, which 
collectively belong to 20 target-site super-classes (TSs) labeled as TS1 to 
TS20 (Table 5-4). A TS is defined as a group of target-sites bound by 
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substrates/ligands of a specific chemical class irrespective of their targets. A 
TC represents a sub-group of target-sites of a specific target class bound by 
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Table 5-4 List of 20 target site superclasses and their corresponding target site classes with examples. The target site superclasses are labeled as 
TS1-TS20 and the target site classes are labeled as TC1-TC45. 
Target Site Superclass Target Site Class Example of Targets 
TS1 amine binding sites 
TC1 amine receptors ligand binding sites 
Dopamine receptors, Histamine receptors, 5HT-
receptors 
TC2 amine transporters substrate binding sites 






Pyrimidine metabolism enzymes substrate 
binding sites 
Thymidylate synthase 









purine nucleoside metabolism enzyme 







DNA metabolism enzymes nucleoside 
phosphate binding sites 
DNA topoisomerases, DNA polymerases 
TC8 
RNA metabolism enzymes nucleoside 
phosphate binding sites 
t-RNA synthetases 
TC9 
nucleoside phosphate receptor ligand binding 
sites 
Adenosine diphosphate receptors 
TC10 
nucleoside phosphate metabolism enzymes 
substrate binding sites 
Na+/K+-ATPase, Na+-k+-atpase transmembrane 
protein 
TC11 kinase ATP binding sites Kinases 
TC12 
steroid metabolism enzyme nucleoside 
phosphates binding sites 
11β-hydroxysteroid dehydrogenase  
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TC13 ATP-gated channel ligand binding sites 
ATP-sensitive k+ channel, ATP-sensitive inward 
rectifier potassium channel  
TC14 calcium channel DHP binding site 
Ca(2+) channels, N-type voltage-dependent calcium 
channels 
TC15 chloride channel CBS domain Glutamate-gated chloride channel 
TC16 




cyclic nucleotide phosphodiesterase substrate 
binding sites 





ribosome 30s subunit aminoacyl-tRNA 
binding sites 









TC20 amino acid receptors ligand binding sites Glutamine receptors, NMDA receptor 
TS8 
amino acid binding 
sites 
TC21 
amino acid metabolism enzymes substrates 
binding sites 
GABA-transaminase 
TC22 Neuropeptide receptor ligand binding sites 





TC23 exopeptidase substrate binding sites 
Aminopeptidase, dipeptidyl peptidase-4, 
Angiotensin-converting enzyme 
TC24 
oligopeptide histone tail metabolism enzymes 
substrate binding sites 
HDAC 
TC25 ribosome 23S rRNA peptidyl transferase sites 23s rRNA 
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TC26 vasoactive peptide receptor binding sites Bradykinin b2 receptor 
TC27 proteasome substrate binding sites 20s proteasome 
TC28 serine endopeptidase  substrate binding sites HIV-1 protease, Factor Xa  
TC29 
β-lactam binding protein peptidoglycan 
binding sites 















TC32 monosaccharide receptor binding sites sweet taste receptor 
TC33 
polysaccharide metabolism enzyme substrates 
binding sites 
1,3-β-D-glucan synthase 









TC36 fatty acid metabolism enzyme substrate sites 







TC37 retinoid receptor ligand binding sites Retinoic acid receptors,  Retinoid X receptor, 
TC38 eicosanoid metabolism enzyme substrate sites Cox2 
TC39 cannabinoid receptor ligand binding sites Cannabinoid receptors 
TC40 
coenzyme A & analog metabolism enzymes 
substrate binding sites 
Serine palmitoyltransferase 
TS16 coenzyme A & TC41 microtubule laulimalide/peloruside site Microtubule 
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analog binding sites 
TS17 microtubule sites 
TC42 microtubule taxoid site Microtubule 
TC43 opiate receptor ligand binding sites Opioid receptors 
TS18 opiate binding sites TC44 Nuclear receptor ligand binding sites Estrogen receptor, Progesterone receptor 
TS19 steroid binding sites TC45 
naphthoquinone binding protein 
naphthoquinone binding sites 




      
 CHAPTER 5 ANALYSIS AND MODELING OF THERAPEUTIC AGENTS  
112 
 
The targets in 53 (96.4%) DCs are from 1-3 TCs (27, 19, 7 DCs from 1, 2, 3 
TCs) with the majority (65.5%) from either 1 TC (27 DCs) or 2-3 TCs of 1 TS 
(9 DCs), and the remaining 2 DCs are from 4 TCs (Figure 5-4). This indicates 
that the similar target-site structural constraints are likely the key factors in 
promoting the clustering of NPLDs in individual DCs.  The targets of 
approved and clinical trial drugs are highly selective in their numbers, 
druggability features, and systems profiles (31, 33, 193, 255), and the 
druggability features have been linked to gene family affiliation to the known 
drug targets (28) and the privileged target-sites with unique physicochemical 
properties (256) for enabling favorable binding by drug-like molecules (257). 
Our revealed links between the clustering of NPLDs in individual DCs and the 
grouping of their targets in selected TCs are consistent with these findings. 
Although multiple drug-like molecules are capable of potent binding to 
various target-sites, only those at the lead sweet spots of the chemical space 
having development potential to be optimized into the drug sweet spots (258) 
with adequate metabolic stability (259), metabolite safety (260), absorption 
(261) and physical forms (262). Therefore, our revealed clustered patterns of 
NPLDs and their links to the selected TCs provide useful information and 
enable further study of the drug lead sweet spots in the chemical space 
particularly with respect to the relevant target-site classes. 
 
 




Figure 5-4 Distribution of the approved NP-related drugs, grouped into 45 
target-site classes (TCs) of 20 target-site super-classes (TSs), in the drug-
productive clusters DC1 to DC60. TSs are colored as: TC1, TC2 of TS1 amine 
sites (LightCoral), TC3, TC4 of TS2 nucleobase sites (OliverGreen), TC5, 
TC6 of TS3 nucleoside sites (PalePurple), TC7-TC16 of TS4 nucleoside 
phosphate sites (Red), TC17 of TS5 cyclic nucleotide sites (Cyan), TC18 of 
TS6 aminoacyl-tRNA sites  (Chocolate), TC19 of TS7 amino acid phosphate 
sites (Magenta), TC20, TC21 of TS8 amino acid sites (Yellow), TC22-TC28 
of TS9 oligopeptide sites (Green), TC29 of TS10 peptidoglycan sites 
(PaleYellow), TC30 of TS11 peptidoglycan sites (Blue), TC31-TC33 of TS12 
saccharide sites (OrangeRed), TC34 of TS13 cyclic oligosaccharide drug 
delivery systems (PaleBrown), TC35 of TS14 lipopolysaccharide sites 
(DarkCyan), TC36-TC39 of TS15 fatty acid, cannabinoid, eicosanoid, retinoid 
sites (PaleBlue), TC40 of TS16 coenzyme A & analog sites (PaleGreen), 
TC41, TC42 of TS17 microtubule sites (DeepPink), TC43 of TS18 opiate sites 
(Purple), TC44 of TS19 steroid sites (Brown), and TC45 of TS20 
naphthoquinone sites (Orange). 
 
Consistent with the reported clustering of GPCR, kinase and protease targeting 
agents in the chemical space (173), the GPCR, kinase and protease TCs are 
primarily targeted by the selected chemical classes of NPLDs in specific DCs. 
For GPCRs, amine receptors (TC1) are primarily targeted by amines (DC31, 
DC44), ergoline alkaloids (DC40, DC41), and indole (DC14, DC42) and 
tropane (DC43) alkaloids, amino acid receptors (TC20) by amino acids (DC7) 
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and oligopeptides (DC9), cannabinoid receptors (TC39) by cannabinoids 
(DC56) and cannabidiols (DC53), purine nucleoside receptors (TC5) by 
purines (DC12, DC13), opiate receptors (TC43) by opiate alkaloids (DC49), 
and monosaccharide receptors (TC32) by phenylpropanoids (DC60). Kinases 
(TC11) are primarily targeted by staurosporines (DC39). For the proteases, 
serine endopeptidases (TC28) are primarily targeted by glycosaminoglycans 
(DC10) and linear amino acid derivatives (DC4), proteasome (TC27) by 
oligopeptides (DC9), and exopeptidases (TC23) by phenethylamines (DC34), 
sesquiterpenes (DC22), larger indole alkaloids (DC14), and linear and cyclic 
peptides (DC38).  
The other drug-prolific DCs are also closely linked to specific TCs (Table 5-
3), with DC19 (steroids) linked to the nuclear receptor ligand binding sites 
(TC44), DC5 (aminoglycosides) to the DNA metabolism enzyme nucleoside 
phosphate (TC7) and ribosome 30s subunit aminoacyl-tRNA (TC18) binding 
sites, DC17 (acarviosins) to the phosphatase substrate (TC19), ribosome 23S 
rRNA peptidyl transferase (TC25) and outer membrane lipopolysaccharide 
(TC35) sites, DC21 (fatty acids, prostanoids) to the retinoid receptor ligand 
(TC37) and coenzyme A analog metabolism enzyme substrate (TC40) binding 
sites, DC28 (cardiac glycosides) to the nucleoside phosphate metabolism 
enzymes substrate binding sites (TC10), and DC8 (-lactams) to the -lactam 
binding protein peptidoglycan binding sites (TC29). 
The clustered distribution of NPLDs (Figure 5-3 and SI Appendix, Figures 
S6-9) are in contrast to the scattered distribution of the 48,216 bioactive NPs 
from the TCM@Taiwan database (246) and literatures (174) (SI Appendix, 
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Figures S10-13). Although our collected bioactive NPs are limited in 
representing bioactive NPs, useful indications may be revealed. These 
bioactive NPs are scattered in 32 of the 33 branches with 78.8% of the 
bioactive NPs located outside the DCs, in sharp contrast to the clustered 
patterns of NPLDs. Therefore, NPLDs are distinguished from bioactive NPs in 
their tendency to cluster together in the chemical space, which is consistent 
with the tendency of drug-productive species families to cluster together in the 
phylogenetic trees (174).  The exploration times of the 442 NPLDs, estimated 
from the time of the first literature report in the Pubmed database, are largely 
comparable to those of the 11,816 bioactive NPs inside and outside the DCs 
(SI Appendix, Figures S14-17). Hence, there is no clear indication to link 
drug-productivity of the DCs to the time (and likely the efforts) of exploration 
by conventional technologies.  
Since 1988, the number of DCs has been gradually increased at an average 
rate of 3.2 new DCs per 5 years, and the majority (60.0%-69.0%) of the 15-32 
newly-approved NPLDs in every 5 years are from preexisting DCs (Table 5-
5). Drug discovery focus has been shifting in terms of targets, chemotypes, 
diseases and therapeutic strategies (193, 263). To study if novel drugs derived 
from shifted focuses are outside pre-existing DCs, we analyze 27 approved 
NPLDs each targeting a novel target with no previously approved drug (Table 
5-6) and thus are novel leads of the time.  At the time of their approval, 18 
(66.7%) of these novel NPLDs are from preexisting DCs, suggesting that 
existing DCs remain good sources of novel drugs. 
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Table 5-5 Chronological data of the natural product leads with the first 
approved drugs and the drug lead productive clusters during every five-year 
period from 1963 to 2012. The six drug lead clusters with only one approved 
drug plus one or more clinical trial drugs were not included here. 
Period 
Number of natural product 
leads with the first approved 
drug in period 
Number of drug lead 












Pre-1963 56 NA 8 NA 
1963-1967 7 20 8 7 
1968-1972 4 9 15 3 
1973-1977 9 8 18 2 
1978-1982 17 56 20 13 
1983-1987 20 20 33 5 
1988-1992 20 12 38 6 
1993-1997 20 9 44 2 
1998-2002 19 10 46 3 
2003-2007 9 6 49 1 
2008-2012 11 6 50 4 
 
Table 5-6 List of drugs targeting 27 “new” targets first successfully explored 
since year 1990. 
Target (Year of First 
Successful Exploration) 
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5-alpha reductase (1992) 
Finasteride (1992) 
Azelaic acid (1995) 
Dutaseride (2001) 
Dutasteride (2001) 
Angiotensin receptor (1994) 




Candesartan cilexetil (1997) 
Telmisartan (1999) 
Olmesartan medoxil (2002) 
DNA topoisomerase I (1994) 
Camptothecin (1994) 
Irinotecan hydrochloride (1994) 
Topotecan hcl (1996) 
Sphingosomal topotecan (2007) 
HIV-1 protease (1995) 
Saquinavir mesylate (1995) 
Ritonavir (1996) 
Indinavir sulfate (1996) 





















Oseltamivir phosphate (1999) 
Zanamivir (1999) 
Myeloid cell surface antigen 
cd33 (2000) 
Gemtuzumab ozogamicin (2000) 
Ferrochelatase (2001) methyl aminolevulinate (2001) 

















Histone deacetylase (2006) 
Vorinostat (2006) 
Romidepsin (2009) 
Chloride channel protein 2 
(2006) 
Lubiprostone (2006) 
Bradykinin B2 receptor (2008) Icatibant (2008) 




Cystic fibrosis transmembrane 
conductance regulator (2012) 
Crofelemer (2012) 
Ivacaftor (2012) 
Somatostatin receptor 5  (2012) Pasireotide diaspartate (2012) 
Smoothened receptor (2012) Vismodegib (2012) 
 
The approved drugs from individual DCs largely target one to a few disease 
classes (Figure 5-5). Specifically, 61.7% of DCs target one (DC1, DC2, 
DC11, DC18, DC23, DC26, DC39, DC46, DC51 and DC60), two (DC3, DC6, 
DC16, DC20, DC22, DC25, DC30, DC34, DC35, DC37, DC50, DC54, DC55, 
DC56, DC57 and DC59) or three (DC4, DC9, DC15, DC28, DC31, DC32, 
DC41, DC47, DC48, DC52 and DC58) disease classes. While the remaining 
DCs target multiple disease classes, most drugs from these DCs target a few 
disease classes. Anti-infectious and anti-parasite drugs are mostly from DC8 
(87 drugs), DC5 (22 drugs), DC17 (19 drugs), DC45 (10 drugs), DC4 (9 drugs) 
and DC13 (8 drugs). Anticancer drugs are primarily from DC19 (31 drugs), 
DC13 (13 drugs), DC50 (9 drugs), DC38 (8 drugs), DC5 (7 drugs), DC14 (5 
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drugs) and DC46 (5 drugs). Circulatory system drugs are largely from DC38 
(17 drugs), DC10 (12 drugs), DC28 (11 drugs), DC13 (9 drugs), DC44 (9 
drugs) and DC21 (6 drugs).  Nervous system drugs are mostly from DC49 (13 
drugs), DC44 (7 drugs) and DC7 (5 drugs). Drugs for endocrine, nutritional 
and metabolic diseases are primarily from DC19 (13 drugs), DC26 (7 drugs), 
DC38 (6 drugs) and DC25 (5 drugs). Genitourinary system drugs are mostly 
from DC19 (15 drugs) and DC8 (5 drugs). 
 
Figure 5-5 Distribution of the approved NP-related drugs, grouped into 
specific disease classes, in the drug-productive clusters DC1 to DC60. Disease 
classes are labeled according to the international classification of diseases 
ICD-10 as: A00-B99 infectious & parasitic diseases (Red), C00-D49 
neoplasms (Blue), D50-D89 blood & immune-related diseases, E00-E90 
endocrine & metabolic diseases (Purple), F01-F99 mental disorders,   G00-
G99 nervous system diseases, H00-H59 eye diseases, I00-I99 circulatory 
system disorders (Green), J00-J99 respiratory system disorders, K00-K95 
digestive system disorders, L00-L99 skin diseases, M00-M99 musculoskeletal 
 CHAPTER 5 ANALYSIS AND MODELING OF THERAPEUTIC AGENTS  
120 
 
system & connective tissue disorders, N00-N99 genitourinary system 
disorders (Orange), O00-O9A reproductive system disorders, P00-P96 
perinatal originated diseases, R00-R99 unclassified disorders, S00-T88 injury 
& poisoning.  
 
The tendencies of NPLDs to cluster together in the chemical space and to 
preferentially bind to the privileged target-sites in the target-space may be 
explored for assessing the development potential of new NP leads. Based on 
the insights derived from our analysis, one can postulate that, apart from its or 
its derivatives’ ability to modulate a validated target, an NP lead may have 
higher probability to be developed into a drug if it is inside a DC, near a DC 
(to form an expanded DC) or near an NPLD outside existing DCs (to form a 
new DC) in the chemical space, and if its target belongs to an existing TC or a 
new TC in an existing TS. This postulation is test on the new NPLDs of FDA 
approved drugs in 2013 – June 2014 (264, 265) unused in finding the NPLD 
distribution patterns and the target-site linkages. We are able to find 4, 3 and 1 
drugs derived from small molecule NPs, peptides and oligonucleotide 
respectively, with 3 small molecule NPLDs retrospectively recognized as 
developable based on our postulation (Table 5-7).  Specifically, the NPLD 
uridine monophosphate of sofosbuvir is inside DC5 and target TC7, the NPLD 
phlorizin of canagliflozin is near DC57 (tanimoto similarity coefficient 0.91 to 
the nearest NPLD) and target monosacharide transporter substrate sites, and 
the imidazole-based NPLD (e.g. mizoribine) of luliconazole is inside DC13 
and target a steroid metabolism enzyme substrate site in TS19 (steroid binding 
sites). Therefore, the insights derived from our analysis may be explored for 
assessing the development potential of NP leads. 
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Table 5-7 The list of natural product derived drugs approved by FDA from 
2013 to 2014 June. The natural product leads, targets and affiliations to drug 








































































































































These insights also provide useful clues to and enable further studies of the 
lead sweet spots in the chemical space with respect to the corresponding 
target-sites. The distribution of NPLDs and the lead sweet spots is collectively 
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influenced by potent binding to the target-sites and such additional factors as 
the optimization potential to reach the drug sweet spots (258) with adequate 
metabolic stability (259), metabolite safety (260), absorption (261) and 
physical forms (262). Further studies are needed for deeper understanding the 
collective influence of these multiple factors on the distribution of NPLDs in 
the chemical space. These coupled with expanded knowledge of drug-like 
structures and physicochemical properties (186) may enable more prioritized 













Chapter 6 Modeling and Prediction of 
Therapeutic Targets 
6.1 Classification of Proteins Functional Classes as 
First Step for Target Discovery 
As described in Section 1.3, using computational methods to predict functions 
of proteins is important for closing the gap between the amount of sequence 
information and functional characterization. SVM, KNN and PNN are widely 
used in the prediction of protein families and have been validated to be 
effective (Chapter 2). In addition, several integrative strategies that 
combining multiple machine learning methods have also been reported for 
prediction of protein families (165, 166), but they only focused on a specific 
protein family and its sub-families. 
SVM-Prot (266) is a web-based support vector machine software which was 
developed by our group for functional classification of a protein from its 
amino acid sequence. It shows a certain degree of capability for the 
classification of distantly related proteins and homologous proteins of 
different function, so it can be used as a protein function prediction tool that 
complements sequence alignment methods. After progress on the protein 
function prediction in the last decade, SVM-Prot still acts as a reliable source 
for providing function information on novel sequenced proteins and has been 
cited in 333 papers so far. However, the number of known function proteins 
has increased dramatically in these years, not only the number of proteins in 




SVM-Prot families, but also the number of proteins in new families. So there 
is a need to update SVM-Prot by retraining original protein families, training 
new protein families, and adding new functions as well. 
In this study, based on the concept of SVM-Prot, we build an integrative 
approach for predicting protein functional classes from its amino acid 
sequence using three machine learning algorithms: SVM, PNN and KNN. Up 
to now, 157 protein families have been trained. These families cover all major 
classes of enzymes, inhibitors, receptors, channels, transporters, binding 
proteins and many other functional families. We also add BLAST analysis 
tools for facilitating the identification and analysis of similar proteins in the 
SVM-Prot predicted functional families. 
6.1.1 Material and Methods 
Data Collection 
Sequences of positive protein families are collected from the enzyme database 
BRENDA (267) and by searching through the UNIPROT (37) molecular 
function keywords (http://www.uniprot.org/keywords/). Negative samples in 
this study are constructed from seed proteins of the manually curated protein 
families in the Pfam database (67). 
Dataset Construction 
Every protein sequence is represented by a 188-dimensional feature vector 
which introduced in Subsection 2.1.1. Three machine learning methods are 
fed and trained with protein examples of a particular functional family as 




positive samples and those that do not belong to this family as negative 
samples. All proteins members with distinct protein name in each family are 
used to construct positive samples for training models. More proteins with the 
same protein name but from different organism are being searched, and which 
are added in training, testing and independent datasets iteratively. The 
negative samples for these three datasets are randomly selected from seed 
proteins of each curated protein families in the Pfam database (67) excluding 
those that belong to the family under study. So finally, all three datasets 
(training, testing and independent dataset) contain positive and negative 
samples. Training set of both positive and negative samples are further 
screened so that only essential proteins that optimally represent each class are 
retained. There is no duplicate protein in each training, testing and 
independent evaluation dataset. 
Model Training and Evaluation 
The training and evaluation processes for SVM, PNN, KNN are under the 
same strategy. The training system for each family is optimized and tested by 
using separate testing datasets with both positive and negative samples. The 
performance of classification is measured by the SE (sensitivity), SP 
(specificity) and ACC (accuracy) described in Subsection 2.3.4. Different 
from other similar studies, we put more emphasis on SP for selecting 
optimized parameters, since there are a huge number of negative samples in 
the real world, small reduction of SP would induce a very large number of 
false positives.    




When the optimized parameters are chosen, the training and testing datasets 
are combined together to form a new training dataset. The selected optimized 
parameters are applied to the new training dataset to train the new model. 
Then the independent dataset is further applied to evaluate the performance of 
model and detect the overfitting problem.  When the parameters pass the 
evaluation, these three datasets (training, testing and independent dataset) may 
be combined and trained to achieve the final model using the optimized 
parameters. In this step, the training dataset covers all positive samples 
currently available and a relatively large number of negative samples.  
6.1.2 Results and Discussion 
The results for the classification of seven protein families are given in Table 
6-1 and Table 6-2 as an example.  For each protein family, performances for 
testing dataset and independent dataset are both evaluated. Most of the 
performances of independent datasets are better than the performances of 
testing datasets; one major reason is that the coverage of training dataset is 












Table 6-1 The testing set performances of three types of models for sample 
protein families. Predicted results are given in SE (sensitivity), SP (specificity).  
Protein 
Family 









SVM PNN KNN 
SE SP SE SP SE SP 
G-protein 
coupled 
receptor 1834 33483 783 12035 87.61 99.9 86.21 99.91 94.13 98.57 
Serine/threoni
ne-protein 
kinase 2445 33094 1077 11908 84.59 99.51 83.38 99.03 66.48 97.9 
Tyrosine-
protein kinase 349 33474 179 12035 91.62 99.97 93.3 99.65 64.8 99.71 
Nuclear 
receptor 1088 23098 293 12068 67.58 99.98 65.53 99.98 74.74 99.5 
Metallopeptid
ase 567 33370 316 11998 83.54 99.97 85.76 99.7 76.9 99.44 
Serine 
protease 1422 33265 808 11961 85.77 99.92 77.35 99.57 79.58 99.01 
Iron-binding 440 23086 338 12063 84.32 99.98 76.04 99.94 40.83 99.93 
 
Table 6-2 The independent set performances of three types of models for 
sample protein families. Predicted results are given in SE (sensitivity), SP 















































































































































































The full list of 157 protein families is as shown in SI Appendix,Table S4. The 
overall accuracy of protein family classification for SVM ranges from 73.57% 
to 99.98%, for PNN ranges from 70.91% to 99.96%, and for KNN ranges from 
85.2% to 99.95%, which are on average comparable to those obtained in other 
machine learning studies of protein function prediction. In addition, the 
specificity ranges from 99.14% to 100%, 97.43% to 100%, and 72.97% to 
99.99%, respectively, which are higher than other reported performances (152, 
153, 164-166).  One important reason for this improvement is that we use  
representative proteins which selected from Pfam curated families as negative 
samples for classifications, this strategy provides a more comprehensive and 
diverse sampling of proteins which are not in a functional family under 
training. This result suggests that our method is potentially useful for the 
classification of protein families. 
However, the practical usefulness of this method can be more rigorously 
evaluated by subjecting it to the real world, so in the next step, proteins that 
from a whole genome can be applied. For further improvement, families from 
GO (72) can also be included to train the models for enriching the coverage of 
families.  
6.1.3 Webserver Construction 
The latest version of SVM-Prot can be freely accessed at 
http://bidd.cz3.nus.edu.sg/cgi-bin/svmprot.cgi and it is shown in Figure 6-1. 
Two sequence submission methods are provided in this version: 
 Single-sequence submission in RAW format. 




 Multiple-sequence submission in FASTA format. 
For single-sequence submission, the amino acid sequence of a protein in RAW 
format can be input in a window provided. If the input sequence contains 
invalid characters or the length of input sequence is less than 50 amino acids, 
an error message of ‘Your input sequence is not a valid sequence’ or ‘Your 
input sequence is less than 50 amino acids’ is displayed, respectively.  
For submitting multiple sequences, users may upload their sequence files in 
FASTA format along with their email addresses. The SVM-Prot checks the 
format of email address and may prompt an error message of ‘Please enter a 
valid email address’ if an invalid email address input.  
Three machine learning methods including SVM, PNN and KNN are ready for 
predicting the protein functional classes; at least one machine learning method 
should be selected in this page. When sequences are submitted, they are 
scanned through the 157 protein families with selected machine learning 
methods, respectively. 





Figure 6-1 The homepage of SVM-Prot. 
 
The computing time for multiple sequences submission may take hours to 
days, which depends on the number of protein sequences uploaded.  The 
computed result will be sent to the email address provided by the user when 
the job finishes (Figure 6-2). 
 
Figure 6-2 An example of SVM-Prot output page for the multiple-sequence 
submission. 
 




The computed result for single-sequence submission is displayed in a separate 
window as shown in Figure 6-3.  If the input protein is predicted to belong to 
one or more functional families by the machine learning methods that the user 
selected, then the name of each protein family is displayed. For the SVM 
method, the probability of the prediction for each family is further provided. 
For some protein families, a cross-link to the respective protein family 
database is provided. If the input protein is predicted to not belong to any of 
the functional classes currently covered by SVM-Prot, then a message of 
‘Your input protein is not in any of the functional classes currently covered by 
SVM-Prot’ is given. By clicking the hyperlink of ‘Search…’, the user may 
further identify and analyze the similar proteins of predicted families to the 
input protein sequence by performing a BLAST searching automatically. 
 
Figure 6-3 An example of SVM-Prot output page for the single-sequence 
submission. 
 
Top 20 similar proteins to the input protein sequence which are in the 
corresponding protein family are identified by BLAST and sorted by E value 




are listed (Figure 6-4). For each protein, a cross-link to the UNIPROT (37) 
database is provided. The user may also click the hyperlink “more…” to get 
the information of more similar proteins in that family. 
 
Figure 6-4 An example of top 20 similar proteins identified by BLAST.




6.2 Prediction of Protein-Protein Interactions 
The genotype to phenotype mapping can only be obtained by considering 
various molecular interactions, since the behavior of the individual 
components is dictated by the system as a whole (268). Protein-Protein 
interactions (PPIs) are involved in virtually all cellular processes and affect 
their outcomes. Proper identification and characterization of PPIs and their 
networks is essential to understand the mechanisms of biological processes on 
a molecular level, and can also facilitate the drug target discovery. As 
described in Subsection 1.4.3, many computational approaches have been 
explored for predicting PPIs. But there are still several challenges that need to 
be improved. Among these challenges, the usability, negative dataset 
construction are two most significant ones. 
Usability  
Implementation of the predicting method in a convenient way is very 
important for the user. However, many PPI predicting methods based on 
complex theories like gene fusion events, genomic and structural properties, 
similarity of phylogenetic profiles etc. Therefore, it is difficult to develop a 
convenient interface to predict the protein pairs, and a user may not be able to 
submit his/her query just because additional information may not be always 
available. Sequence information is generally more abundant and readily 
available than other information used for predicting PPIs. For instance, 
sequence, GO annotation, domain, 3D structure, post-translational 
modifications, and subcellular localization information are available for 100%, 




84.2%, 66.7%, 1.3%, 1.4%, and 18.5% of the ORFs in the yeast genome 
respectively. The percentage of genes with at least one GO annotation is 
significantly lower in many genomes. Therefore, it is highly desirable to 
explore methods that predict PPIs directly from sequence or sequence-derived 
properties (61, 118, 121, 269). 
Moreover, most predicting models that developed before are species-specific. 
Contribution of amino acid residues in protein interaction follow different 
pattern in various organisms. Model developed on one organism could not be 
applied to prediction interaction in another organism (270). So it is also 
important to develop a general model that can be applied to all organisms, so 
that the users can easy to use this model no matter where the protein-protein 
pairs come from. 
Negative Dataset Construction 
Several strategies are used for constructing negative data set. One way is 
based on such an assumption that proteins occupying different sub-cellular 
localizations do not interact (107, 271), but these negative examples lead to a 
biased estimate of the accuracy of a predictor of PPI (272). The second way is 
generating the non-interacting pairs by randomly pairing proteins, and then 
excluding the positive protein pairs in the end (273-276). However, this 
method may not get the protein representatives evenly in the functional area. 
The third way is use artificial protein sequences (61, 277), but artificial 
sequences may have the possibility of not containing any motifs or domains, 
which makes them more distinguished than real protein sequences. So creation 
of negative dataset is much more difficult than that of positive dataset, and 




will affect the performance of the model. In order to reduce the false hit rate as 
illustrated in Subsection 6.2.1, a putative negative dataset which is different 
from those above strategies is generated. 
In this study, we attempt to develop a fast, reliable and general method for 
predicting PPIs with high prediction specificity, which can be further applied 
to a genome-wide protein interactions prediction. A new set of 188 feature 
vectors generated by sequence or sequence-related properties is constructed as 
described in Subsection 2.1.1. Known PPIs of high-confidence values from 
DIP (96), BIND (98), HPRD (99), MINT (97) and IntAct (100) databases and 
the representative protein-pairs of the non-PPIs containing protein-family pairs 
derived from curated Pfam families are used to train a SVM model to classify 
protein-pairs into either the PPI or non-PPI class. A significantly broader 
spectrum of non-PPIs than those of previous studies are used so as to enhance 
the coverage and performance of the model, which are evaluated by a genome-
wide PPIs search test as well as an independent set of PPIs. 
6.2.1 Material and Methods 
Data Collection 
Sufficiently diverse set of known PPIs and non-PPIs is needed to train a SVM 
prediction model. A total of 30,672 PPIs are collected from the core PPI sets 
of DIP database (96), and additional protein-pairs are from BIND (98), HPRD 
(99), MINT (97) and IntAct (100) databases (Table 6-3) that are either 
supported by more than one independent experiments or more than one 
references. Interactions with more than two proteins are removed, since no 




information is available to confirm which two proteins in such complexes 
have physical interactions. After this, PPIs dataset is further divided into two 
datasets according to their release time. 29,714 PPIs that before year 2010 are 
selected for training the model and the left 958 PPIs are put aside for 
independent evaluation. The species distribution of the training dataset is 
shown in Figure 6-5. Construction of non-PPIs is the most critical step for 
model training in machine learning studies. In this thesis, a new method is 
used for selecting putative non-PPIs. 
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Figure 6-5 The species distribution of positive training dataset. 
 
Dataset Construction 
In this study, the feature vector used to represent a protein pair is characterized 
by concatenating the feature vectors of each protein (same as the prediction of 
functional families of proteins introduced in Section 2.1.1) in the pair. 
However, for a pair of protein A and protein B, there are two feature vectors: 
AB and BA. Both feature vectors are used to construct the model. Non-PPIs 
are generated by selecting representative protein-pairs from those Pfam 
family-family combinations (PFFCs) that do not contain a known PPI. Pfam 















functional architecture that is conserved through evolution. Many of the 
protein-interaction problems can be reduced to the problem of domain-domain 
interactions (56, 118, 278-280). Therefore, it is reasonable to construct non-
PPIs on the basis of PFFCs. A method that uses the PPI-depleted protein-pairs 
in a genome as non-PPIs has been found to predict PPIs in that genome 
consistent with experimental findings (279). Hence, this concept can be 
expanded to derive non-PPIs from representative protein-pairs of the non-PPI 
containing PFFCs. In selecting non-PPIs, one protein is selected randomly 
from the seed proteins of each Pfam families. For reducing the computational 
complexity, these selected proteins are clustered into 200 groups using K-
means algorithm. These 200 groups paired with each other and evolution 
Euclidean distances between positive PFFCs and other PFFCs are calculated. 
The PFFCs that closest to positive PFFCs, along with PFFCs that closest to 
two centers of the paired groups, are selected as the representatives of non-
PPIs. This process makes the selected non-PPIs evenly distributed to their best 
extent in the sequence space rather than clustered in regions of high protein 
concentrations. A total of 123,034 non-PPIs, representing 5,898 Pfam families, 
are finally generated by this process. 
Model Training and Evaluation 
The model for predicting PPIs is constructed by SVM. In this work, libsvm 3.0 
(http://www.csie.ntu.edu.tw/~cjlin/libsvm/) is employed. A RBF is chosen as 
the kernel function. To further reduce the complexity of parameter selection, 
hard margin SVM with threshold C  equals 10,000 instead of soft margin is 
used. The kernel width parameter   is optimized using grid searching. In 




statistical prediction, sub-sampling test is used as a validation method. It is 
reported that sub-sampling test cannot avoid arbitrariness (281, 282); however, 
for an extremely large dataset in this study, sub-sampling test is still a 
compromising validation method. 
In total, 57,289 PPI pairs and 123,034 non-PPI pairs have been collected and 
generated. Three-fifths of the proteins pairs randomly selected from both PPI 
and non-PPI pairs are used to construct SVM training dataset, while the 
remaining two-fifths are all used to form testing dataset. A series of SVM 
models are then constructed by scanning different parameter . By applying 
these newly generated models to testing datasets, three parameters including 
sensitivity (SE), specificity (SP) and accuracy (ACC) are used as indicators for 
model performance evaluation.  
6.2.2 Results and Remarks 
In Table 6-4, performances of SVM models based on different parameters are 
shown. From the table, we can see with decrease of parameter  , the 
prediction specificity increases and the prediction sensitivity decreases. As we 
know, specificity is the key factor indicating the false positive prediction rate. 
Take the identification of PPI pairs from human genome as an example. A 
decrease of 1% in specificity may generate 
                                                          
falsely predicted PPI pairs. As estimated (283), there are about    
                                               true PPI pairs for 
human. In other word, 1% lost in specificity can generate a huge amount of 




falsely predicted PPI pairs which are 40 times larger than the number of true 
PPI pairs. Therefore, in order to reduce the false identification rate and keep a 
reasonably high prediction sensitivity, sigma 30 is selected as the ideal 
parameter for PPI prediction model.  
Table 6-4 Performances of SVM models based on different parameters. 
*Sigma is a parameter to adjust parameter Gamma, and it is more sensitive 
than Gamma. Gamma = 1 / (Sigma * Sigma). TP, TN, FP, FN, SEN, SP, AC 
and MCC are true positive, true negative, false positive, false negative, 
sensitivity, specificity, accuracy and Matthews correlation coefficient, 
respectively. 
Sigma* Gamma TP TN FP FN SE SP ACC MCC 
25 0.0016 7439 49040 158 15466 32.48 99.68 78.33 0.24 
26 0.001479 8594 48992 206 14311 37.52 99.58 79.87 0.28 
27 0.001372 9638 48916 282 13267 42.08 99.43 81.21 0.31 
28 0.001276 10670 48862 336 12235 46.58 99.32 82.57 0.35 
29 0.001189 11580 48812 386 11325 50.56 99.22 83.76 0.39 
30 0.001111 12475 48753 445 10430 54.46 99.1 84.92 0.42 
35 0.000816 15711 48502 696 7194 68.59 98.59 89.06 0.56 
40 0.000625 17822 48371 827 5083 77.81 98.32 91.8 0.66 
45 0.00049 19064 48335 863 3841 83.23 98.25 93.48 0.72 
50 0.0004 19816 48285 913 3089 86.51 98.14 94.45 0.76 
55 0.000331 20233 48238 960 2672 88.33 98.05 94.96 0.78 
60 0.000278 20447 48172 1026 2458 89.27 97.91 95.17 0.79 
 
By applying the newly generated model (Sigma=30) to those 958 independent 
evaluation PPI dataset identified after year 2010, 62.1% of these PPIs can be 
predicted. Moreover, the practical usefulness of this model can be more 
rigorously evaluated by subjecting it to the tests of genome-wide PPIs search. 
The sensitivity P+ of each genome search test can be estimated by the 
percentages of correctly predicted known PPIs in that genome. The specificity 
P- of each test can be estimated as follows: the number of PPIs in a genome 
NPPI has been estimated as 3N~10N (N is the number of its encoded genes) 




(283), from which the minimum number of non-PPIs, Nnon-PPI can be estimated 
as N×N-10N. Let NPPI be the number of predicted PPIs in a genome, P- can be 
estimated as P- = 1 – (NPPI –P+*NPPI)/(N×N-10N). The yeast genome is firstly 
scanned, 7,038 proteins of yeast are downloaded from the Swiss-Prot database, 
the estimated P+ and P- for the yeast genome search tests, which are 61.6% and 
91.4%.  
As our observation, though the result is comparable to other studies (61, 148), 
taking the previous human genome estimation as an example, the specificity of 
the model is still not high enough for genome scans. We check the Pfam 
families’ distribution of the training dataset, and find that there are 4,546 Pfam 
families in the positive dataset and 5,898 Pfam families in the negative dataset, 
but there are only 1,602 distinct Pfam families involved in the negative dataset. 
That means many non-PPIs share the same Pfam and their diversity is not high 
enough. So in the next step, we could add additional criteria into the non-PPIs 
selection: every Pfam family can only appear a certain times in non-PPIs 
selection. Thus the families of negative dataset may cover more distribution 
space and improve the specificity of the prediction. Moreover, a thoroughly 
parameter searching such as five-fold cross-validation can be performed to get 
the most suitable parameter and enhance the performance of the model. 
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Chapter 7 Conclusion and Future Work 
This final chapter summarizes the major findings and contributions of this 
study (Section 7.1). Limitations of present study and suggestions on possible 
areas for further studies are discussed in Section 7.2. 
7.1  Major Findings and Contributions 
Corresponding to three sub-objectives which proposed in Subsection 1.5.1, 
this section is also separated into three subsections.  
7.1.1 Data Collection and Computational Methods Integration 
In modern time, with the data explosion in the field of pharmaceutical research, 
data collection and representation become more important than before. TTD 
serves as a pioneering and reliable knowledge base on the information of 
drugs, targets and related others, has been widely used in the of studies of drug 
discovery. However, data collection and updating is a never end progress, 
updating TTD to let it keep up with the expansion speed of modern data in the 
field of pharmaceutical research remains critical. In this work, we significantly 
update TTD contents to include: 
 388 successful, 461 clinical trial, and 1467 research targets. 
 2,003 approved (1,008 NP derived), 3,147 clinical trial (369 NP 
derived), and 14,856 experimental drugs. 
 200 drug scaffolds for 700 drugs. 
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Moreover, modern drug development is transferring from being primarily 
focused on targeted therapeutics to stratified and personalized medicines. For 
better serving multiple bench-to-clinic communities, we use a new strategy by 
using widely used ICD codes to retrieve the target, drug and biomarker 
information. This strategy can facilitate automatic data access, processing and 
exchange by different communities, particularly non-domain experts. 
Currently, almost 900 targets, 6,000 drugs and 1,800 biomarkers related to 900 
disease conditions are cover by ICD-9-CM and ICD-10-CM. The ATC 
Classification System codes for 1,521 approved drugs are also added for 
supporting the convenient and automated access of clinical drug data. All 
these efforts make TTD become a potential useful source for the development 
of stratified and personalized medicines.  
To take the challenge that tools for cheminformatics are mostly difficult to use 
and the number of them is few, Molfeat is developed. It combines four kinds 
of analysis directions for small molecules: 
 molecular representation methods (molecular descriptors and 
fingerprints).  
 molecules clustering methods (hierarchical clustering, K-means 
clustering).  
 molecules classification methods (SVM, KNN, PNN). 
 21 QSAR models.   
Besides combining different kinds of small molecules analysis tools together, 
one outstanding feature of Molfeat is that it has the ability to automatically 
generate putative inactive molecules used for machine learning methods. 
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Finally, coupled with the user-friendly webpage design, Molfeat is accessible 
not only to scientists with limited computational background, but also to those 
advanced users. 
7.1.2 Analysis and Modeling of Therapeutic Agents 
As describe in Section 1.2, almost 20 years after discovery focus has shifted 
away from natural NPs, nature-derived drugs still represent substantial share 
of newly approved drugs. This raises three important questions that have not 
been addressed:  
1) are the recently approved nature-derived small molecule drugs the old era 
leftovers or the new era products?  
2)  what characters, sources and methods have contributed to the selection of 
their natural product leads when the odds were supposed to be against 
them  
3)  what are the deficiencies in these leads and what strategies have been  
used for overcoming them in optimizing them into drugs. 
In this study, we address these questions by evaluating the characters and 
development history of 32 nature-derived small molecule drugs approved by 
FDA in 2008-2012 with respect to other drugs approved in 2008-2012 and 
before 2008. Apart from pharmaceutical industry, a large number of research 
labs are working on lead discovery and optimization, and on NP based 
discovery, but many are inexperienced in lead selection and having difficulties 
in lead optimization. Thus this work can help them in revealing discovery 
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trends, lead characters, and successful optimization strategies for guiding their 
efforts. 
Some NPLDs are known to congregate in the sweet spots of the chemical 
space. But the extent, patterns and causes of NPLD congregation need to be 
studied. We investigate these questions by profiling 442 NPLDs in the 
chemical space represented by the scaffold and substructure-fingerprint trees 
of 137,836 non-redundant NPs. For the first time, we derive the most 
comprehensive distribution patterns of NPLDs in the chemical space and find 
that they tend to cluster together in the chemical space. In the scaffold trees, 
62.7% approved and 37.4% clinical trial NPLDs congregate in 62 drug-
productive scaffolds/scaffold-branches. In the substructure-fingerprint tree, 
82.5% approved and 63.0% clinical trial NPLDs are clustered in 60 drug-
productive clusters (DCs), because of their preferential binding to 45 
privileged target-site classes.  
Analysis of these clustered NPLDs with respect to historical drug approvals 
and the distribution profiles and exploration timelines of bioactive NPs 
suggest that these clusters expand slowly in number by using conventional NP 
extraction and drug discovery technologies, and the lack of drug outside these 
clusters is not necessarily due to under exploration and late exploration by 
conventional technologies. New technologies (250, 251, 284) are expected to 
significantly expand the NP sub-spaces and the pool NPLDs (250, 251). 
However, their impact on the distribution of NPLDs is yet to be determined. 
Our revealed tendencies of NPLDs to cluster together in the chemical space 
and to preferentially bind to the privileged target-sites in the target space may 
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provides useful clues about new NP leads, and lead sweet spots in the NP-
subspaces with respect to the corresponding target-sites . These derived 
insights are useful for NPLD discovery as demonstrated by the recognition of 
the new NPLDs of 2013-2014 approved drugs. In addition, coupled with 
expanded knowledge of drug-like structures (186-188) may enable more 
prioritized and rational exploration of the NP-subspaces and NP scaffolds for 
drug discovery. 
7.1.3 Modeling and Prediction of Therapeutic Targets 
In this study, we have built an integrative method for functional classification 
of a protein from its amino acid sequence using three machine learning 
algorithms: SVM, KNN and PNN. 157 protein families are trained and 
covering all major classes of enzymes, inhibitors, receptors, channels, 
transporters, binding proteins and many other functional families. The overall 
accuracy ranges from 73.57% to 99.98% for SVM models, ranges from 70.91% 
to 99.96% for PNN models, and ranges from 85.2% to 99.95% for KNN 
models, which are on average comparable to that obtained in other machine 
learning studies of proteins, and the specificity ranges from 99.14% to 100%, 
97.43% to 100%, and 72.97% to 99.99%, respectively, which are higher than 
previous reported methods (152, 153, 164-166). This study suggests that our 
method has potential in the classification of proteins into functional families, 
and may be used as a protein function prediction tool that complements 
sequence alignment methods, and further provide useful information for 
protein target discovery. 
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For PPI prediction, a SVM model also based on primary sequence has been 
developed. Non-PPIs are generated by selecting representative protein-pairs 
from PFFCs, and this new strategy provides a significantly broader spectrum 
of non-PPIs than those used in previous studies so as to enhance the coverage 
and performance. The practical usefulness of this model is further validated by 
a yeast genome search study; the estimated sensitivity and specificity are 61.6% 
and 91.4%.  In this study, different from other related studies, we focus on 
specificities of models more than their sensitivities, since there are a huge 
number of proteins and their interactions in the real world. A slight decline of 
specificity would induce tremendous false positives. The final results suggest 
that our methods are potentially useful for PPI analysis. 
7.2  Limitations and Suggestions for Future Studies 
Consistent with the reported studies on specific NP drug scaffolds and several 
drug target classes, we find that to a larger extent the NPLDs are primarily 
clustered together in the NP-subspaces of the chemical space because of their 
preferential binding to privileged target-site classes. Our revealed NPLD 
distribution pattern provides useful clues about the drug-productive and 
potentially-promising regions of NP-subspaces and specific NP scaffolds, 
which coupled with expanded knowledge of drug-like structures, may enable 
more prioritized and rational exploration of the NP-subspaces and NP 
scaffolds for drug discovery. However, we have not answered what 
physicochemical properties of NPLDs are contributing to the clustering in this 
work.  
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Lipinsk’s RO5 (285), which is derived from a database of drug candidates 
achieved Phase II clinical status, states that a high probability that oral activity 
problems are likely to happen when physicochemical properties of a molecule 
meets one or more following criteria: molecular weight of the molecule is 
larger than 500 daltons; the calculated octanol-water patition coefficient logP 
(ClogP) is larger than 5; the number of hydrogen-bond donors (sum of O and 
N atoms with one or more hydrogen atoms) is larger than 5; and the number of 
hydrogen-bond acceptors (sum of O and N atoms) is larger than 10. This rule 
has been commonly used in the screening of orally active compounds, and 
gained wide acceptance as an approach to reduce attrition in drug discovery 
and development. So finding some physicochemical parameter ranges for NPs 
is definitely an attractive study topic.     
Hence, the further work can be conducted by comparing physicochemical 
profiles with different strategies: 
 Comparing compounds which fall in the drug-productive and potentially-
promising regions with those outside the regions to find the specific 
properties of clusters. 
 Comparing NPLDs in different clinical stages with the rest of NPs to find 
drug-like properties of NPs. 
Moreover, machine learning methods may also be applied to classify the 
potential NPLDs from NPs based on the data we collected in this study. 
For the study of protein functional class prediction, several factors may affect 
the accuracy of prediction, where the diversity of protein samples is the most 
important one. It is likely that not all functional classes have adequate 
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representatives of possible types of proteins. However, along with the 
availability of more protein data, this problem can be improved. In addition, 
more rigorous genome-wide search may be performed to validate the 
performance of each protein family. Based on this search, training parameters 
can be refined to better fit the real world applications.  For PPIs prediction, as 
described in Subsection 6.2.2, the estimated sensitivity and specificity of PPI 
prediction on the yeast genome search are 61.6% and 91.4%. The result is 
comparable to those of other studies. However, the specificity of the model is 
still not high enough for genome scans, which is partly due to the limitation of 
computing capability.  In this study, 13,671 Pfam seed proteins are randomly 
selected and grouped into 200 clusters for generating the non-PPIs. 200 is 
relatively small comparing to 13,671 Pfam family number. So in the next step, 
a much larger number of groups can be attempted to apply.  Moreover, a 
thorough parameter searching method such as five-fold cross-validation can be 
performed to get the most suitable parameters and enhance the performance of 
the model. More comprehensive and refined set of protein descriptors may 
also be applied to these two studies to further improve the performances. 
For the TTD, continuing efforts can be made to expand the linkage of the ICD 
and ATC codes to more complete sets of drugs, efficacy targets and 
biomarkers. Ensure TTD to provide the latest and comprehensive information. 
A new ICD version ICD-11 is in development and scheduled for endorsement 
by WHO in 2015, which offers more refined disease classifications based on 
more recent scientific understanding of the disease mechanisms. For instance, 
small cell lung cancer, which represent ~13% of all lung cancer diagnoses 
(286), is not explicitly classified in the ICD-10 and earlier ICD versions but is 
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now explicitly represented in the ICD-11 beta draft. Therefore, ICD-11 is 
expected to be more useful for developing a more refined disease 
classification system for stratified and personalized medicine. Effort will be 
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Homoharringtonine (HHT) is a natural alkaloid that is 
obtained from various Cephalotaxus species. In mid 1990s, 
HHT was studied  as salvage therapy for patients with chronic 
myeloid leukemia (CML) after failure on interferon-alpha 
therapy. However, the remarkable success of imatinib 
mesylate in the treatment of CML relegated HHT to oblivion. 
The development of omacetaxine mepesuccinate, a 
subcutaneously bioavailable semisynthetic form of HHT, and 
its activity in imatinib-resistant CML has established this agent 
for the second time as a valuable option in the management of 
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Crofelemer, a purified proanthocyanidin oligomer extracted 
from the blood-red bark latex of the South American medicinal 
plant Croton lechleri (dragon's blood). The sap of C. lechleri 
has been used in South American countries like Ecuador and 
Peru for many years to treat diarrheas, including dysentery and 
cholera, and various lung, stomach, and other conditions. In 
early 1990s, Crofelemer was isolated from the plant latex used 
by the indigenous people. In late 1990s, additional 
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Epoxomicin was first discovered by Bristol-Myers Squibb 
strain, No. Q996-17, based on its in vivo antitumor activity 
against murine B16 melanoma tumors. Despite its promising 
antitumor activity, epoxomicin did not draw much attention 
because of its poor drug-like properties, namely the presence 
of a peptide backbone and the labile epoxy ketone 
pharmacophore,  epoxomicin possesses unprecedented 
selectivity for proteasome,  an effort to optimize the compound 
via a classical medicinal chemistry approach led to YU-101, 
which showed more potent nhibitory activity against the 
proteasome than both epoxomicin and bortezomib, a boronic 
acid-based synthetic proteasome inhibitor previously known 
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The unique pharmacological effects of  the natural ligand 
SRIF-14 are from its universal high-affinity binding to all 
somatostatin receptor subtypes sst1-sst5. However, SRIF-14 
has a very short in vivo half-life of less than 3 min, limiting its 
therapeutic utility, capitalizing on structure-activity 
relationships and involving transposition of functional groups 
from SRIF into a reduced size cyclohexapeptide template, has 
led to the discovery of SOM230, a novel, stable 
cyclohexapeptide somatostatin mimic that exhibits unique 
high-affinity binding to human somatostatin receptors 
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Isolated in 1986, shown good activity in 1987, and good PK in 
2004, remained unexplored until the late 90’s when Optimer 
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In 1993-1994, abiraterone acetate (AA) was developed as a 
selective and irreversible inhibitor of CYP17. Building on the 
efficacy of ketoconazole while trying to address its limitations, 
AA was developed by rational design based on a pregnenolone 
parent structure. Identification of key molecular features  
provided for more potent inhibition of CYP17, clinical trial 
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Reported in 2002, HTS of 500K compounds identified a lead 
with NP scaffold, optimization leads to Highly Potent, 
Selective, Long-Acting, and Orally Bioavailable DPP-4 
Inhibitor, A unique characteristic of linagliptin that 
differentiates it from other members of the class is its 









































Reported in 2000, using ATP, the natural antagonist (pIC50 = 
3.5) of the P2Y12 receptor, as a chemical starting point, 
Ticagrelor was discovered as a potent and selective P2Y12 
























































Soon after the NNRTIs were being used in clinical settings, it 
became apparent that this class of RT inhibitors is vulnerable 
to HIV’s high mutation rate, Mutations in the NNRTI binding 
pocket render the inhibitors inactive without affecting dversely 
the catalytic competency of the RT enzyme, structural 
modification of loviride lead to DATA, but it is ineffective 
against then newly emerged double mutants of the HIV-1 
virus. In 1998, replacement of key components by NP 
pyrimidine and further structual modification of other 
structural components lead to an atractive drug lead DAPY 
(R147681) with potent inhibition against double mutations, 
further optimization in 1999 and 2001 lead to the discovery of 






















































  HCV 
Reported in 2000, Initial studies to make a peptidomimetic 
inhibitor began with truncation of a decamer peptide inhibitor 
derived from the natural NS5A-5B substrate, based on the 
Examination of the crystal structure that shows protease active 
site is extremely hydrophobic, flat and exposed to solvent, 
with few pockets to increase the affinity for an inhibitor to 
bind, parts of the natural substrate that were critical for binding 
to the protease active site were spread over a large surface 
area, consistent with the co-complex crystal structure of the 
HCV protease domain with the decamer peptide, To 
compensate and increase affinity,  a reversible covalent 
inhibitor tetraaldehyde peptide was developed and used as a 
starting point for deriving the drug (22068541) 


























































Reported in 1999, The Bradykinin B2 receptor antagonist 
HOE 140 (D-Arg-Arg-Pro-Hyp-Gly-Thi-Ser-D-Tic-Oic-Arg) 
was used as a template for the de novo design and synthesis of 
a small number of non-peptide lead compounds based on the 
1,4-benzodiazepin-2-one framework. Two of the compounds 
have been found to exhibit moderate K(i) values of 8.9 and 9.2 
microM at the human Bradykinin B2 receptor, which in 2001 















































In late 1970s,  glucocorticoid receptor antagonist  RU 38486 
was derived based on Progesterone scaffold, which also 
displayed marked antiprogestin activity, leading to the 
development of mifepristone, then Ulipristal (CDB-2914) were 
subsequently developed in the 2000s for improved target 
selectivity (i.e. good progesterone antagonist and lower 





























































Reported in 1987, GLP-1 was identified as an incretin 
hormone and shown to be more effective than GIP in 
stimulating insulin release on a molar basis. In 1993, GLP-1 
was found to have anti-diabetes effect,  but is degraded by 
DPP-4 leading to shortend half-life, since early 2000s efforts 
have been directed at the development of non-peptide analogs 












































Reported in 1979, peptides resembing thrombin natural 
substrate sequence was found to inhibit thrombin, In early 
1990s, NAPAP was derived as peptidomimetic thrombin 
inhibitor, In 2002, on the basis of the X-ray crystal structure of 
the peptide-like thrombin inhibitor NAPAP complexed with 
bovine thrombin, non-peptide analog was developed for 





























































In mid 1980s,  highly potent anticancer Halichondrin B was 
discovered from compounds isolated from a marine species 
based on bioassays, In 2004, structurally simplified analog of a 
resource-strained  bioactive NP, Halichondrin B, was derived 
















































In early 1990, ISP-1 was identified as the source of 
immunosuppressant activity from the culture broth of Isaria 
sinclairii and displayed a nearly 10-fold increase in activity 
over cyclosporin A. Remarkably ISP-1 achieves its biological 
ctivity in a much simpler structure than cyclosporin A. The 
amphiphilic nature of ISP-1, imparts the compound with poor 
cellular permeability and oral bioavailability; since 1995 the 
lead optimization effort sought to improve these properties, 
Simplification of the parent structure by removing 
functionality or chirality helped to identify the minimum 
pharmacophore required for activity, many of the simplified 
analogs continued to be more potent than cyclosporin A in 
vitro, quite a remarkable result given the further simplification 
of the parent. The next breakthrough was the replacement of a 
part of the fatty acid side chain with 1,4-disubstituted phenyl 









































Taxol was discovered in the mid 1960s by LTS. Cabazitaxel is 
a semisynthetic taxane that was selected for development in 


















































In 2000, some cephalosporin derivatives were generated and 
found to possess anti-MRSA activities comparable to that of 
vancomycin, but with unsatisfactory physicochemical and 
pharmacokinetic properties,  only one of them possess 
sufficient water-solubility  but insufficient chemical stability 
for drug storage, in 2003 that compound was optimized into a 







































Artemisinin, discovered in 1971 from traditional Chinese 
medicinal plants,  has low solubility and stability because of its 
lactone ring, In late 1970s to early 1980s, successful reduction 
of this lactone ring was achieved with sodium borohydride, 
which lead to the formation of dihydroartemisinin, which had 
a two-fold higher antimalarial activity than its mother 
compound, is well tolerated, and its production is easier and 
cheaper. Although hydroartemisinin was still poorly soluble, it 
was used for the preparation of several first generation 
derivatives, Subsequent studies showed that the secondary 
hydroxy group of dihydroartemisinin provides the only site for 
derivatization without loss of antimalarial activity, in 1998, 
further optimization efforts led to the drug with improved drug 



















































Vancomycin was discovered in mid 1950s, In 1989-1993, to 
design drugs against vancomycin-resistant bacteria, 
vancomycin was modified by adding hydrophobic substituents, 
which impart unfavorable ADME with prolonged elimination 
half life and high tissue accumulation, subsequent optimization 
efforts by adding hydrophilic group leading to the drug lead 



















































Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-
CoA) (‘statins’), initially isolated from nature in mid 1970s, 
have been widely used clinically, but some of them are 
metabolized by P450, making them prone to drug-drug 
interaction induced serious adverse effects, in late 1990s 
Pitavastatin was derived based on the statin scaffold as a 
















































The NP rapamycin, isolated in 1975 and found to have 
anticancer effect in 1984, binds to FK506-binding protein 12 
(FKBP12), and the resultant protein–drug complex inhibits the 
kinase activity of mTOR4. Rapamycin has 
immunosuppressive, antifungal and anticancer activity, but its 
development as an immunosuppressant was prioritized, and it 
was approved by the FDA for the prevention of transplant 
rejection in 1999. Multiple derivatives of rapamycin have been 
synthesized and evaluated with the aim of improving its 
pharmaceutical properties, and such efforts led to the 
discovery and development of temsirolimus (which is 
administered intravenously) for RCC and everolimus  (which 
can be orally administered). In 2003, everolimus was approved 
for the prevention of transplant rejection in Europe, where it is 






























































In late 1990s, A compound screening campaign against 
VEGFR2 kinase was conducted using kinase - focused 
screening sets comprised of compounds from (1) prior and 
ongoing kinase programs, (2) literature - based kinase  
hemotypes, and (3) chemotypes that originated through 
structure - based design, which identified an olomocine 
derivative (olomocine is a zeatin derivative) as a potent 
inhibitor, which is further optimized into potent drug with 

































































In 1975, based on the hypothesis of that substrate analogs may 















































In 1993, in screening of anticancer NPs, an NP was found to 
show anticancer acvitity, subsequently, it was found to inhibit 
multiple cell-lines in NCI60 screening, in 1998, it was found 
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In the late 1970s, it was that cancerous cells take in natural 
folate through a protein RFC-1. Further research showed that 
when normal cells evolve into cancerous cells they often 
overproduce RFC-1 to ensure they get enough folate, reported 
in 1993, potent NP derivatives (folate analogs) were optimized 
for deriving  an antifolate agent that could be more effectively 
internalized into tumors (transported into the cells through 
RFC-1) led to the discovey of the drug that is 5 times more 
























































Antidepressant drug discovery effort was focused on the multi-
targeting of (1)reuptakes and (2) the down-regulation of 8-
adrenoceptors caused by chronic antidepressant therapy. 
Natural product alkaloid libraries such as benzylamines have 
been generated and evaluated as sources for drug discovery, 
some of these benzylamines have been found to produce 
analgic effect, based on which benzylamine derivatives were 
derived, in particular, ciramadol was derived in 1975 that 
showed potent analgesic activity due to its opioid agonist and 
antagonist activity. Reported in 1990, because of its structural 
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derivatives were derived for finding antidepressant agents with 
the ability to both inhibit neurotransmitter uptake inhibitory 
and desensitize 6-adrenoceptors, which derived venlafaxine,  
further optimization for reducing interaction with CYP and 
Pgp to improve PK (metabolism and BBB crossing) lead to 
























Methylnaltrexone (MNTX) is one of the newer agents of 
peripherally-acting μ-opioid antagonists with ability to reverse 
some of the side effects of opioid drugs such as constipation 
without affecting analgesia or precipitating withdrawals. 
Thousands of opioid-like molecules had been synthesized by 
pharmaceutical companies looking for the better analgesic , in 
1963, screening these compounds led to the examination of 
putative antagonists which when modified might not readily 
cross the blood–brain barrier based on their size and charge, 
MNTX looked promising and passed initial screening in which 
rodents were given opioids along with charcoal meals to track 
GI transit, and were tested for analgesia in the late 1970s, In 
December 2005, Wyeth and Progenics entered into an 
exclusive, worldwide agreement for the joint development and 
commercialization of methylnaltrexone for the treatment of 
opioid-induced side effects (US patent 3101339, US patent 































































Peptide and mimetic GnRH antagnosts have been derived 
since the early 1970s. Reported in 2000, GnRH decapeptide 
mimetics have low solubility that affect bioavailability and 
formulation, these were further optimized for improved 
solubility and half-life (metabolic stability and delayed 






































































In 2000, Ro 63-9141 was derived as a new member of the 
pyrrolidinone-3-ylidenemethyl cephem series of 
cephalosporins, and found to have potent antibacterial activity. 
It differs from older, broad-spectrum cephalosporins in that it 






















































The NP drug artemisinin has low solubility and stability 
because of its lactone ring, In late 1970s to early 1980s, a 
water soluble derivative Artesunate was derived and 
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SI Appendix Table S2 Statistics of the 62 drug lead productive scaffolds in the scaffold hunter derived molecular scaffold trees of 134,097 









Drug-Productive Scaffold(s) in DS 
No of 
Scaffolds 













1 2 (2/0) 3 (3/0) 
DS2 (2) 
 
1 2 (1/2) 5 (2/3) 
DS3 (2) 
 
2 3 (3/0) 5 (5/0) 





2 3 (3/0) 6 (6/0) 
DS5 (2) 
   
3 4 (4/2) 18 (16/2) 
DS6 (3) 
 
1 3 (3/0) 3 (3/0) 
DS7 (3) 
  
2 2 (1/1) 2 (1/1) 





2 2 (2/0) 2 (2/0) 
DS9 (3) 
 
1 2 (2/0) 3 (3/0) 
DS10 (3) 
    
    
17 39 (32/8) 84 (72/12) 
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1 2 (1/1) 4 (3/1) 
DS12 (4) 
   
3 3 (3/0) 21 (21/0) 
DS13 (4) 
   
3 5 (5/0) 11 (11/0) 
DS14 (4) 
 
1 2 (2/0) 7 (7/0) 
DS15 (5) 
 
1 3 (3/0) 5 (5/0) 





4 4 (4/0) 5 (5/0) 
DS17 (5) 
   
3 7 (7/0) 11 (11/0) 
DS18 (5) 
    
4 4 (4/0) 14 (14/0) 





2 2 (1/1) 5 (1/4) 
DS20 (6) 
 
1 2 (1/2) 6 (1/5) 
DS21 (7) 
  
2 2 (2/1) 3 (2/1) 
DS22 (8) 
   
4 5 (5/0) 5 (5/0) 





   
3 3 (3/0) 8 (8/0) 
DS24 (9) 
 
1 7 (4/3) 15 (10/5) 
DS25 (9) 
  
2 2 (1/2) 11 (3/8) 





1 2 (2/1) 3 (2/1) 
DS27 (11) 
  
2 2 (1/1) 3 (1/2) 
DS28 (12) 
 
1 4 (4/1) 7 (5/2) 
DS29 (12) 
  
2 2 (2/1) 3 (2/1) 
DS30 (13) 
 
1 2 (2/0) 3 (3/0) 





2 5 (5/0) 9 (9/0) 
DS32 (13) 
 
1 4 (4/0) 7 (7/0) 
DS33 (14) 
  
2 2 (2/0) 3 (3/0) 





2 3 (3/1) 13 (9/4) 
DS35 (16) 
 
1 3 (3/0) 9 (9/0) 
DS36 (16) 
  
2 2 (2/0) 2 (2/0) 
DS37 (17) 
 
1 3 (3/0) 5 (5/0) 




   
3 4 (3/2) 33 (11/22) 
DS39 (18) 
  
2 2 (2/0) 2 (2/0) 
DS40 (19) 
  
2 2 (1/2) 8 (1/7) 
DS41 (20) 
 
1 2 (2/1) 56 (51/5) 





1 2 (1/2) 15 (8/7) 
DS43 (20) 
 
1 3 (3/0) 31 (31/0) 
DS44 (21) 
 
1 4 (4/1) 13 (10/3) 





1 2 (2/0) 3 (3/0) 
DS46 (22) 
 
1 2 (2/0) 2 (2/0) 
DS47 (23) 
 
1 2 (2/1) 5 (4/1) 





1 4 (4/0) 7 (7/0) 
DS49 (25) 
 
1 2 (2/0) 2 (2/0) 
DS50 (26) 
 
1 2 (1/1) 2 (1/1) 
DS51 (27) 
 
1 3 (3/0) 7 (7/0) 





1 2 (2/0) 2 (2/0) 
DS53 (29) 
 
1 2 (2/1) 6 (4/2) 
DS54 (30) 
 
1 2 (2/0) 1 (1/0) 
DS55 (31) 
 
1 3 (2/1) 4 (3/1) 





1 2 (2/0) 2 (2/0) 
DS57 (33) 
 
1 2 (2/0) 7 (7/0) 
DS58 (34) 
 
1 2 (1/2) 6 (2/4) 
DS59 (35) 
 
1 21 (18/5) 51 (43/8) 





1 2 (1/1) 2 (1/1) 
DS61 (37) 
 
1 2 (2/0) 12 (12/0) 
DS62 (38) 
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SI Appendix Table S3 Statistics of the 60 drug lead productive clusters in the molecular-fingerprint Tanimoto-coefficient similarity clustering 
tree of the natural product chemical space represented by 137,836 natural products and 442 natural product leads. These clusters are labeled as 

























Target Site SuperClass 
(TS) 
TS Id Target Site Class (TC) TC Id 
DC1 (1) 11 2 (2/0) 3 (3/0) Uracil  analogs nucleobase binding sites TS2 
Pyrimidine metabolism 
enzymes substrate binding 
sites 
TC3 










DC3 (1) 28 2 (2/0) 3 (3/0) 
Sulfur-containing 
amino acids 




fatty acid metabolism 
enzyme substrate sites 
TC36 
DC4 (3) 225 4 (4/2) 14 (12/2) 
linear derivatives of 
amino acids with 
very short acyclic 




serine endopeptidase  








































DC7 (3) 217 15 (15/0) 23 (23/0) 
Amino acids with 
acyclic hydroxyl side 
chain & derivatives 
amino acid binding sites TS8 
amino acid receptors ligand 
binding sites 
TC20 
amino acid metabolism 
enzymes substrates binding 
sites 
TC21 




ß-lactam binding protein 
peptidoglycan binding sites 
TC29 
DC9 (3) 258 7 (3/4) 8 (4/4) Larger oligopeptides 
amino acid binding sites TS8 



















serine endopeptidase  




67 4 (1/4) 10 (1/9) 
Polyketide 
macrolactones, 











180 5 (5/0) 9 (9/0) 
Purine base analogs, 
modified purine base 
analogs 
nucleoside binding sites TS3 
purine nucleoside receptor 
















nucleoside binding sites TS3 
purine nucleoside receptor 










receptor ligand binding 
sites 
TC9 






4104 5 (5/1) 31 (15/16) 
Larger indole 
alkaloids 
amine binding sites TS1 














71 3 (2/1) 5 (4/1) 
Mono-, Sesqui-, Di-
terpenes with simple 
fatty acid, cannabinoid, 
eicosanoid, retinoid 
TS15 
retinoid receptor ligand 
binding sites 
TC37 
                                                                                                                                                                                                                 APPENDICES                                                                                                                                                                         
204 
 
ring scaffolds binding sites 
DC16 
(13) 
11 3 (2/3) 9 (3/6) Small cyclic peptides 









oligopeptide histone tail 
metabolism enzymes 

















ribosome 23S rRNA 
peptidyl transferase sites 
TC25 










steroid binding sites TS19 





546 37 (32/5) 93 (85/8) 
Steroids & 
derivatives 
steroid binding sites TS19 





34 2 (2/0) 2 (2/0) Leukotrienes         
DC21 
(14) 
423 9 (8/1) 27 (26/1) 
Fatty acids & 
derivatives, 
Prostanoids 




retinoid receptor ligand 
binding sites 
TC37 
coenzyme A & analog 
binding sites 
TS16 
coenzyme A & analog 
metabolism enzymes 
substrate binding sites 
TC40 
DC22 185 3 (2/1) 3 (2/1) Sesquiterpene oligopeptide binding TS9 exopeptidase substrate TC23 





sites binding sites 
DC23 
(16) 



















259 5 (5/0) 5 (5/0) 
Oligo-, Poly-,  
Cyclic- saccharides 
cyclic oligosaccharide 
drug delivery systems 
TS13 





3 2 (2/0) 7 (7/0) Secosteroids steroid binding site TS19 





9 2 (2/0) 7 (7/0) Statins 
coenzyme A & analog 
binding sites 
TS16 
coenzyme A & analog 
metabolism enzymes 




1394 8 (4/5) 13 (4/9) 
Sesqui-, Di-terpenes 
with steroid-like 











ribosome 23S rRNA 
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Macrocyclic lactones calcium channel DHP 
binding site 
TC14 





30 2 (2/0) 2 (2/0) 
ß-triketones , Cyclic 
ketones of the 
hydroaromatic 
terpene group 
        
DC31 
(8) 
399 5 (4/1) 9 (8/1) 
Phenethylamines & 
Benzylamines with a 
shorter side-chain, 
Chalconoids 
amine binding sites TS1 

















393 4 (4/1) 16 (13/3) 
Nitrobenzene 
analogs, benzene-1,4- 
dicarboxylic acids & 












ribosome 23S rRNA 




331 3 (2/1) 3 (2/1) 
Phenethylamines 










67 6 (2/4) 8 (2/6) 
Depsipeptides, 
Cyclotetrapeptides, 




oligopeptide histone tail 
metabolism enzymes 
substrate binding sites 
TC24 
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cell wall peptidoglycan 
sites 
TC30 
saccharide binding sites TS12 
polysaccharide metabolism 
enzyme substrates binding 
sites 
TC33 










ribosome 23S rRNA 




33 7 (7/1) 34 (32/2) 
Intermediate-sized 









ligand binding sites 
TC22 












kinase ATP binding sites TC11 




DC40 519 7 (5/3) 12 (8/4) Porphyrins, Reduced amine binding sites TS1 amine receptors ligand TC1 






,  Epibatidine- 
alkaloids 
binding sites 
nucleobase binding sites TS2 DNA intercalation sites TC4 
DC41 
(26) 
78 2 (1/1) 3 (2/1) 
Smaller indole 
alkaloids 
amine binding sites TS1 












amine binding sites TS1 





29 5 (5/0) 10 (10/0) Tropane alkaloids amine binding sites TS1 








358 5 (5/0) 21 (21/0) 
Catecholamines, 
Small alkaloids with 
an amine group 
amine binding sites TS1 
amine receptors ligand 
binding sites 
TC1 
opiate binding sites TS18 























20 3 (3/1) 7 (5/2) Vinca alkaloids microtubule sites TS17 microtubule taxoid site TC42 
DC47 
(33) 

















substrate binding sites 
TC17 








943 4 (4/1) 5 (4/1) 
Colchicine  alkaloids, 
Phthalideisoquinoline 
alkaloids 
microtubule sites TS17 microtubule taxoid site TC42 
DC49 
(32) 




amine binding sites TS1 
amine receptors ligand 
binding sites 
TC1 
opiate binding sites TS18 





















27 2 (2/1) 5 (3/2) 
Calicheamicins, 
Enediynes 
        
DC52 
(10) 
663 3 (3/0) 4 (4/0) 
Small phenolic 
molecules 
fatty acid, cannabinoid, 
eicosanoid, retinoid 
TS15 
retinoid receptor ligand 
binding sites 
TC37 
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binding sites eicosanoid metabolism 




2531 9 (5/4) 17 (9/8) 
Cannabinoids, Small 
phenolic molecules 
with a long tail 




fatty acid metabolism 
enzyme substrate sites 
TC36 




















472 3 (3/0) 5 (5/0) 
Anthraquinones & 
derivatives 
nucleobase binding sites TS2 DNA intercalation sites TC4 
DC56 
(11) 

















        
DC58 
(12) 
105 2 (2/0) 5 (5/0) Furanochromones         
DC59 
(12) 
500 3 (3/2) 5 (3/2) Flavanones 




fatty acid metabolism 




32 2 (1/1) 2 (1/1) 
Phenylpropanoids & 
derivatives 
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SI Appendix Table S4 List of protein families, statistics of datasets and prediction results. 
 
Protein Family 
Training Set Testing Set 
Independent 
Set 































SE SP SE SP 
AC
C 
SE SP SE SP 
AC
C 




on the CH-OH 
































on the aldehyde 
or oxo group of 
































on the CH-CH 
































on the CH-NH2 






























on the CH-NH 
































on NADH or 




































































on a sulfur 
































on a heme 



































































on a peroxide 
































on hydrogen as 

































donors with O2 
as oxidant and 
incorporation of 
oxygen into the 

































donors, with O2 
as oxidant and 
incorporation or 
reduction of 



































































































on CH or CH2 



































































or arsenic in 
































on X-H and Y-
H to form an X-

































































































































EC2.3 22716 43549 10172 11542 9604 10987 50. 99. 60. 99. 81. 53. 99. 61. 99. 81. 90. 89. 93. 88. 90.





01 97 35 92 46 33 96 37 94 95 2 82 78 4 91 
EC2.4 
Glycosyltransfe

































alkyl or aryl 
groups, other 
than methyl 










































































































































































































































































































































































































































































































































































EC4.4 Carbon- 2133 35113 943 12051 868 11494 68. 99. 77. 99. 98. 56. 99. 66. 99. 97. 51. 99. 66. 99. 96.
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sulfur lyases 93 98 07 97 37 31 98 71 98 65 96 53 36 12 82 
EC4.6 
Phosphorus-
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inhibitor 337 35218 147 12086 143 11529 
97.
96 100 100 100 100 
97.



















































































































































































































































































































































































































































































































































































































































































































Initiation factor 11494 34446 4891 11828 4509 11272 
60.
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Toxin 4290 34731 562 11913 389 11382 67. 99. 69. 99. 98. 60. 99. 63. 99. 98. 76. 98. 75. 98. 97.
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97 99 67 99 99 5 97 5 99 79 33 68 58 75 99 
Transmembran
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SI Appendix Figure S1 Distribution of the natural product leads of approved 
and clinical trial drugs in branches 1-4 of the molecular scaffold trees of the 
134,097 natural products and 411 natural product leads. The drug-productive 
scaffolds or scaffold parent-child sub-branches (DSs) are indicated by red dots 
or red dots connected by red lines, which are marked by the respective label 
DS1, DS2, etc. The green triangles indicate the natural product leads which 
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SI Appendix Figure S2 Distribution of the natural product leads of approved 
and clinical trial drugs in branches 5-8 of the molecular scaffold trees of the 
134,097 natural products and 411 natural product leads. The coloring and 
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SI Appendix Figure S3 Distribution of the natural product leads of approved 
and clinical trial drugs in branches 9-12 of the molecular scaffold trees of the 
134,097 natural products and 411 natural product leads. The coloring and 
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SI Appendix Figure S4 Distribution of the natural product leads of approved 
and clinical trial drugs in branches 13-16 of the molecular scaffold trees of the 
134,097 natural products and 411 natural product leads. The coloring and 
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SI Appendix Figure S5 Distribution of the natural product leads of approved 
and clinical trial drugs in branches 17-20 of the molecular scaffold trees of the 
134,097 natural products and 411 natural product leads.  The coloring and 






                                                                                                       APPENDICES                                                                                                                                                                         
230 
 
SI Appendix Figure S6 Distribution of the natural product leads of approved 
and clinical trial drugs in branches 1-9 of the molecular-fingerprint Tanimoto-
coefficient similarity clustering tree of the 137,836 natural products and 442 
natural product leads. The drug-lead productive clusters are red-orange 
colored and marked by the respective cluster label. The red, purple and blue 
lines on top of the clustering tree indicate the locations of the approved, 
approved + clinical trial, and clinical trial drug-leads with the height 
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SI Appendix Figure S7 Distribution of the natural product leads of approved 
and clinical trial drugs in branches 10-18 of the molecular-fingerprint 
Tanimoto-coefficient similarity clustering tree of the 137,836 natural products 
and 442 natural product leads. The coloring and labeling schemes are the same as 
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SI Appendix Figure S8 Distribution of the natural product leads of approved 
and clinical trial drugs in branches 19-27 of the molecular-fingerprint 
Tanimoto-coefficient similarity clustering tree of the 137,836 natural products 
and 442 natural product leads. The coloring and labeling schemes are the same as 
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SI Appendix Figure S9 Distribution of the natural product leads of approved 
and clinical trial drugs in branches 28-33 of the molecular-fingerprint 
Tanimoto-coefficient similarity clustering tree of the 137,836 natural products 
and 442 natural product leads. The coloring and labeling schemes are the same as 
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SI Appendix Figure S10 Distribution of the bioactive natural products (green 
colored lines) with respect to the leads of approved and clinical trial drugs (the 
red, purple and blue lines on top of the clustering tree) in branches 1-9 of the 
molecular-fingerprint Tanimoto- coefficient similarity clustering tree of the 
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SI Appendix Figure S11 Distribution of the bioactive natural products with 
respect to the leads of approved and clinical trial drugs in branches 10-18 of 
the molecular-fingerprint Tanimoto-coefficient similarity clustering tree of the 
137,836 natural products and 442 natural products and 442 natural product leads. 
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SI Appendix Figure S12 Distribution of the bioactive natural products with 
respect to the leads of approved and clinical trial drugs in branches 19-27 of 
the molecular-fingerprint Tanimoto-coefficient similarity clustering tree of the 
137,836 natural products and 442 natural product leads. The line coloring 
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SI Appendix Figure S13 Distribution of the bioactive natural products with 
respect to the leads of approved and clinical trial drugs in branches 28-33 of 
the molecular-fingerprint Tanimoto-coefficient similarity clustering tree of the 
137,836 natural products and 442 natural products and 442 natural product leads. 
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SI Appendix Figure S14 The exploration times of the bioactive natural 
products (green colored lines on top of the clustering tree) and the leads of 
approved and clinical trial drugs (the red, purple and blue lines on top of the 
clustering tree) in branches 1-9 of the molecular-fingerprint Tanimoto-coefficient 
similarity clustering tree. The length of each line on top of the tree correlates to the 
exploration time of a natural product or a drug lead with a scale of 1 to 11 
corresponding to ≤5, 5-10, … , 45-50, and ≥50 years from 2012. The drug-lead 
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SI Appendix Figure S15 The exploration times of the bioactive natural 
products and the leads of approved and clinical trial drugs in branches 10-18 
of the molecular-fingerprint Tanimoto-coefficient similarity clustering tree. 
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SI Appendix Figure S16 The exploration times of the bioactive natural 
products and the leads of approved and clinical trial drugs in branches 19-27 
of the molecular-fingerprint Tanimoto-coefficient similarity clustering tree. 






                                                                                                       APPENDICES                                                                                                                                                                         
241 
 
SI Appendix Figure S17 The exploration times of the bioactive natural 
products and the leads of approved and clinical trial drugs in branches 28-33 
of the molecular-fingerprint Tanimoto-coefficient similarity clustering tree. 
The line coloring scheme is the same as in Supplementary Figure S14. 
 
 
 
 
 
 
 
 
 
